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ABSTRACT
Temple, Kayla J. Ph.D., Purdue University, December 2013. Synthesis of Novel Isoprenoid
Diphosphate Analogs as Chemical Tools to Investigate Protein Prenylation. Major Professor:
Richard Gibbs.
Many proteins require prenylation in order to be biologically functional. Some such
proteins include the small Ras and Rho GTPase superfamilies, nuclear lamins A and B, and the
kinesin motor proteins CENP-E and F. Prenyltransferase (PTase) inhibition is currently being
explored as a possible treatment not only for cancer but for a wide variety of other diseases.
Clinical studies revealed that the effectiveness of farnesyltransferase inhibitors (FTIs) to
treat Ras-dependent tumors is determined by which isoform of Ras is overactive. Unfortunately
the majority of Ras-dependent tumors have a mutation in either the N- or K-Ras isoforms; both of
these isoforms can be alternatively prenylated by GGTase-I and, therefore, do not respond to FTI
treatment. This sparked our interest in developing GGTase-I inhibitors and exploring
requirements needed for alternative prenylation by GGTase-I.
Clinical studies also brought about the discovery that FTIs were effective toward some
Ras-independent tumors (e.g. breast cancer, chronic & acute myeloid leukemia, multiple
myeloma, and advanced myelodyplastic syndrome). Presumably, these results are due to the
prenylation of one or more essential proteins required for tumorigenesis. The identity of the
protein(s) responsible for the observed antitumor affect in Ras-independent tumors remains
elusive. Identifying tumors reliant on proteins that are solely prenylated by one prenyltransferase
could open up new avenues for therapeutic intervention by FTIs or GGTIs.

Thus, identifying

xix
prenylated proteins and the prenyltransferase(s) required for this modification is of great interest
and importance.
Chemical tools capable of modulating prenylation of specific proteins would allow
researchers to more precisely investigate proteins’ individual roles in the cell as well as the
function of their lipid moieties. To this end we use a combinatorial approach in which we screen
isoprenoid pyrophosphate analogs against a synthetic Dansyl-GCaaX peptide library (the minimal
recognition sequence of PTases; Dansyl-G = Dansyl-glycine, C = Cys, a = aliphatic amino acid,
X = a small subset of amino acids, which in general designates which PTase modifies the CaaX
sequence). This approach revealed that for each pyrophosphate analog, both FTase and GGTaseI exhibit unique patterns of reactivity among various CaaX sequences. Our laboratory has also
developed a tagging-via-substrate proteomic method to identify farnesylated proteins within cells.
The aim of this research focuses not only on extending our current techniques into the realm of
geranylgeranylation in order to study the enzymatic requirements of GGTase-I, but also on
developing cellular probes that would allow for the identification of geranylgeranylated proteins.
The initial goal of this project was to advance our knowledge of GGTase-I substrate
specificity in terms of both prenyl and protein substrates and to investigate GGTase-I versus
FTase substrate specificity. The overall goal of this project was the development of biologically
useful chemical tools that could in the future be developed into proteomic probes for GGTase-I in
order to identify and characterize geranylgeranylated proteins.
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CHAPTER 1. INTRODUCTION

1.1

Posttranslational Modifications

Posttranslational modifications are chemical modifications that proteins undergo
following their biosynthesis resulting in enhanced protein biodiversity. The human genome
predicts 30,000 genes; however, due to posttranslational modifications, the human proteome is
hypothesized to contain 300,000 – 3,000,000 different forms of proteins.1 The dynamicity of
proteins and their ability to change in the presence of various cellular stimuli via posttranslational
modifications are what dictate various cellular functions and activities.
Posttranslational modifications can be classified into two general groups: covalent
modifications and covalent cleavage.

The majority of covalent modifications (e.g. acetylation,

glycosylation, methylation, lipidation, phosphorylation, and ubiquitination) can be categorized in
accordance with the type of amino acid side chain modified, the extent of reversibility of the
modification, and classification of the modifying enzyme.1 Covalent cleavage or hydrolytic
cleavage of peptide backbones in proteins is catalyzed by proteases or, less commonly, by
autocatalytic cleavage.1
Protein lipidation is a posttranslational modification that aids in membrane targeting by
covalently attaching at least one lipid anchor to a protein. Many proteins involved in human
diseases are modified by the covalent linkage of fatty acids or isoprenoid groups. The attachment
of hydrophobic groups to proteins aids in regulating protein structure and function.
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Major types of protein lipidation include: N-myristoylation, S-acetylation, S-prenylation,
palmitylation, and the attachment of glycosyl phosphotidylinositol anchors.1

1.2

Protein Prenylation

After protein prenylation’s first appearance in the late 1970’s in fungal peptide
pheromones, it was realized in the late 1980’s that the Ras superfamily of proteins underwent
protein prenylation, a type of posttranslational modification, which localized the proteins to the
plasma membrane.2, 3 Many proteins require prenylation in order to be biologically functional;
these proteins include critical proteins such as the small Ras and Rho GTPase superfamilies,
nuclear lamins A and B, and the kinesin motor proteins CENP-E and F.4
Protein prenylation, a type of lipidation, occurs on a cysteine four residues from the Cterminus. Prenylated proteins contain a C-terminal “CaaX box” sequences, where ‘C’ denotes
cysteine, ‘a’ is typically an aliphatic amino acid, and ‘X’ represents a small subset of amino acid
residues.5 Proteins containing a CaaX box are recognized by prenyl transferases located in the
cytosol. The prenyl transferase enzymes catalyze the formation of a thioether bond between the
cysteine residue of the CaaX box and isoprenyl lipids.6

There are three categories of

prenyltransferases in mammalian cells: farnesyl transferase (FTase), geranylgeranyl transferase-I
(GGTase-I), and geranylgeranyl transferase-II (GGTase-II aka RabGGTase).

FTase and

GGTase-I are CaaX prenyltransferases. FTase catalyzes the covalent attachment of a 15-carbon
farnesyl isoprenoid (farnesyl pyrophosphate, FPP)7 while GGTase-I catalyzes the attachment of a
20-carbon geranylgeranyl isoprenoid (geranylgeranyl pyrophosphate, GGPP) to cysteine.8 Both
isoprenoid chains are derived from the mevalonate pathway. In comparison, GGTase-II catalyzes
the attachment of two 20-carbon geranylgeranyl isoprenoids to a C-terminal CXC or CC motif.9
The three types of protein prenylation modifications are shown in Figure 1.1. After covalent
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attachment of the isoprenoid(s), the protein then relocates to the endoplasmic reticulum where it
undergoes proteolytic cleavage of the “-aaX” residues by the endoprotease Ras-converting
enzyme-1 (Rce-1).2, 5 To eliminate the charge of the free carboxylate, the C-terminal cysteine is
methyl-esterified by isoprenylcysteine carboxyl methyl transferase (Icmt), utilizing S-adenosyl
methionine as the methyl donor.10,

11

Upon completion of these modifications, the newly

isoprenylated protein can be anchored in the membrane and regulate various cellular functions
(Figure 1.2) such as cell signaling (Ras & others), cell division (CENP-E & CENP-F), and
organelle structure (lamins).12
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Figure 1.1.
Post-translational modifications of CaaX or CXC-containing peptides by
prenyltransferase enzymes: A) FTase; B) GGTase-I; C) RabGGTase.
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Figure 1.2. Post translational modifications of Ras proteins by FTase & GGTase-I and a
simplified version of the Ras signaling pathway. Ras signals downstream to the MEK/MAPK
pathway.
1.3

Ras Family of Proteins

It has been estimated that approximately 0.5-2% of all mammalian proteins are
prenylated, but roughly only 60 proteins have been identified thus far.13 Of the known prenylated
proteins, many exhibit a plethora of cellular functions including cell signaling, cell mobility, cell
division, organelle structure, and vascularization.14-20 Due to its diverse functionalities, it is not
surprising that protein prenylation is currently being explored as possible treatments not only for
cancer but for a wide variety of other diseases such as neurodegradation, Progeria,
arteriosclerosis, as well as parasitic and viral infections.
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The RAS superfamily of GTPases is a well-studied class consisting of over one hundred
small monomeric G proteins that act as molecular switches.2 Members of this superfamily
include the Ras family of proteins: H-Ras, N-Ras, & K-Ras (K-Ras4a & K-Ras4b). In addition to
prenylation, all three isoforms of Ras require additional modifications for proper membrane
localization. H-Ras and N-Ras both require palmitoylation for membrane localization while KRas does not need to be alternatively lipidated.21 Instead, K-Ras has a polylysine sequence
located near the prenylated cysteine residue that offers additional membrane affinity for
localization to the plasma membrane.
Ras acts as a molecular switch and cycles between an active-GTP bound and an inactiveGDP bound state that is controlled predominately by guanine nucleotide exchange factors
(GEFS).22

In its active-GTP bound state Ras localizes to the inner leaflet of the plasma

membrane where it can interact with other cofactors and initiate a signaling cascade. At the
plasma membrane, growth factors bind to membrane-bound receptor tyrosine kinases (RTK)
which results in RTK phosphorylation. This allows for docking proteins, such as growth factor
receptor-bound protein 2 (GRB2), to bind to the phosphorylated RTK via Src-homology 2 (SH2)
domains. Next, via an SH3 domain, GRB2 can associate with Son of Sevenless (SOS), a GEF,
thus activating SOS. Activated SOS converts the membrane-anchored, inactive-GDP bound Ras
to the active-GTP bound Ras. Activated Ras can then associate with, and in turn activate, Raf-1
which leads to the upregulation of cell growth and proliferation via the MAPK pathway (Figure
1.2).23
Oncogenic Ras is stabilized in an active GTP-bound state that promotes cellular signaling
and, consequently, tumorigenesis. The constitutive activation of these proteins was linked to a
single point mutation in the Ras gene and implicates the Ras proteins in a number of cancers.24, 25
Approximately 30% of all tumors have an activating mutation in one of the RAS genes with high
incidence rates in pancreatic (~90%), colon (~50%), lung (~40%) and acute myeloid leukemia
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cancers (~20%).26-28 The constitutive activation of Ras contributes to deregulation of tumor-cell
growth, programmed cell death, invasiveness, and angiogenesis. Moreover, Ras farnesylation is
required for proper cell signaling and was implicated as the cause of oncogenic transformations in
cells.29

1.4 Targeting Protein Prenylation & Alternative Prenylation in Cancer

When it was discovered that the Ras family of proteins is farnesylated and their function
depends on their association with the inner face of the plasma membrane, FTase as a drug target
along with its biochemical mechanisms became of great interest among the scientific community.
Over the past two decades, several FTase inhibitors (FTIs) have been developed and evaluated as
potential cancer therapeutics in an effort to treat Ras-dependent tumors. These FTIs include: 1)
FPP analogs (non-peptidomimetic) that compete with the isoprenoid substrates,30-32 2)
peptidomimetic inhibitors that mimic the CaaX sequence of target proteins such as Ras,33-35 and
3) bisubstrate analogs which mimic both the isoprenoid and the CaaX sequence.36-38
Several FTIs showed promising results, both in vitro and in vivo, in preclinical
experiments with low nanomolar IC50 values; however, clinical trials brought about more
questions than answers.39 These studies revealed that the effectiveness of FTIs to treat Rasdependent tumors is reliant upon which isoform of Ras is overactive. FTIs are general effective
toward H-Ras diseases. This is a consequence of the fact that H-Ras can only be prenylated by
FTase. Unfortunately, the majority of Ras-dependent tumors have a mutation in either the N- or
K-Ras isoforms; in particularly, K-Ras4B is the main oncogenic form of Ras.40 It was discovered
that both of these isoforms of Ras can be alternatively prenylated by GGTase-I.41 Due to
alternative prenylation, N- and K-Ras tumors do not respond to FTI treatment.
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Moreover, preclinical studies brought about the revelation that although FTIs are not
effective for treating the Ras-dependent tumors they were originally envisioned for (due to
alternative prenylation), FTIs were effective toward some Ras-independent tumors (e.g. breast
cancer, chronic & acute myeloid leukemia, multiple myeloma, and advanced myelodyplastic
syndrome).4, 27, 42 Presumably, these results are due to the prenylation of one or more essential
proteins required for tumorigenesis. This finding sparked the quest to identify “Protein X,” the
true target(s) responsible for the observed antitumor effects in Ras-independent tumors. The
identity of the proteins(s) responsible for the observed antitumor affect in Ras-independent
tumors remains elusive.

1.5 The CaaX Prenyltransferase Enzymes

In the early 1990’s, two enzymes were identified that catalyze the CaaX protein
prenylation reactions: farnesyltransferase and geranylgeranyltransferase-I.

As previously

mentioned, the primary functions of these cytosolic enzymes are to covalently attach isoprenoid
chains to the sulfur of a C-terminal cysteine via a thioether linkage. This posttranslational
modification serves as a method to localize and anchor proteins to cellular membranes, or other
cellular locations, to ensure proper cellular functioning.
FTase catalyzes the transfer of a 15-carbon isoprenoid onto a cysteine residue.
Mammalian FTase is a heterodimeric protein consisting of a 46 kD α-subunit and a 48 kD βsubunit that, as revealed by X-ray crystal structure, are predominantly alpha-helical.5, 7 The active
site of this enzyme is located in a groove found between the α- and β-subunits; thus, both subunits
are essential for substrate binding and catalysis. For protein recognition, FTase uses a C-terminal
“CaaX” motif. Generally, the “X” residues control enzyme-substrate recognition between FTase
and GGTase-I.

The “X” residues that designate farnesylation are serine, methionine, or

8
glutamine. On the other hand, GGTase-I recognizes protein substrates where the “X” residues are
typically leucine, phenylalanine, and occasionally methionine.5,

6, 8, 43

A list of some known

farnesylated and geranylgeranylated proteins can be found in Table 1.1.
Mammalian GGTase-I is also a heterodimeric zinc metalloenzyme consisting of a 46 kD
α-subunit and a 43 kD β-subunit that are predominantly alpha-helical.4,

6

In fact, FTase and

GGTase-I have the same α-subunit but differ in their β-subunits. The extensive interface at the αand β-subunits essentially buries ~20% of the accessible surface area of each subunit.6 Unlike
most subunit interfaces, the α/β-interface of both FTase and GGTase-I exhibits greater
hydrophilic character resulting in nearly double the number of hydrogen bonds.
Although the β-subunits share only ~25% sequence homology, they have very similar
structures consisting of 14 α-helices in FTase and 13 α-helices in GGTase-I (Figure 1.3).6 The αα barrel shown in Figure 1.3C is made up of twelve of these α-helices. The core of this barrel
consists of six parallel helices while the other six helices are parallel with each another but
antiparallel in regard to the core helices and form the outside of the barrel. In both enzymes, one
end of the α-α barrel is open to solvent while the opposing end is blocked by a loop formed from
the C-terminal residues of the β-subunit. This conformation creates the active site which is a
deep, funnel-shaped cavity in the center of the barrel. The active site cavity has a depth of 14Å
and a diameter of 15Å.6
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Figure 1.3. Structural representation of FTase (A) and GGTase-I (B) with the α-subunit shown
in red. (C) Overlay of the β-subunits of FTase (blue) and GGTase-I (yellow).6

1.5.1

Mechanism of Catalysis and Kinetics of CaaX Prenyltransferases

Both FTase and GGTase-I have been identified in a number of various species including
mammals,44, 45 protists,46, 47 plants,48, 49 and fungi.50, 51 The CaaX prenyltransferases are essential
for the function of these organisms and elimination of these enzymes have severe detrimental
effects and in some instances, lethality.50, 52-54 As mentioned previous, both FTase and GGTase-I
are cytosolic heterodimeric zinc metalloenzymes with unique, yet similar, kinetics of binding and
catalytic mechanisms. In fact, all three prenyltransferases have a conserved prenyl binding site
and have an ordered binding mechansim.6-8, 55 The catalytic cycle begins with the binding of the
pyrophosphate substrate (FPP or GGPP depending on the enzyme) to the active site located at the
interface of the α- and β-subunits. Following FPP/GGPP binding, the CaaX protein or peptide
binds to the active site to form a ternary complex.8, 56, 57 It is believed that the CaaX protein binds
to the active site as the thiol but is rapidly deprotonated and binds tightly to the zinc atom as the
thiolate.58-60
In the case of FTase, the zinc atom is embedded within the active site in the β-subunit and
coordinates to three important amino acids in the β-subunit (D297β, C299β, and H362β) and is
located 2.5 Å from the cysteine sulfur of the CaaX box.6,

8

The Zn2+ atom is present in
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stoichiometric amounts and has been shown to be crucial for enzyme activity.58, 61 In addition to
Zn2+, Mg2+ is also present in the mechanism of action. Although it is not essential for enzyme
catalysis, Mg2+ has been shown to enhance the rate of FTase activity by several hundred fold.62 It
is believed that the catalytic role of Zn2+ in farnesylation is to generate and coordinate to the
cysteine thiolate, while the Mg2+ plays the important role of positioning the FPP substrate prior to
catalysis.56, 63, 64 There are also implications that Mg2+ aids in the stabilization of the diphosphate
leaving group that results from the chemical lipidation with farnesyl pyrophosphate.62 Taken
together, Zn2+ and Mg2+ ensure the efficient function of FTase by properly orienting FPP and
forming/activating the cysteine thiolates (Figure 1.4).
Analogous to FTase, the Zn2+ atom in GGTase-I also coordinates to three strictly
conserved residues (D269β, C271β, and H321β), as well as to the thiolate group of the cysteine
residue of the CaaX box.8 Kinetic studies revealed that although FTase requires millimolar
amounts of Mg2+ for full catalytic efficiently, GGTase-I is Mg2+ independent.65 It has been
hypothesized that FTase requires Mg2+ in order to stabilize the negative charge on the phosphate
group that develops as the bond between the α-phosphate and the C1 atom of the farnesyl group
breaks.62 In fact, structural studies show that the Mg2+ coordinates to residue D352β of FTase and
the pyrophosphate moiety of FPP.6 Sequence alignment of FTase and GGTase-I revealed that the
D352β residue of FTase corresponded to a lysine residue in GGTase-I (K311β).8 FTase and
GGTase-I superimposition revealed that the lysine residue of GGTase-I adopts a conformation
that positions the positively charged side chain amine (Nε) at the site of the Mg2+ in FTase.6
Mutagenesis studies confirm these theories.63, 66 Mutating the D352β residue of FTase to a lysine
abolished Mg2+ dependence while mutating the K311β of GGTase-I to either alanine or aspartate
introduced Mg2+ dependence (Figure 1.4).66
After the binding of the pyrophosphate and CaaX protein to the enzyme, the following
chemical step proceeds quickly via a mechanism that is still highly controversial. This chemical
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step consists of the formation of the thioether linkage between the isoprenoid chain and the
cysteine thiolate with the pyrophosphate acting as the leaving group.62, 67 The rate limiting step of
protein prenylation is the product release.68 To induce product release, a second molecule of the
isoprenoid pyrophosphate must bind to the active site.69, 70 This causes the newly added prenyl
motif of the CaaX protein to move into the “exit groove” located in the β-subunit where it is then
transferred to the endoplasmic reticulum for further modifications by RCE-1 and ICMT (Figures
1.5 & 1.6).

Figure 1.4. Transition state model of protein prenylation. Hydrogen bonds are shown as dashed
red lines. Red amino acid residues correspond to GGTase-I & blue amino acid residues
correspond to FTase. (Figure adapted from Lane & Beese).6
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Table 1.1. Summary of FTase & GGTase-I requirements.6
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Figure 1.5. Reaction pathway of farnesylation (PDB: 1FT1, 1FT2, 1K2P, 1K2O).6

Figure 1.6. Reaction pathway of geranylgeranylation (PDB: 1N4P, 1N4Q, 1N4S)
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1.5.2

Comparing the Isoprenoid Binding Pockets of FTase & GGTase-I

Interestingly, FTase is capable of binding to geranyl pyrophosphate (GPP, 10 carbon
isoprenoid chain) and GGPP. In fact, FTase can catalyze reactions with either GPP or FPP,
although GPP is a much poorer substrate than FPP. On the other hand, it has been shown that
GGPP is a competitive inhibitor of FTase.69,

71

When bound to FTase, GGPP hinders proper

CaaX binding/alignment in such a manner that catalysis cannot occur. Conversely, FPP can act
as a substrate for GGTase-I, albeit with 300-fold less affinity than GGPP. These findings can be
partially explained by taking a closer look at the enzymes’ active sites.
The major portion of the enzyme that interacts with the isoprene diphosphate is the βsubunit.6 As mentioned previously, the β-subunits of FTase and GGTase-I are only ~25%
homologous; however, the portion of the β-subunits that interact with the isoprene are strikingly
similar (Figure 1.7A). Comparing the binding pockets of FTase and GGTase-I shows that FPP
binds to FTase in an extended conformation, but GGPP binds in such a way that the last isoprene
unit of GGPP is nearly perpendicular with respect to the rest of the molecule within the active site
(Figure 1.7B).6 This can be attributed to the fact that W102 β and W106β in FTase-I correspond
to T49β and F53β, respectively, in GGTase-I. The differences in the amino acids within the
active site allow for a larger binding pocket in GGTase-I. Thus, this could explain why GGPP
acts as a competitive inhibitor of FTase. The isoprenoid chain of GGPP can be recognized by and
bind into the FTase binding pocket; however, due to the longer chain of GGPP, the diphosphate
head group cannot orientate properly to coordinate with the zinc ion (Figures 1.7C & D).
Therefore, the geranylgeranyl isoprenoid chain cannot be transferred to the Cys residue of a
protein to form the thioether linkage via FTase.
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Figure 1.7. Comparison of FTase & GGTase-I β-subunits within the binding pocket. Amino
acid residues that interact with the isoprene unit are shown as sticks; FPP (red) and GGPP (pink).
(A) Overlay of FTase (blue) and GGTase-I (yellow) reveals several identical amino acids (green).
(B) Unique amino acids of the β-subunits within the binding pocket are shown. (C) Surface view
of FTase. A much smaller binding pocket is available due to W102β and W106β. GGPP does
not fit properly into the cavity. (D) Surface view of GGTase-I. The W102 β and W106β of
FTase-I correspond to T49β and F53β in GGTase-I allowing for a larger isoprenoid pocket.
(PDB: 1N4P (FTase) and 1K2O (GGTase)).
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1.6

GGPP Analogs as Chemical Tools

While the reaction mechanisms of the prenyltransferases have been vastly studied and are
well understood, there are many unanswered questions pertaining to their in vivo function(s).
Bioinformatic analysis predicts that there are hundreds of prenylated proteins, but only a small
percentage of proteins have been experimentally confirmed. Thus, the true number of prenylated
proteins, referred to as the prenylome, remains unknown. Moreover, FTase and GGTase-I have
been shown to display overlapping substrate specificities with a subset of substrates; however, the
in vivo extent and the physiological significance of this overlap have been studied on a very
limited number of substrates.
The identification of the elusive “Protein-X targets” can be accomplished via a variety
of different techniques. One such method is the use of prenyltransferase inhibitors (PTIs) to
evaluate the role of individual proteins; however, this approach can be inconvenient due to the
non-specific nature of PTIs. It is presumed that FTIs and GGTIs (GGTase-I inhibitors) affect
farnesylation and geranylgeranylation, respectively, on a global level. Hence, upon inhibitor
administration, monitoring the cellular effect(s) of a single protein would be an extremely
difficult and daunting task when taken into consideration that it is predicted ~2% of all
mammalian proteins are prenylated (i.e. 6,000-60,000 proteins).
Fortunately, there are other more attractive approaches that our laboratory has taken
advantage of in the past. One such approach is the use of unnatural pyrophosphate analogs.31, 72-76
These unnatural analogs can be very beneficial when they behave as either selective substrates or
selective inhibitors of specific CaaX proteins. For example, if we could design and synthesize a
GGPP analog that was a selective inhibitor for K-Ras, we could evaluate the role of
geranylgeranyl-KRas in cells without the interference of other geranylgeranylated proteins.
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Another approach utilized for elucidating the biological effects of one prenylated protein
from another is with the use of farnesylated pyrophosphate analogs containing either a
fluorophore and/or an affinity tag (Figure 1.8).4 Such analogs provide researchers with a means
to purify farnesylated proteins from cell lysates and/or a method to visualize farnesylated proteins
in vivo. While PTIs are a great tool to study global prenylation, selective FPP/GGPP analogs and
affinity-labeled FPP/GPP analogs are far superior chemical tools to aid in the elucidation of the
prenylome and “protein-X”.

In the past, these approaches have been largely focused on

farnesylation; hence, unique GGPP analogs are still largely unexplored.
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Figure 1.8. Examples of farnesylated pyrophosphates containing affinity tags or fluorophores
utilized in the past.4

Many of the modifications made to the FPP scaffold that our laboratory has investigated
are shown in Figure 1.9. These analogs have been extensively screened with various libraries of
dansylated-CaaX containing peptides and many show activity in our in vitro fluorescence assays
as either substrates or inhibitors.31, 73, 75-82 Only three of the eight modifications shown have been
extended to develop analog libraries of GGPP. With the exception of the 3-substituted analogs,
the modified GGPP analogs show similar activity/selectivity trends in reference to their FPP
counterparts. Thus, the remaining five modifications shown in Figure 1.9 (blue) provide an
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opportunity to develop novel GGPP analogs that could provide insight into protein
geranylgeranylation. By developing selective GGPP analogs in combination with an affinity tag
and/or fluorophore for purification and/or visualization would provide investigators with novel
chemical tools for monitoring protein geranylgeranylation in vivo.

Figure 1.9. Modifications of the farnesyl scaffold explored by our laboratory. Green: These
modifications have been evaluated on the geranylgeranyl scaffold. Blue: These modifications
have yet to be investigated utilizing a geranylgeranyl scaffold allowing for new opportunity.

1.7

In vitro Fluorescence Screening Assay for FTase & GGTase-I Activity

In order to determine the activity of FTase and GGTase-I, a fluorescence-based approach
was originally developed by Pompliano and coworkers and later modified by Poulter and
collegues.83, 84 This approach takes advantage of two facts: 1) the minimal recognition sequence
of FTase and GGTase-I is the tetrapeptide CaaX sequence, and 2) the unique properties of the
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dansyl fluorophore. In a simple assay buffer solution, the dansyl group emits at a wavelength of
550 nm with a 340 nm excitation; however, upon lipidation of a fluorescently labeled peptide, the
fluorophore undergoes a blue shift to an emission of 505 nm and also leads to a large increase in
fluorescence (Figure 1.10). Although it is not quite understood how the increase in hydrophobic
environment elicits such a response, it has been proven that these assays are robust and
reproducible. Due to the added hydrophilic character, prenylation can be confirmed by HPLC.
With our laboratories optimized conditions, the unprenylated proteins have a retention time of ~12 minutes whereas the prenylated product has a retention time of ~23 minutes. Therefore, by
utilizing pentapetides of the form dansyl-GCaaX, we can observe the extent of protein
prenylation by monitoring the change in fluorescence of the dansyl group that results from
lipidation.

Emission Wavelength

Figure 1.10. Single cuvette fluorometic assay.

Time Based Single Wavelength Scan
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1.8

Protein Prenylation & Other Diseases

Due to the vastness of protein prenylation, it is not surprising that recent studies have
brought to light prenylation as a key player in several diseases. While protein prenylation is most
well-known and investigated for its pivotal role in cancer, it has also been implicated or could be
a potential target in a variety of other diseases such as neurodegeneration (e.g. Alzheimer’s),85, 86
atherosclerosis/restenosis,87,

88

angiogenesis,19 retinal degradation,89,

90

premature aging (e.g.

Hutchinson-Gilford progeria syndrome),91-93 osteoporosis,94 parasitic disease (e.g. malaria),95,

96

Hepatitis δ virus,97 Costello Syndrome,98, 99 renal disease,100, 101 and asthma.102 It is important to
remember that protein prenylation is present in all types of cells and a key regulator of a variety
of cellular functions. Thus, identifying prenylated proteins and understanding their individual
cellular roles will aid researchers to determine the best approach to a given disease and perhaps
even uncover novel therapeutic targets.

The first step is designing selective substrates or

inhibitors of this cellular pathway to be used as chemical tools to probe the prenylome.

1.9

Significance of Work

The prenylome is believed to consist of 60-600 thousand proteins; however, only a small
percentage of these proteins have been confirmed. Moreover, there is a grey area to protein
prenylation in which a subset of known proteins can be prenylated by either FTase or GGTase-I.
This can make therapeutic intervention difficult for diseases reliant on prenylation. For example,
FTIs were originally designed for Ras driven tumors; however, K-Ras, the major form of
oncogenic Ras, can be geranylgeranylated by GGTase-I, rendering FTIs ineffective. On the other
hand, Hutchinson-Gilford progeria syndrome and Costello syndrome are genetic disorders caused
by mutations of the LMNA (lamin A) and H-RAS genes, respectively. Both lamin A and H-Ras
are farnesylated proteins; thus, FTIs are being explored as treatment options for these disorders
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and preliminary findings are promising. While FTIs and GGTIs have the potential to be highly
effective therapeutic treatments, researchers still lack the ability to determine which diseases FTIs
and GGTIs would be effective against. Hence, possessing tools that can identify prenylated
proteins, unravel their biological significance, and/or determine which prenyltransferase is
responsible for said prenylation would be of great significance.
Much work has been focused on the elucidation of farnesylated proteins. The use of
unnatural FPP analogs as selective substrates or inhibitors of FTase has been employed in an
effort to reveal each farnesylated proteins’ biological impact. The development of selective
geranylgeranylating substrates or inhibitors would allow researchers to evaluate one or a few
proteins at a time. Thus, these analogs should greatly increase the amount of information
obtained from a single biological assay about a given proteins’ physiological significance.
The overall goal of this research is to identify geranylgeranylated proteins and to evaluate
the enzymatic requirements of FTase and GGTase-I utilizing unnatural GGPP analogs. Based on
the crystallographic analysis of FTase and GGTase-I by the Beese laboratory, as well as our
laboratory’s success with the development of unnatural FPP analogs, we have synthesized a small
library of unnatural GGPP analogs with frame-modifications. This library can be classified into
four subgroups: saturated, frame-shifted, alkynyl-tagged, and ω-modified GGPP analogs.
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CHAPTER 2. SYNTHESIS & BIOCHEMICAL EVALUATION OF ARYL-MODIFIED
GERANYLGERANYL PYROPHOSPHATE ANALOGS

2.1

Introduction

In the past, structural studies of FTase by the Beese group have unveiled a hydrophobic
binding pocket rich with aromatic amino acid residues such as Tyr, Trp, and Phe.7, 56, 57 Such
findings sparked many researchers, our group included, to explore the possibility of pi-pi stacking
interactions between these aromatic amino acids and FPP analogs containing aromatic motifs.4, 32,
82, 103

Many of the previously synthesized aromatic FPP analogs have aryl-modifications at the

terminal isoprene and have displayed some interesting biochemical results (Figure 2.1). While
these aryl-modifications have been greatly explored as FTase substrates and inhibitors, little
remains known of these modifications in GGTase-I binding ability.
Previously, our laboratory has concentrated on generating GGPP analogs containing
substitutions either at the 3 position, the 7 position, or both.74, 80 Although some of these analogs
have been shown to act as efficient substrates of GGTase-I, others have high nanomolar IC50
values. The synthesis of aryl-modified analogs would allow us to investigate greater structural
diversity in GGPP analogs. Although some of the aromatic residues (W102, Y361) in FTase
correspond to non-aromatic resides in GGTase-I (T49, F53, respectively) in order to allow for a
more spacious binding pocket to accommodate the longer isoprene chain of GGPP,6, 8 structural
studies of GGTase-I have revealed that it too has a hydrophobic binding pocket abundant with
aromatic residues (Figure 2.2). The potential of aryl-containing GGPP analogs to participate in
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pi-pi stacking interactions with the aromatic amino acid residues of the GGTase-I binding pocket
prompted us to synthesize and evaluate a small library of aryl-modified GGPP analogs.
When considering which analogs to evaluate, our goal was to select analogs that best
mimicked the terminal isoprene unit (Figure 2.3). In order to do this, we overlaid several
potential compounds with GGPP in the GGTase-I binding pocket using PyMol (Figure 2.5). The
two analogs that best simulate the isoprene unit were 2.6d and 2.6e, which both contain methylsubstituted benzene rings. The addition of a methyl substituent on the aromatic ring allows the
molecule to mimic both terminal CH3 groups of the isoprene unit. Analogs 2.6a and 2.6b also
aligned well with GGPP. While they lack the extra CH3 of 2.6d-e, both of these analogs provide
the double bond of the terminal isoprene unit. In comparison, 2.6a-b may provide great insight
into the need or lack thereof the methyl substitution of the aromatic ring. Analog 2.6c was
included to determine if hydrophobic bulk would be sufficient to bind to GGTase-I or, as we
hypothesize, aromaticity would be more beneficial.
Due to its unique characteristics such as small size and high electronegativity, fluorine
has been used to alter physical properties and binding interactions.104 In general, addition of
fluorine or fluorinated groups results in an increase in lipophilicity of organic molecules,
especially aromatic compounds.105 Fluorine also has three sets of lone-pair elections that it can
share with electron-deficient atoms such as acidic hydrogens bound to heteroatoms.

More

recently, polar C-F bond-protein interactions have been shown to be crucial in stabilizing
fluorine-containing compounds and their protein targets. These types of interactions have been
found between C-F bonds and polar functional groups such as carbonyls (C-F···C=O) and
guanidinium ion moieties (C-F···C(NH2)(=NH)) of amino acid side chains.105 Thus, it is not
surprising that fluorine substituents have been known to enhance binding interactions; therefore,
compound 2.6f was chosen to evaluate the effects of electronics on the aromatic ring.
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Recently, our lab has synthesized a potent hIcmt inhibitor designated “TAB” (Figure
2.4).106 Unfortunately, there is no crystal structure of Icmt; however, it is know that both
farnesylated and geranylgeranylated proteins bind to hIcmt and are methylated after they are
proteolytically cleaved by Rce-1. Thus, it stands to reason that Icmt and the prenyltransferases
have similar prenyl-binding pockets.
inhibitor of FTase and GGTase-I.

Therefore, we wished to evaluate 2.15 as a potential
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Figure 2.1. Aryl-modified FPP analogs previously evaluated.32, 82

A

B

Figure 2.2. Aromatic rich GGTase-I binding site. Amino acids of the β-subunit that interact
with GGPP (cyan) are shown in yellow. (A) Interacting amino acids are shown as sticks; (B)
Surface view of binding pocket.
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Figure 2.3. Aromatic groups as isoprenoid mimics.

Figure 2.4. Comparing protein prenylation with our laboratory’s nanomolar Icmt inhibitor. Blue
box represents isoprenoid mimic and purple circle corresponds to the protein.

Figure 2.5. Overlay of aryl-modified GGPP analogs and GGPP (green) in the GGTase-I binding pocket.
27
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2.2

Synthesis of Aryl-Modified Geranylgeranyl Pyrophosphate Analogs

The synthesis of the aryl-modified GGPP analogs was designed in such a way that all
compounds could be generated from a common intermediate, 2.3. Additionally, the availability
of a wide variety of commercially available Grignard reagents and benzylic/phenylic halides in
addition to the ease of introduction of the aryl-motifs motivated us to explore this synthetic route.
To begin the synthesis, THP-protected farnesol (2.1) underwent oxidation in the presence of SeO2
followed by a NaBH4 reduction to generate alcohol 2.2.107-109 Next, diethyl chlorophosphate is
subjected to a displacement reaction in the presence of 2.2 and DIEA to generate diethyl
phosphate 2.3 in 74% yield. There were a few advantages of choosing this type of intermediate.
One advantage to using diethyl phosphate 2.3 is that it can be stored for longer periods of time
than the corresponding allylic halides which are unstable and easily degrade. More so, the
corresponding allylic halides generally undergo Grignard displacement reactions to give a
mixture of SN2 and SN2’ products usually in fairly equal quantities and isolations of one isomer
are not facile.110 Thus, with common intermediate 2.3 in hand, a similar method as Snyder &
Treitler was employed and a variety of Grignard reagents could be utilized in an SN2
displacement reaction to generate the aryl-modified GGPP analogs 2.4 a-f.111 These analogs were
first deprotected using PPTS in EtOH to generate alcohols 2.5 a-f and then converted into the
corresponding pyrophosphates (2.6 a-f) utilizing the method of Davisson et al.112, 113
The synthesis of the “TAB-pyrophosphate” 2.15 was accomplished according to the
procedure of Bergman et al.106 It began with the conversion of 4-bromobut-1-yne (2.7) to alcohol
2.8 using Negishi’s zirconium-catalyzed asymmetric carbo-alumination (ZACA) reaction.114
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Next, alcohol 2.8 was THP-protected using a standard procedure to generate compound 2.9. The
second half of the molecule was generated by subjecting biphenyl-iodide 2.10 to the 1(trimethylsilyl)-1-propyne (2.11) anion followed by TMS deprotection with TBAF to afford
alkyne 2.12. Alcohol 2.9 was then converted into the corresponding azide in situ by displacement
of the primary bromide with sodium azide.

Utilizing standard Cu(I) mediated conditions,

biphenyl alkyne (2.12) was then “clicked” with the freshly generated azide resulting in a 1,4disubstituted 1,2,3-triazole (2.13).115-118 These analogs were first deprotected using PPTS in
EtOH to generate alcohol 2.14. Halogenations of triazole-containing compounds via standard
Corey-Kim conditions using NCS has been revealed to be problematic in the past. Thus, alcohol
2.14 was first converted in to the mesylate and then converted into the corresponding
pyrophosphate (2.15) utilizing the method of Davisson et al.112, 113
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Scheme 2.1. Synthesis of Aryl-Modified GGPP analogs. (a) i. DHP, PPTS, DCM; ii. SeO2, tBuOOH, salicylic acid, DCM; ii. NaBH4, EtOH (37% - 3 steps); (b) DIEA, (EtO)2POCl, Et2O
(74%); (c) R-MgX, THF, o/n ; (d) PPTS, EtOH, 70°C; (e) NCS, DMS, DCM, 2.5 hr.; (f)
(NBu4)3HP2O7, ACN, 3 hr.
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Scheme 2.2. Synthesis of “TAB” pyrophosphate. (a) Me3Al, Cp2ZrCl2, DCM, 0°C, 18 hr then
(CH2O)n, 3hr (83%); (b) PPTS, DHP, DCM (79%); (c) i. TMS-propyne, n-BuLi, THF, -78°C; ii.
K2CO3, MeOH, 12 hr (36% - 2 Steps); (d) NaN3, CuSO4·5H2O, Sodium ascorbate, DMF, 55°C
(20%); (e) PPTS, EtOH, 70°C (85%); (f) MsCl, DMAP, DCM, 2.5 hrs; (g) (NBu4)3HP2O7, ACN,
3 hr (89%).
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2.3

Biochemical Evaluation of Aryl-Modified Geranylgeranyl Pyrophosphate Analogs

Previously, our laboratory and others have shown that aryl-modified FPP analogs can
behave as substrates or inhibitors of FTase with various CaaX-peptides. Thus, we aimed to
explore these modifications when applied to GGTase-I.

The aryl-modified GGPP analogs

synthesized (2.6a-f & 2.15) were evaluated for their biochemical activity in an in vitro continuous
spectrofluorometric assay with GGTase and the co-substrate CaaX-peptide dansyl-GCVLL (the
CaaX sequence of cdc42). All biochemical assays were performed in our collaborator Dr. Carol
Fierke’s laboratory at the University of Michigan by Elia Wright.
Among the aryl-modified compounds tested, six of the seven compounds synthesized
displayed substrate activity. It was not surprising that 2.15 was not a substrate as it was based off
of an Icmt inhibitor recently synthesized in our laboratory. As mentioned previously, due to the
fact that both farnesyl and geranylgeranyl proteins are further processed by Icmt, we
hypothesized that Icmt and the prenyltransferases have similar prenyl-binding pockets (Figure
2.4). Therefore, our original motive for synthesizing this compound was to determine if this
isoprene-mimic could also inhibit GGTase-I. Further studies are currently underway to test the
ability of 2.15 to act as an inhibitor of protein prenylation.
The remaining six compounds (2.6e-f) all displayed varying degrees of substrate activity.
From these results (Figures 2.6 & 2.7) it is evident that chain length plays a role in substrate
ability. For example, the homobenzyl analog 2.6a is the same overall length as GGPP and
displays substrate activity comparable to GGPP. On the other hand, removing one methylene unit
to afford the benzyl analog 2.6b greatly diminished the substrate ability. In the case of both 2.6a
and 2.6b, it appears that our original hypothesis proved true. By adding a methyl substituent on
the benzene ring to mimic the terminal isoprene, substrate activity increased (2.6d and 2.6e);
however, it is important to note that the shorter carbon chain analog (2.6e) still displayed
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significantly less substrate ability than analogs that have the same overall carbon chain length as
GGPP (e.g. 2.6d).
The results of the remaining two analogs (2.6c and 2.6f) were interesting. We had
hypothesized that our aromatic compounds would have the added benefit of being able to
participate in additional favorable interactions with the binding site (such as pi-pi stacking).
Thus, we believed the aromatic compounds would display a greater degree of activity than a nonaromatic counter part due to the large number of aromatic residues in the binding pocket of
GGTase-I. This did not prove to be true in the case of analog 2.6c. By comparing analogs 2.6c
and 2.6b, the only difference is the lack of aromaticity in 2.6c; however, 2.6c displays slightly
greater substrate activity than its aromatic counterpart 2.6b. Thus, hydrophobicity may play a
greater role than aromaticity; however, further studies are needed before a definite conclusion can
be reached.
Due to its small size, high electronegativity, and unique chemical reactivity, fluorine is
becoming more and more common place in medicinal chemistry and drug discovery. In fact,
fluorine’s unique nature has been linked to enhancing binding interactions, changing physical
properties (lipophilicity/solubility), metabolic stability, and selective reactivities.104 Additionally,
the incorporation of fluorine into our laboratory’s “TAB” compound resulted in a more potent
Icmt inhibitor. Assuming the Icmt and GGTase-I binding pockets are similar, we hypothesized
that a fluorinated aryl-GGPP compound could be beneficial to enzyme activity. Thus, the last
analog, 2.6f, was a difluoro compound whose substituent potions were selected based on previous
data of a “TAB” derivative. The in vitro analysis revealed that 2.6f displayed substrate activity
comparable to GGPP (Figure 2.6) and may even be more efficient as a substrate than GGPP
(Figure 2.7).
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Figure 2.6. Bar graphs of substrate activity represented in RFI of aryl-modified GGPP analogs
2.6a-d versus GGPP (+ control) with 5 µM dansyl-GCVLL and 50 nM GGTase-I. Error bars
represent mean ± SD (n = 3). *Values given are for 10 µM analog at 2 hours.
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2.4

Conclusions

The goal of this aim was to focus on the synthesis of a small library of aryl-modified
GGPP analogs. While many aromatic derivatives of FPP have been synthesized and investigated
in the past, these modifications had yet to be extended into the realm of GGTase-I. Additionally,
the majority of the FPP analogs previously explored contained either an amine or ether linkage
between the isoprene chain and the aromatic moiety.
This aim focused on designing a robust synthetic route which would allow us to quickly
and efficiently produce a small library of aryl-modified analogs (2.6a-f). Moreover, this route
allowed us to produce compounds that contain an all carbon backbone which more effectively
mimics the natural isoprenoid chain of GGPP.

The synthesis was dependent on the allylic

diethyl phosphate 2.3 which proved to be more stable than the corresponding allylic halide and
could be stored over time.

This allowed us to produce larger quantities of the common

intermediate 2.3 which could rapidly be converted into several aryl-modified GGPP analogs.
Upon in vitro biochemical evaluation of these analogs, it was discovered that all of these
analogs displayed substrate activity; however, the length of the carbon chain plays an important
role. Having two methylene units between the aromatic ring and the terminal double bond
(homobenzyl moiety) provides compounds that have substrate ability comparable to GGPP. By
decreasing the methylene unit to one (benzyl moiety) the substrate activity was greatly reduced.
Another important factor that increased substrate activity was the introduction of fluorine
substituents on the homobenzyl ring (2.6f).

This resulted in an analog that appears to be

comparable to GGPP. Unfortunately, the analogs were tested at only three concentrations (1, 5,
& 10 µM) and many of the reactions did not reach completion at 5 or 10 µM of analog (Figure
2.8). In order to determine accurate kcat and Km values, these analogs are currently being retested

at more concentrations.
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Moreover, we also synthesized an aromatic analog (2.15) that was based on a nanomolar
inhibitor of Icmt previously developed in our laboratory. If the Icmt and GGTase-I isoprenoid
binding pockets are similar, then 2.15 has the potential of being an inhibitor of GGTase-I. As
expected, the in vitro substrate assay revealed that 2.15 did not display substrate activity; further
testing is currently underway to determine whether or not 2.15 is an inhibitor of GGTase-I.
We have successfully synthesized a library of aryl-modified GGPP compounds in which
the ω-isoprene units has been replaced by an aromatic group. The preliminary biochemical
evaluation of these compounds revealed several intriguing results.

At a later date, these

compounds will be screened with an expansive library of dansyl-GCaaX peptides to determine if
these analogs globally or selectively geranylgeranylate proteins.

38
2.5

Experimental Procedures Utilized for the Synthesis & Biochemical Evaluation of ArylModified Geranylgeranyl Pyrophosphate Analogs

General Experimental Procedures: All reactions were performed with oven-dried or flame-

dried glassware and under dry argon gas. All commercial reagents and solvents were used
directly without subsequent purification. For the organometallic coupling reactions, anhydrous
THF was freshly distilled from sodium and benzophenone. All other anhydrous solvents were
purchased from Acros Organics as extra dry solvents and were bottled over molecular sieves.
Reactions were monitored by thin layer chromatography and visualized with one or more of the
following:

UV

light,

iodine,

vanillin

solution,

potassium

permanganate

dinitrophenylhydrazine solution, and/or phosphomolybdic acid solution.

solution,

All products were

purified using flash chromatography silica gel 60 M purchased from Macherey-Nagel.

All

reactions involving either triphenyl phosphine or triphenyl phosphine oxide were first dry-loaded
with sodium sulfate before column purification. All NMR spectra were taken either on a 300
MHz Bruker ARX300 or a 500 MHz Bruker DRX500 spectrometer. Low-resolution MS (EI/CI)
were recorded with a Hewlett Packard Engine and low-resolution MS (ESI) were taken on a
Thermoquest LCQ. All high-resolution mass spectra were recorded on a FinniganMAT XL95.
HO

OTHP

(2E,6E,10E)-2,6,10-trimethyl-12-((tetrahydro-2H-pyran-2-yl)oxy)dodeca-2,6,10-trien-1-ol
(2.2a):

To an Erlenmeyer flask charged with t-BuOOH (2.0 eq, 40 mmol, 70% in water) and 60
mL of CH2Cl2 is added MgSO4. The solution was then filtered into a round bottom flask
equipped with a magnetic stir bar. Next, SeO2 (0.12 eq, 2.4 mmol) and salicylic acid (0.5 eq, 10
mmol) were added to the reaction mixture. While the solution stirred, THP-protected farnesol,
2.1 (1.0 eq, 20 mmol) was added dropwise to the reaction vessel. The reaction mixture was
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allowed to stir for 12 hours. The CH2Cl2 was removed and the resulting residue is resuspended in
Et2O. Next, 10% NaOH was added to solution, the organic layer was removed, and the aqueous
layer was extracted 3 × Et2O (40 mL). The organic layers are combined, washed with brine, dried
with MgSO4, filtered, and concentrated. In an oven-dried round bottom flask, the crude reaction
product was diluted with 80 mL of ethanol and NaBH4 (1.0 eq, 20 mmol) was added in several
portions to the reaction vessel. The reaction was allowed to stir for 1 hour and then diluted with
200 mL of water. The aqueous layer was extracted 3 × Et2O (40 mL) and the organic layers were
combined, washed 2 × H2O, washed with brine, dried with MgSO4, filtered, and concentrated.
The crude reaction product was purified by column chromatography using 15% Ethyl
Acetate/Hexanes as the mobile phase to afford 2.2 in 37% yield.

1

H NMR (300 MHz,

Chloroform-d) δ 5.41 – 5.25 (m, 2H), 5.08 (t, J = 6.3 Hz, 1H), 4.59 (t, J = 3.4 Hz, 1H), 4.19 (dd, J
= 11.9, 6.4 Hz, 1H), 4.06 – 3.91 (m, 3H), 3.85 (ddd, J = 11.1, 7.4, 3.3 Hz, 1H), 3.47 (dt, J = 10.4,
4.7 Hz, 1H), 2.24 – 1.90 (m, 7H), 1.81 – 1.24 (m, 17H).

13

C NMR (75 MHz, CDCl3) δ 140.07

(s), 134.77 (s), 134.68 (s), 125.62 (s), 124.07 (s), 120.53 (s), 97.54 (s), 68.67 (s), 63.50 (s), 62.11
(s), 39.48 (s), 39.18 (s), 30.55 (s), 26.09 (s), 26.02 (s), 25.39 (s), 19.44 (s), 16.31 (s), 15.89 (s),
13.59 (s).
EtO

O
O
P

OTHP

OEt

Diethyl ((2E,6E,10E) - 2,6,10 - trimethyl -12-((tetrahydro-2H-pyran-2-yl)oxy) dodeca-2,6,10trien-1-yl) phosphate (2.3a):
To a round bottom flask equipped with a magnetic stir bar was added alcohol 2.2 (1.0 eq,
8.1 mmol) in 10 mL of CH2Cl2. Next, Et3N (7 eq, 56.7 mmol) was added to the reaction vessel
and the mixture was cooled to 0°C, where diethyl chlorophosphate (5.5 eq, 44.8 mmol) was
added dropwise to the reaction. The reaction was allowed to warm to room temperature and
stirred for 12 hours. Next, 10% NH4Cl(aq) was added to solution, the organic layer was removed,
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and the aqueous layer was extracted 3 × Et2O (20 mL). The organic layers are combined, washed
with brine, dried with MgSO4, filtered, and concentrated. The crude reaction product was purified
by column chromatography using 50% Ethyl Acetate/Hexanes as the mobile phase to afford
diethyl phosphpate 2.3 in 74% yield. NMR: 1H NMR (300 MHz, Chloroform-d) δ 5.46 (t, J =
6.4 Hz, 1H), 5.33 (t, J = 5.6 Hz, 1H), 5.09 (t, J = 6.1 Hz, 1H), 4.67 – 4.54 (m, 1H), 4.36 (d, J =
6.9 Hz, 2H), 4.21 (dd, J = 11.9, 6.4 Hz, 1H), 4.16 – 3.93 (m, 5H), 3.87 (ddd, J = 11.0, 6.9, 3.7 Hz,
1H), 3.49 (ddd, J = 11.3, 6.3, 3.5 Hz, 1H), 2.27 – 1.89 (m, 9H), 1.69 – 1.62 (m, 6H), 1.63 – 1.41
(m, 8H), 1.31 (td, J = 7.1, 1.0 Hz, 6H).

13

C NMR (75 MHz, Chloroform-d) δ 140.28, 134.79,

130.54 (d, J = 6.9 Hz), 129.94, 124.47, 120.76, 97.94, 73.42 (d, J = 5.8 Hz), 63.81, 63.77, 63.73,
62.44, 39.72, 39.12, 30.87, 26.52, 26.43, 25.65, 19.79, 16.58, 16.35, 16.26, 16.14, 13.74.
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P

NMR (122 MHz, Chloroform-d) δ -0.25.

Representative procedure for the synthesis of 2.5a-c utilizing commercially available
Grignard reagents:

OTHP

2-(((2E,6E,10E)-3,7,11-trimethyl-13-phenyltrideca-2,6,10-trien-1-yl)oxy)tetrahydro-2H-pyran
(2.4a):

To an oven-dried round bottom flask equipped with a magnetic stir bar was added diethyl
phosphate 2.3 (1.0 eq, 0.5 mmol) dissolved in 2 mL of THF and cooled to 0°C.

Next,

benzylmagnesium bromide (2 M in THF, 5 eq, 2.5 mmol) was added dropwise to the reaction
mixture and the reaction was allowed to stir for 12 hours. The reaction was quenched with 10%
NH4Cl, the organic layer was removed, and the aqueous layer was extracted 3 × Et2O (5 mL).
The organic layers are combined, washed with brine, dried with MgSO4, filtered, and
concentrated. The crude reaction product was purified by column chromatography using 5%
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Ethyl Acetate/Hexanes as the mobile phase to afford 2.4 a in 76% yield. NMR: 1H NMR (300
MHz, Chloroform-d) δ 7.33 – 7.23 (m, 2H), 7.24 – 7.14 (m, 3H), 5.38 (t, J = 6.9 Hz, 1H), 5.13 (q,
J = 6.6 Hz, 2H), 4.64 (t,1H), 4.26 (dd, J = 11.9, 6.4 Hz, 1H), 4.04 (dd, J = 11.9, 7.4 Hz, 1H), 3.91
(ddd, J = 11.1, 7.3, 3.3 Hz, 1H), 3.52 (dt, J = 10.5, 4.8 Hz, 1H), 2.81 – 2.65 (m, 2H), 2.33 – 2.22
(m, 2H), 2.19 – 2.02 (m, 6H), 2.02 – 1.92 (m, 2H), 1.92 – 1.79 (m, 1H), 1.70 (s, 3H), 1.67 (s, 3H),
1.63 (s, 1H), 1.61 (s, 3H), 1.59 – 1.47 (m, 4H).

13

C NMR (75 MHz, Chloroform-d) δ 142.66,

140.45, 135.36, 134.61, 128.55, 128.38, 125.81, 124.90, 124.12, 120.75, 97.96, 63.83, 62.46,
41.84, 39.84, 39.80, 34.99, 30.91, 26.80, 26.49, 25.71, 19.83, 16.64, 16.35, 16.22.

OTHP

2-(((2E,6E,10E)-3,7,11-trimethyl-12-phenyldodeca-2,6,10-trien-1-yl)oxy)tetrahydro-2H-pyran
(2.4b):

Yield: 46%. NMR: 1H NMR (300 MHz, Chloroform-d) δ 7.34 – 7.24 (m, 2H), 7.23 –
7.13 (m, 3H), 5.38 (t, J = 7.3 Hz, 1H), 5.24 (t, J = 6.3 Hz, 1H), 5.13 (t, J = 6.4 Hz, 1H), 4.71 –
4.57 (m, 1H), 4.25 (dd, J = 11.9, 6.4 Hz, 1H), 4.04 (dd, J = 11.9, 7.4 Hz, 1H), 3.90 (ddd, J =
11.2, 7.1, 3.8 Hz, 1H), 3.58 – 3.45 (m, 1H), 3.28 (s, 2H), 2.08 (tdd, J = 16.4, 8.7, 5.2 Hz, 8H),
1.69 (s, 3H), 1.67 – 1.44 (m, 10H). 13C NMR (75 MHz, Chloroform-d) δ 140.46, 135.25, 134.46,
129.00, 128.34, 126.57, 126.05, 124.29, 120.76, 97.97, 63.84, 62.48, 46.44, 39.83, 30.92, 26.82,
26.49, 25.71, 19.83, 16.64, 16.19, 15.99.

OTHP

2-(((2E,6E,10E)-12-cyclohexyl-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)oxy)tetrahydro-2Hpyran (2.4c):
Yield: 54%. NMR:

1

H NMR (300 MHz, Chloroform-d) δ 5.38 – 5.30 (m, 1H), 5.15 –

4.91 (m, 2H), 4.64 – 4.55 (m, 1H), 4.21 (dd, 1H), 4.00 (dd, J = 11.9, 7.4 Hz, 1H), 3.87 (ddd, J =
11.2, 7.1, 3.8 Hz, 1H), 3.60 – 3.36 (m, 1H), 2.19 – 1.90 (m, 7H), 1.88 – 1.77 (m, 3H), 1.73 – 1.34
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(m, 20H), 1.29 – 0.98 (m, 4H), 0.93 – 0.64 (m, 2H).

13

C NMR (75 MHz, Chloroform-d) δ

140.51, 135.41, 133.73, 125.64, 124.11, 120.73, 97.97, 63.84, 62.49, 48.25, 39.98, 39.89, 39.85,
35.68, 33.48, 30.93, 26.92, 26.77, 26.64, 26.49, 25.72, 19.85, 16.64, 16.19.

Representative procedure for the synthesis of 2.4d-f utilizing freshly synthesized Grignard
reagents:

OTHP

2-(((2E,6E,10E)-3,7,11-trimethyl-13-(o-tolyl)trideca-2,6,10-trien-1-yl)oxy)tetrahydro-2H-pyran
(2.4d):

To an oven-dried round bottom flask equipped with a magnetic stir bar was added
magnesium powder (40 eq, 20 mmol) and 6 mL of anhydrous Et2O and an iodide chip was added
to the round bottom and the mixture was stirred for 5 minutes. Next, 2-methylbenzyl chloride (10
eq, 5 mmol) in 2 mL of Et2O was added dropwise to the reaction vessel over a 10 minute period
and the reaction mixture was stirred for 4 hours. After the allotted time, the reaction mixture was
cooled to 0°C where diethyl phosphate 2.3 (1.0 eq, 0.5 mmol) dissolved in 2 mL of THF was
added dropwise to the mixture and the reaction was allowed to stir for 12 hours. The reaction
was quenched with 10% NH4Cl, the organic layer was removed, and the aqueous layer was
extracted 3 × Et2O (5 mL). The organic layers are combined, washed with brine, dried with
MgSO4, filtered, and concentrated. The crude reaction product was purified by column
chromatography using 5% Ethyl Acetate/Hexanes as the mobile phase to afford 2.4d in 61%
yield. NMR: 1H NMR (300 MHz, Chloroform-d) δ 7.20 – 6.99 (m, 4H), 5.44 – 5.32 (m, 1H),
5.21 – 5.04 (m, 2H), 4.62 (dd, J = 4.3, 2.7 Hz, 1H), 4.24 (dd, J = 11.8, 6.4 Hz, 1H), 4.03 (dd, J =
11.9, 7.4 Hz, 1H), 3.89 (ddd, J = 11.1, 7.6, 3.3 Hz, 1H), 3.62 – 3.46 (m, 1H), 2.73 – 2.58 (m, 2H),
2.31 (s, 3H), 2.25 – 2.17 (m, 2H), 2.16 – 1.93 (m, 8H), 1.91 – 1.78 (m, 1H), 1.68 (s, 6H), 1.60 (s,
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3H), 1.59 – 1.47 (m, 5H).

13

C NMR (75 MHz, Chloroform-d) δ 140.89, 140.50, 136.00, 135.40,

134.96, 130.27, 128.96, 126.08, 126.01, 124.77, 124.17, 120.75, 97.99, 63.86, 62.50, 40.59,
39.87, 39.83, 32.58, 30.93, 26.86, 26.52, 25.71, 19.84, 19.47, 16.67, 16.41, 16.25.

OTHP

2-(((2E,6E,10E)-3,7,11-trimethyl-12-(m-tolyl)dodeca-2,6,10-trien-1-yl)oxy)tetrahydro-2H-pyran
(2.4e):

Yield (45%). NMR: 1H NMR (300 MHz, Chloroform-d) δ 7.20 – 7.11 (m, 1H), 6.99 (t, J
= 9.2 Hz, 3H), 5.37 (t, J = 6.3 Hz, 1H), 5.23 (t, J = 6.3 Hz, 1H), 5.12 (t, J = 6.2 Hz, 1H), 4.62 (dd,
J = 4.2, 2.6 Hz, 1H), 4.24 (dd, J = 11.8, 6.4 Hz, 1H), 4.03 (dd, J = 11.9, 7.4 Hz, 1H), 3.89 (ddd, J
= 11.2, 7.3, 3.7 Hz, 1H), 3.51 (ddd, 1H), 3.23 (s, 2H), 2.32 (s, 3H), 2.20 – 1.98 (m, 7H), 1.85
(ddd, J = 17.9, 8.1, 5.4 Hz, 2H), 1.68 (s, 3H), 1.63 – 1.46 (m, 11H).

13

C NMR (75 MHz,

Chloroform-d) δ 140.56, 140.42, 137.80, 135.26, 134.52, 129.78, 128.20, 126.78, 126.41, 126.00,
124.23, 120.75, 97.92, 63.80, 62.44, 46.36, 39.81, 30.89, 26.84, 26.47, 25.69, 21.60, 19.80, 16.62,
16.19, 15.97.
F

OTHP

F

2-(((2E,6E,10E)-13-(3,4-difluorophenyl)-3,7,11-trimethyltrideca-2,6,10-trien-1yl)oxy)tetrahydro-2H-pyran (2.4f):
Yield (65%). NMR: 1H NMR (300 MHz, Chloroform-d) δ 7.08 – 6.95 (m, 2H), 6.89 –
6.78 (m, 1H), 5.34 (tq, J = 7.6, 6.0, 1.4 Hz, 1H), 5.14 – 4.99 (m, 1H), 4.60 (dd, J = 4.5, 2.6 Hz,
1H), 4.22 (dd, J = 11.9, 6.4 Hz, 1H), 4.00 (dd, J = 11.9, 7.4 Hz, 1H), 3.87 (ddd, J = 11.1, 7.3, 3.5
Hz, 1H), 3.49 (ddd, J = 10.6, 5.5, 3.6 Hz, 1H), 2.62 (dd, J = 9.3, 6.6 Hz, 2H), 2.29 – 1.72 (m,
11H), 1.66 (s, 3H), 1.63 – 1.42 (m, 11H).

19

= 20.7, 11.5, 8.2 Hz), -115.88 – -116.29 (m).

F NMR (282 MHz, Chloroform-d) δ -112.23 (ddd, J
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Representative procedure for the THP-deprotection of 2.5a-f:
OH

(2E,6E,10E)-3,7,11-trimethyl-13-phenyltrideca-2,6,10-trien-1-ol (2.5a):
In a scintillation vial equipped with a magnetic stir bar, 2.4a (1.0 eq, 0.38 mmol) was
dissolved in 5.0 mL of absolute EtOH and PPTS (0.1 eq, 0.038 mmol) was added to the vial. The
reaction mixture was heated to 75°C and stirred for 12 hours. Next, the reaction was cooled to
room temperature where it was poured into a separator funnel containing water and Et2O and the
aqueous layer was extracted 3 × 5 mL Et2O. The organic layers were combined and washed with
water then brine, dried with magnesium sulfate, and concentrated. The crude reaction product
was purified by column chromatography using 15% Ethyl Acetate/Hexanes as the mobile phase
to afford 2.5 a in 65% yield. NMR: 1H NMR (300 MHz, Chloroform-d) δ 7.33 – 7.24 (m, 2H),
7.24 – 7.15 (m, 3H), 5.43 (tq, J = 7.0, 5.4, 2.7, 1.3 Hz, 1H), 5.13 (tq, J = 8.1, 6.8, 5.6, 1.4 Hz,
2H), 4.16 (d, 2H), 2.76 – 2.66 (m, 2H), 2.34 – 2.21 (m, 2H), 2.21 – 1.92 (m, 8H), 1.70 (s, 3H),
1.67 (s, 3H), 1.61 (s, 3H).13C NMR (75 MHz, Chloroform-d) δ 142.59, 139.89, 135.42, 134.59,
128.48, 128.32, 125.75, 124.80, 123.93, 123.43, 59.51, 41.77, 39.71, 39.67, 34.91, 26.72, 26.43,
16.43, 16.29, 16.14. MS (EI) m/z [M++H]; MS (CI) m/z [M++H].

OH

(2E,6E,10E)-3,7,11-trimethyl-12-phenyldodeca-2,6,10-trien-1-ol (2.5b):
Yield (53%). NMR: 1H NMR (300 MHz, Chloroform-d) δ 7.28 (ddd, J = 7.7, 6.3, 1.6
Hz, 2H), 7.24 – 7.13 (m, 3H), 5.47 – 5.36 (m, 1H), 5.29 – 5.21 (m, 2H), 5.17 – 5.09 (m, 2H), 4.16
(d, J = 6.9 Hz, 2H), 2.27 – 1.86 (m, 9H), 1.69 (s, 77H), 1.62 (s, 3H), 1.54 (s, 3H).

13

C NMR (75

MHz, Chloroform-d) δ 140.65, 139.98, 135.38, 134.50, 129.01, 128.35, 126.54, 126.06, 124.16,
123.51, 59.59, 46.43, 39.79, 39.74, 26.81, 26.50, 16.51, 16.19, 15.99. MS (EI) m/z 298 [M+]; 280
[M+-H2O]; MS (CI) m/z 281 [(M++H)-H2O].
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OH

(2E,6E,10E)-12-cyclohexyl-3,7,11-trimethyldodeca-2,6,10-trien-1-ol (2.5c):
Yield (59%). NMR: 1H NMR (300 MHz, Chloroform-d) δ 5.41 (td, J = 6.6, 6.2, 1.7 Hz,
1H), 5.10 (t, 1H), 5.03 (t, 1H), 4.15 (d, J = 6.8 Hz, 2H), 2.05 (tt, J = 15.2, 5.8 Hz, 7H), 1.82 (d, J
= 7.1 Hz, 2H), 1.75 – 1.48 (m, 15H), 1.34 – 1.02 (m, 5H), 0.91 – 0.59 (m, 2H).

13

C NMR (75

MHz, Chloroform-d) δ 139.95, 135.46, 133.69, 125.52, 123.90, 123.41, 59.52, 48.17, 39.88,
39.68, 37.88, 35.59, 33.40, 26.84, 26.76, 26.67, 26.56, 26.43, 16.42, 16.11. MS (EI) m/z 304
[M+]; 286 [M+-H2O]; MS (CI) m/z 287 [(M++H)-H2O].
OH

(2E,6E,10E)-3,7,11-trimethyl-13-(o-tolyl)trideca-2,6,10-trien-1-ol (2.5d):
Yield (61%). NMR: 1H NMR (300 MHz, Chloroform-d) δ 7.19 – 7.04 (m, 4H), 5.41 (tq,
J = 7.0, 5.5, 2.6, 1.3 Hz, 1H), 5.20 – 5.03 (m, 2H), 4.14 (d, J = 6.9 Hz, 2H), 2.74 – 2.60 (m, 2H),
2.31 (s, 3H), 2.26 – 2.15 (m, 2H), 2.15 – 1.89 (m, 8H), 1.67 (s, 6H), 1.60 (s, 3H).

13

C NMR (75

MHz, Chloroform-d) δ 140.85, 139.98, 135.97, 135.50, 134.98, 130.25, 128.94, 126.07, 126.00,
124.72, 124.03, 123.48, 59.58, 40.57, 39.80, 39.76, 32.55, 26.82, 26.51, 19.46, 16.50, 16.39,
16.22. MS (EI) m/z 308 [M+-H2O]; MS (CI) m/z 309 [(M++H)-H2O].

OH

(2E,6E,10E)-3,7,11-trimethyl-12-(m-tolyl)dodeca-2,6,10-trien-1-ol (2.5e):
Yield (71%). NMR: 1H NMR (300 MHz, Chloroform-d) δ 7.22 – 7.09 (m, 1H), 6.98 (t,
J = 8.8 Hz, 3H), 5.47 – 5.38 (m, 1H), 5.29 – 5.20 (m, 1H), 5.18 – 5.08 (m, 1H), 4.14 (d, J = 7.0
Hz, 2H), 3.25 (d, J = 10.4 Hz, 2H), 2.32 (s, 3H), 2.19 – 1.91 (m, 8H), 1.68 (d, J = 1.3 Hz, 3H),
1.61 (d, J = 1.4 Hz, 3H), 1.53 (d, J = 1.3 Hz, 3H).

13

C NMR (75 MHz, Chloroform-d) δ 140.54,
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139.89, 137.82, 135.39, 134.55, 129.78, 128.21, 126.78, 126.38, 126.00, 124.11, 123.48, 59.53,
46.35, 39.79, 39.72, 26.82, 26.49, 21.60, 16.47, 16.18, 15.98. MS (EI) m/z 294 [M+-H2O]; MS
(CI) m/z 295 [(M++H)-H2O].
F

OH

F

(2E,6E,10E)-13-(3,4-difluorophenyl)-3,7,11-trimethyltrideca-2,6,10-trien-1-ol (2.5f):
Yield (26%). NMR: 1H NMR (300 MHz, Chloroform-d) δ 7.10 – 6.90 (m, 2H), 6.90 –
6.72 (m, 1H), 5.41 (dt, 1H), 5.22 – 4.84 (m, 2H), 4.15 (d, J = 7.0 Hz, 2H), 2.65 (t, 2H), 2.29 –
2.17 (m, 2H), 2.14 – 2.01 (m, 6H), 2.00 – 1.91 (m, 2H), 1.68 (s, 3H), 1.63 (s, 3H), 1.58 (s, 3H),
2.71 – 2.53 (m, 3H).

13

C NMR (126 MHz, Chloroform-d) δ 150.46 (dd, J = 181.6, 12.6 Hz),

148.50 (dd, J = 180.1, 13.0 Hz), 139.95, 139.46 (dd), 135.38, 133.81, 125.53, 124.31 (dd, J = 5.9,
3.4 Hz), 124.05, 123.49, 117.22 (d, J = 16.6 Hz), 116.92 (d, J = 16.8 Hz), 59.58, 41.47, 39.74,
39.72, 33.96, 26.73, 26.48, 16.48, 16.25, 16.17.

19

F NMR (282 MHz, Chloroform-d) δ -111.86 –

-112.44 (m), -115.95 – -116.22 (m). MS (EI) m/z 330 [M+-H2O]; MS (CI) m/z 331 [(M++H)H2O].

Representative procedure for the synthesis of pyrophosphates 2.6a-f.

OPP

(2E,6E,10E)-3,7,11-trimethyl-13-phenyltrideca-2,6,10-trien-1-yl diphosphate (2.6a):
To an oven-dried round bottom flask equipped with a magnetic stir bar was added NCS
(2.5 eq, 0.39 mmol) in 0.8 mL of CH2Cl2 and cooled to -30°C where dimethyl sulfide (2.5 eq,
0.39 mmol) was added dropwise to the reaction. Following the addition, the mixture is then
placed in a 0°C ice bath and stirred for 5 minutes before being recooled back to -30°C. Next,
alcohol 2.5a (1 eq, 0.16 mmol) is dissolved in 0.3 mL of CH2Cl2 and added dropwise to the
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reaction mixture. The mixture is then placed in a 0°C ice bath and stirred for 2.5 hours coming to
room temperature. After the allotted time, brine is added to the reaction mixture and the organic
layer was extracted. The aqueous layer was further extracted 3 × 5 mL CH2Cl2 and the organic
layers were combined, dried with magnesium sulfate, and concentrated. The crude reaction
product was used immediately in the following step.
To another oven-dried round bottom flask equipped with a magnetic stir bar was added
tris (tetrabutylammonium) hydrogen pyrophosphate (3.0eq, 0.47 mmol) dissolved in 2.0 mL of
acetonitrile. Next, a solution of crude allylic chloride dissolve in 1.4 mL acetonitrile was added
dropwise to the reaction vessel. The reaction was stirred for 3 hours at room temperature and
then the solvent was removed by rotary evaporation at 34°C. The residue was the dissolve in a
minimal amount of ion exchange NH3HCO3 buffer (700mg NH3HCO3, 1 L of deionized H2O, 20
mL of isopropanol) and the resulting solution was passed through a Dowex AG 50 × 8 ion
exchange column (2 × 8 cm) using the NH3HCO3 buffer as an eluent and 25 mL was collected in
a flask. The resulting solution was lyophilized for 3-5 hours. The resulting residue was then
redissolved in deionized watered and purified by cellulose flash column chromatography (3 × 15
cm) using isopropanol:deionized H2O:acetonitrile: NH3HCO3 buffer (500 mL : 250 mL : 250 mL
: 4 g) as the eluent. In a beaker was collected 40 mL of eluent, then twenty-four 2.5 mL fractions
were collected. Typically, fractions 12-18 were collected and the organic solvents were removed
by rotary evaporation at 34°C.

The resulting solution was then lyophilized to afford

pyrophosphate (2.6a) as a white fluffy solid in 58% yield. 1H NMR (500 MHz, Deuterium Oxide)
δ 7.02 – 6.91 (m, 3H), 6.92 – 6.81 (m, 2H), 5.35 (s, 1H), 5.11 (s, 2H), 4.40 (s, 2H), 2.42 (s, 2H),
1.95 (d, J = 45.4 Hz, 10H), 1.80 (s, 3H), 1.62 (s, 6H).

31

P NMR (202 MHz, Deuterium Oxide) δ -

10.77 (d, J = 19.3 Hz), -13.91 (d, J = 17.9 Hz). HRMS 471.1706 [M+2H]-, calculated 471.1702
(C22H33O7P2).
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OPP

(2E,6E,10E)-3,7,11-trimethyl-12-phenyldodeca-2,6,10-trien-1-yl diphosphate (2.6b):
Yield (51%). 1H NMR (500 MHz, Deuterium Oxide) δ 6.99 (s, 2H), 6.92 (s, 3H), 5.51 –
5.01 (m, 3H), 4.44 (s, 2H), 3.19 (s, 2H), 2.03 (d, J = 41.5 Hz, 8H), 1.68 (s, 3H), 1.58 (s, 3H), 1.55
(s, 3H).

31

P NMR (202 MHz, Deuterium Oxide) δ -10.06, -13.94. HRMS 457.1554 [M+2H]-,

calculated 547.1545 (C21H31O7P2).

OPP

(2E,6E,10E)-12-cyclohexyl-3,7,11-trimethyldodeca-2,6,10-trien-1-yl diphosphate (2.6c):
Yield (60%). 1H NMR (500 MHz, Deuterium Oxide) δ 5.41 (s, 1H), 5.14 (s, 1H), 5.08 (s,
1H), 4.44 (s, 2H), 2.03 (d, J = 53.2 Hz, 8H), 1.83 (d, J = 6.9 Hz, 2H), 1.69 (s, 3H), 1.69 – 1.59
(m, 6H), 1.60 (s, 3H), 1.55 (s, 3H), 1.29 – 1.04 (m, 5H), 0.81 (d, J = 11.5 Hz, 2H).
MHz, Deuterium Oxide) δ -12.36, -14.33.

31

P NMR (202

HRMS 463.2022 [M+2H]-, calculated 463.2015

(C21H37O7P2).

OPP

(2E,6E,10E)-3,7,11-trimethyl-13-(o-tolyl)trideca-2,6,10-trien-1-yl diphosphate (2.6d):
Yield (75%). 1H NMR (500 MHz, Deuterium Oxide) δ 6.80 (s, 4H), 5.36 (s, 1H), 5.01 (s,
2H), 4.42 (s, 2H), 2.39 (s, 2H), 2.24 – 1.79 (m, 13H), 1.64 (s, 3H), 1.47 (s, 3H), 1.43 (s, 3H).31P
NMR (202 MHz, Deuterium Oxide) δ -11.24 (d, J = 19.1 Hz), -13.98 (d, J = 17.6 Hz). HRMS
485.1860 [M+2H]-, calculated 485.1858 (C23H35O7P2).
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OPP

(2E,6E,10E)-3,7,11-trimethyl-12-(m-tolyl)dodeca-2,6,10-trien-1-yl diphosphate (2.6e):
Yield (87%).

1

H NMR (500 MHz, Deuterium Oxide) δ 6.81 (s, 3H), 6.70 (s, 2H), 5.39

(s, 1H), 5.09 (d, J = 26.3 Hz, 2H), 4.43 (s, 2H), 2.98 (s, 2H), 2.09 (s, 3H), 2.00 (s, 8H), 1.65 (s,
3H), 1.50 (s, 3H), 1.36 (s, 3H). 31P NMR (202 MHz, Deuterium Oxide) δ -10.17 (d, J = 16.2 Hz),
-13.92 (d, J = 16.2 Hz). HRMS 471.1704 [M+2H]-, calculated 471.1702 (C22H33O7P2).
F

OPP

F

(2E,6E,10E)-13-(3,4-difluorophenyl)-3,7,11-trimethyltrideca-2,6,10-trien-1-yl diphosphate (2.6f):
Yield (94%). 1H NMR (500 MHz, Deuterium Oxide) δ 6.82 (s, 1H), 6.69 (d, J = 26.5 Hz,
2H), 5.36 (s, 1H), 4.99 (s, 1H), 4.94 (s, 1H), 4.41 (s, 2H), 2.44 (s, 2H), 2.00 (s, 2H), 1.91 (s, 6H),
1.78 (s, 2H), 1.63 (s, 3H), 1.47 (s, 6H).

31

13.0 Hz), -13.75 (d, J = 10.6 Hz).

P NMR (202 MHz, Deuterium Oxide) δ -9.98 (d, J =
HRMS 507.1518 [M+2H]-, calculated 507.1513

(C22H31F2O7P2).

Br

OH

(E)-5-bromo-3-methylpent-2-en-1-ol (2.8):
Cp2ZrCl2 (0.25 eq, 3.75mmol) was dissolved in 15 mL dichloromethane and the solution
was cooled to 0°C, where a Me3Al solution (2.0 M in heptanes, 2.5eq, 37.5mmol) was added
dropwise. After stirring the reaction mixture at 0°C for 30 minutes, 4-bromo-1-butyne (1.0 eq, 15
mmol) was diluted in 7.5 mL of dichloromethane and added to the reaction mixture dropwise.
The reaction mixture was allowed to slowly warm to room temperature and stirred an additional
12 hours. Next, the reaction mixture was cooled to 0°C, where (CH2O)n (5 eq, 75 mmol) was
added in several portions. The reaction continued to stir for 3 hours after which it was slowly
poured into an ice-cold 10% HCl(aq) solution. The solution was then filtered over a pad of Celite
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545, extracted with 3 × 50 mL dichloromethane, washed with brine, dried with magnesium
sulfated, filtered, and concentrated.

Column chromatography (30% Ethyl acetate in Hexanes)

afforded 2.8 in 85% yield.

Br

OTHP

(E)-2-((5-bromo-3-methylpent-2-en-1-yl)oxy)tetrahydro-2H-pyran (2.9):
(E)-5-bromo-3-methylpent-2-en-1-ol (1 eq, 31.32 mmol) was dissolved in 100 mL of
dichloromethane where PPTS (0.1 eq, 3.13 mmol) and 2,3-dihydropyran (3.0 eq, 94 mmol) were
added to the reaction vessel. The reaction was allowed to stir for 1 hour at room temperature and
was then concentrated down and loaded directly onto a silica flash column ( % Ethyl acetate in
Hexanes) to afford 2.9 in 79% yield. 1H NMR (300 MHz, Chloroform-d) δ 5.46 – 5.38 (m, 1H),
4.60 (t, J = 3.5 Hz, 1H), 4.21 (dd, J = 12.2, 6.3 Hz, 1H), 4.02 (dd, J = 12.2, 7.3 Hz, 1H), 3.91 –
3.79 (m, 1H), 3.43 (t, J = 7.5 Hz, 2H), 2.56 (t, J = 7.4 Hz, 2H), 1.89 – 1.71 (m, 1H), 1.67 (s, 3H),
1.64 (d, J = 1.0 Hz, 1H), 1.61 – 1.43 (m, 5H).

13

C NMR (75 MHz, Chloroform-d) δ 136.82 (s),

124.04 (s), 98.09 (s), 77.65 (s), 77.23 (s), 76.80 (s), 63.56 (s), 62.58 (s), 42.83 (s), 30.99 (d, J =
19.6 Hz), 25.66 (s), 19.81 (s), 16.23 (s).

4-(but-3-yn-1-yl)-1,1'-biphenyl (2.12):
An oven-dried round bottom flask equipped with a magnetic stir bar was charged with 1(trimethylsilyl)propyne (2.5 eq, 7.5 mmol) dissolved in 9.5 mL of anhydrous THF and cooled to 78°C. Next, n-BuLi (2.5 eq, 7.5 mmol) was slowly added to the mixture and the reaction was
allowed to stir 1.5 hours. After the allotted time, 2.10a (1.0 eq, 3 mmol) in 15 mL of THF was
added dropwise to the reaction vessel at -78°C. The reaction was allowed to stir for an additional
12 hours after which time the reaction was quenched by the addition of 10% NH4Cl. The organic
layer was removed, and the aqueous layer was extracted 3 × Et2O (5 mL). The organic layers
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were combined, washed with brine, dried with MgSO4, filtered, and concentrated. The crude
reaction product was then dissolved in a saturated K2CO3/MeOH solution and stirred for an
additional 4 hours. Next, the reaction was poured into a separator funnel containing water and
Et2O and the aqueous layer was extracted 3 × 15 mL Et2O. The organic layers were combined
and washed with water then brine, dried with magnesium sulfate, and concentrated. The crude
reaction product was purified by column chromatography using 2.5% Ethyl Acetate/Hexanes as
the mobile phase to afford 2.12 in 36% yield. NMR: 1H NMR (300 MHz, Chloroform-d) δ 7.62
– 7.49 (m, 4H), 7.42 (t, J = 7.8 Hz, 2H), 7.37 – 7.26 (m, 3H), 2.88 (t, J = 7.5 Hz, 2H), 2.52 (td, J
= 7.5, 2.6 Hz, 2H), 1.99 (t, J = 2.6 Hz, 1H). 13C NMR (75 MHz, Chloroform-d) δ 139.70, 139.53,
129.04, 128.93, 127.35, 127.22, 83.99, 69.22, 34.67, 20.75.

N

OTHP

N N

(E)-4-(2-([1,1'-biphenyl]-4-yl)ethyl)-1-(3-methyl-5-((tetrahydro-2H-pyran-2-yl)oxy)pent-3-en-1yl)-1H-1,2,3-triazole (2.13):
To a scintillation vial equipped with a magnetic stir bar was added bromide 2.9 (1.0 eq,
0.85 mmol) and 4.5 mL of DMF. Next, NaN3 (3 eq, 2.55 mmol), sodium ascorbate (0.5 eq,.43
mmol), and CuSO4·H2O (0.25 eq, 0.21 mmol) are added sequentially to the vial. Alkyne 2.12
(1.2 eq, 1.02 mmol) was then dissolved in 2.3 mL of DMF and added to the vial. The reaction
was heated to 70°C and allowed to stir for 36 hours. The reaction was then quenched with 10%
NH4Cl and the aqueous layer was extracted 3 × EtOAC (10 mL). The organic layers were
combined, washed with brine, dried with MgSO4, filtered, and concentrated. The crude reaction
product was purified by column chromatography using 60% Ethyl Acetate/Hexanes as the mobile
phase to afford 2.13 in 20% yield. 1H NMR (300 MHz, Chloroform-d) δ 7.60 – 7.20 (m, 9H),
7.11 (s, 1H), 5.33 (s, 1H), 4.53 (t, J = 3.6 Hz, 1H), 4.39 (t, J = 7.4 Hz, 2H), 4.23 – 3.91 (m, 2H),
3.83 (s, 1H), 3.50 (s, 1), 3.03 (q, J = 3.3 Hz, 4H), 2.55 (t, J = 7.4 Hz, 2H), 1.68 (s, 5H), 1.51 (tq, J
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= 7.3, 4.3, 2.9 Hz, 4H). 13C NMR (75 MHz, Chloroform-d) δ 147.27, 141.04, 140.46, 139.12,
135.13, 129.02, 128.86, 127.21, 127.08, 124.46, 120.95, 98.10, 63.42, 62.50, 48.63, 40.26, 35.35,
30.80, 27.58, 25.56, 19.72, 16.41.

OH

N
N N

(E)-5-(4-(2-([1,1'-biphenyl]-4-yl)ethyl)-1H-1,2,3-triazol-1-yl)-3-methylpent-2-en-1-ol (2.14):
In a scintillation vial equipped with a magnetic stir bar, 2.13 (1.0 eq, 0.17 mmol) was
dissolved in 5.0 mL of absolute EtOH and PPTS (0.1 eq, 0.02 mmol) was added to the vial. The
reaction mixture was heated to 75°C and stirred for 12 hours. Next, the reaction was cooled to
room temperature where it was poured into a separator funnel containing water and EtOAc and
the aqueous layer was extracted 3 × 5 mL EtOAc. The organic layers were combined and washed
with water then brine, dried with magnesium sulfate, and concentrated. The crude reaction
product was purified by column chromatography using 5% MeOH/ CH2Cl2 as the mobile phase to
afford 2.14 in 85% yield. 1H NMR (300 MHz, Chloroform-d) δ 7.65 – 6.97 (m, 9H), 5.46 – 5.21
(m, 1H), 4.38 (t, J = 7.2 Hz, 2H), 4.07 (d, J = 6.7 Hz, 2H), 3.03 (h, J = 1.9 Hz, 4H), 2.53 (t, J =
7.2 Hz, 2H), 1.67 (s, 3H).

13

C NMR (75 MHz, Chloroform-d) δ 147.41, 147.38, 141.09, 140.50,

140.47, 139.19, 134.52, 129.13, 128.96, 127.32, 127.27, 127.14, 127.09, 121.08, 59.21, 48.66,
40.31, 35.35, 27.57, 16.33. MS (ESI) m/z 348 [M++H].

N

OPP

N N

(E)-5-(4-(2-([1,1'-biphenyl]-4-yl)ethyl)-1H-1,2,3-triazol-1-yl)-3-methylpent-2-en-1-yl
diphosphate (2.15):
To an oven-dried round bottom flask equipped with a magnetic stir bar was added
methanesulfonyl chloride (1.3 eq, 0.09 mmol), DMAP (1.5 eq, 0.10 mmol) and 0.4 mL of
dichloromethane. The mixture was cooled to 0°C and a solution of alcohol 2.14 in 0.2 mL of
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dichloromethane was added dropwise to the reaction vessel and allowed to stir for 2.5 hours.
Hexanes were then added to the reaction vessel and the solution was filtered and concentrated.
Next, Et2O was added to the crude product and was again filtered and concentrated. The crude
allylic chloride was then converted to the pyrophosphate following the same method described
for 2.6a-f. Yield (89%). 1H NMR (500 MHz, Deuterium Oxide) δ 7.93 – 6.96 (m, 10H), 5.27 (s,
1H), 4.34 (s, 2H), 4.20 (s, 2H), 2.80 (s, 4H), 2.35 (s, 2H), 1.53 (s,3H).

31

P NMR (202 MHz,

Deuterium Oxide) δ -9.89 (d, J = 14.0 Hz), -13.85 (d, J = 18.0 Hz). HRMS 506.1252 [M+2H]-,
calculated 506.1246 (C22H26N3O7P2).

General procedure for in vitro biochemical substrate screening:

All biochemical evaluations were performed in our collaborator Dr. Carol Fierke’s
laboratory at the University of Michigan by Elia Wright.

Preliminary evaluation of all

pyrophosphate analogs were performed using GGPP analog (1, 5, or 10 µM), the peptide dansylGCVLL (5 µM), recombinant mammalian GGTase-I (50 nM), 50 nM HEPPSO (N-2hydroxyethylpiperazine-N’-2-hydroxypropanesulfonic

acid)

pH

7.8,

5

mM

tris(2carboxyethyl)phosphine (TCEP), and 5 mM MgCl2 at 25°C in 96 well plates (Corning).
Protein prenylation was determined by monitoring the dansylated peptide using a continuous
spectrofluorometic assay and all assays were performed in triplicate. Upon prenylation of the
peptide, the activity was measured by an increase in fluorescence intensity of the dansyl group
(λex = 340 nm, λem = 520 nm) in a POLARstar Galaxy plate reader. Peptide in assay buffer was
utilized as a negative control and the baseline fluorescence of the peptide was subtracted from the
reaction signal.
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CHAPTER 3. SYNTHESIS & BIOCHEMICAL EVALUATION OF SATURATED
GERANYLGERANYL PYROPHOSPHATE ANALOGS

3.1

Introduction

It is known that the first isoprene is critical for substrate activity. Addition of one methylene
unit between the double bond of the first isoprene and the pyrophosphate moiety of FPP converts
the native substrate of FTase into an inhibitor.80 It is still unclear whether or not the other
isoprene units are required for substrate activity. In the past, there have been several inhibitors of
GGTase-I that contain long saturated hydrocarbon chains with some of these inhibitors displaying
submicromolar IC50’s.119

Some of these inhibitors are bisubstrate inhibitors that contain

components that mimic both the peptide substrate (Figure 3.1, blue) and the isoprenoid chain
(Figure 3.1, red). Such compounds led us to question whether or not the β, γ, and ω isoprene
units are essential for enzyme activity (Figure 3.2). To address the query, we synthesized a
variety of pyrophosphate analogs in which one or more of the isoprene units were removed.
In order to determine if the α-isoprene is sufficient to produce substrate activity, the first set
of analogs synthesized contained compounds in which the β, γ, and ω isoprene units were
removed from GGPP and replaced with aliphatic chains (Figure 3.3). Next, analogs that contain
only the α- and β-subunits were synthesized. This means that the ω-isoprene is missing in the
case of FPP or that both the γ and ω-isoprene units are missing in GGPP. These analogs vary in
length between that of FPP and GGPP and will determine if the first two isoprene units are
sufficient for substrate activity.
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Next, the ω-isoprene unit was re-installed to obtain compounds that lack the β and γ isoprene
units. These compounds will examine the importance of the central isoprene units and whether or
not they are required for substrate activity.
tetrahydrogeranylgeranyl

pyrophosphate

Finally, we synthesized (2E,6E)-10,11,14,15and

(2E,6E,10E)-14,15-dihydrogeranylgeranyl

pyrophosphate (Figure 3.3). The dihydro-GGPP analog lacks the ω double bond but retains the
methylene unit at the 15 position (Figure 3.2). The tetrahydro-GGPP analog lacks both the γ and
ω double bonds but retains the methylene units at the 11 and 15 positions (Figure 3.2). When
compared to the saturated GGPP analogs and GGPP itself, these analogs will aid in determining
the significance of the “isopropyl” motif.
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Figure 3.1. Inhibitors of GGTase-I that contain saturated hydrocarbon moieties.119
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Figure 3.2. Conventional method of isoprene unit labeling.

Figure 3.3. Saturated GGPP analogs synthesized.
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3.2

Synthesis of Saturated Geranylgeranyl Pyrophosphate Analogs

The synthesis of the saturated GGPP analogs began with the compounds containing only
the α-isoprene unit. The synthesis of these three analogs was simple and straight forward
(Scheme 3.1). Briefly, commercially available alkynes 3.1 were subjected to Negishi’s ZACA
reaction and quenched with paraformaldehyde to afford alcohols 3.2a-c in 50-58% yields.114
Next,

these

alcohols

underwent

Corey-Kim

chlorination

with

NCS

followed

by

pyrophosphorylation according to the procedure of Davisson et al. to produce the pyrophosphates
3.3a-c in moderate to good yields.112, 113

Next, we focused on the synthesis of analogs that contain only the α- and β-subunits
(Scheme 3.2). To synthesize these compounds, commercially available alkynes 3.4 underwent
Negishi’s ZACA reaction followed by and iodine quench to provided vinyl iodides 3.5a-d.
Previously synthesized bromide 2.8 can then be converted into the organoborane and coupled to
vinyl iodides 3.5a-d via a Suzuki coupling reaction to yield alcohols 3.6a-d.120 Following a THP
deprotection with PPTS/EtOH and standard chlorination/pyrophosphorylation procedures,112, 113
diphosphates 3.7a-d were obtained in moderate to good yields.
We then turned our attention to the synthesis of analogs where the ω-isoprene unit was
reinstalled to obtain compounds that lack the β- and γ-isoprene units (Scheme 3.3). In general,
commercially available diol 3.7 was subjected to mono-iodination. With halo-alcohols 3.7 and
3.10 in hand, Swern oxidations afforded aldehydes 3.8 and 3.11, which then underwent Wittig

reactions to install the ω-isoprene of 3.9 and 3.12. With these two alkenyl iodides in hand, we
turned our attention to synthesizing vinyl iodide 3.14. This was accomplished by first generating
the Schwartz’s reagent in situ following a method developed by Huang & Negishi.121 Following
the addition of TBDMS-protected but-2-yn-1-ol, hydrozirconation-iodinolysis proceeds to yield
vinyl iodide 3.14. Alkyl iodides 3.9 and 3.12 were then converted into their corresponding
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organoboranes and coupled to vinyl iodide 3.14 via Suzuki coupling to yield vinyl alcohols
3.15a-b. Utilizing standard chlorination/pyrophosphorylation procedures, diphosphates 3.16a-d

were afforded.
The synthesis of tetrahydro-GGPP began with the synthesis of diethyl phosphate 3.18,
which was accomplished in a similar manner as 2.3 (Scheme 3.4).111 The remainder of this
synthesis followed the methodology used to synthesize the aryl-modified analogs of Chapter 2.
First, Grignard reagent 3.17 was generated from the corresponding bromide followed by the slow
addition of diethyl phosphate 3.18 to the reaction lead to a SN2 displacement of the phosphate
group. Next, standard THP-deprotection yielded alcohol 3.20. Again, standard chlorination and
pyrophosphorylation procedures were utilized to generate diphosphate 3.21.
The final compound of this series, dihydro-GGPP (3.26), was accomplished using a
Cu(I)-mediated Grignard displacement of an allylic THP-ether.110, 122 Briefly, alcohol 3.22 was
protected as the THP-ether and then deacetylated using standard protocols. After Grignard
reagent 3.24 was generated from the corresponding bromide, it was slowly added to a cooled
solution of THP-ether 3.23 and Cu(I)Br to yield alcohol 3.25. It is crucial to keep this reaction at
-10°C to avoid degradation of the organocuprate intermediate.

Following standard

chlorination/pyrophosphorylation procedures, diphosphate 3.26 was afforded in 28% yield.
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Scheme 3.1. Synthesis of α-containing pyrophosphates. (a) i. Me3Al, Cp2ZrCl2, DCM 0°C, 18
hr; ii. (CH2O)n, 3 hr; (b) NCS, DMS, DCM, 0°C to rt, 2.5 hr; (c) (NBu4)3 HP2O7, ACN, 2.5 hr.

Scheme 3.2. Synthesis of α & β-containing pyrophosphates. (a) i. Me3Al, Cp2ZrCl2, DCM, 0°C,
18 hr, then I2, 3 hr, (b) i. t-BuLi, Et2O, -78°C, ii. β-MeO-9-BBN, THF, -78°C warming to RT o/n,
iii. K3PO4, PdCl2(dppf), DMF, 85°C, 18 hr; (c) PPTS, MeOH, 60°C (Yields given for 2 steps); (d)
NCS, DMS, DCM, 0°C to rt, 2.5 hr; (e) (NBu4)3HP2O7, ACN, 2.5 hr.
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Scheme 3.3. Synthesis of α & ω-containing pyrophosphates. (a) PPh3, Imidazole, I2, DCM, 0°C;
(b) (COCl)2, DMSO, Et3N, DCM, -78°C (28%); (c) i-PrPh3I, n-BuLi, THF, -78°C; (d) i.
Cp2ZrCl2, DIBAL, THF, 0°C, 0.5 hr; ii. 3.13, warm to rt, 1.5 hr; iii. I2, THF, -78°C, 0.5 hr; (e) i.
DIEA, TBDMSCl, DCM (95%); ii. DIBAL, Cp2ZrCl2, THF, 0°C (40%); (f) i. t-BuLi, Et2O, 78°C, ii. β-MeO-9-BBN, THF, -78°C warming to RT o/n; iii. K3PO4, PdCl2(dppf), DMF, 85°C,
18 hr; (g) TBAF, THF, 0°C; (h) NCS, DMS, DCM, 0°C to rt, 2.5 hr; (i) (NBu4)3 HP2O7, ACN,
2.5 hr.
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Scheme 3.4. Synthesis of tetrahydro-GGPP. (a) R-MgX, THF, o/n (15%); (b) PPTS, EtOH,
70°C (70%); (c) NCS, DMS, DCM, 2.5 hr.; (d) (NBu4)3HP2O7, ACN, 3 hr (52% - 2 steps).

Scheme 3.5. Synthesis of dihydro-GGPP. (a) i. DHP, PPTS, DCM; (b) saturated K2CO3/MeOH,
(74% - 2 steps); (c) 3.24, Cu(I)Br, THF, -10°C, 48 hr (17%); (d) NCS, DMS, DCM, 2.5 hr; (e)
(NBu4)3HP2O7, ACN, 3 hr (28%).
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3.3

Biochemical Evaluation of Saturated Geranylgeranyl Pyrophosphate Analogs

In the past, little has been done to investigate the isoprene requirements of GGTase-I.
While it is known that the α-isoprene is required for substrate activity, it is unclear if the
remaining three isoprenes are essential for enzyme recognition and activity. Therefore, our goal
was to synthesize a library of compounds that was lacking the β, γ, or ω isoprene units or lacking
a combination of isoprene units. These analogs were designed to range in length between FPP
(12 carbons long) and GGPP (16 carbons long). The saturated GGPP analogs synthesized (3.3ac, 3.7a-d, 3.16a-b, 3.21, & 3.24) were evaluated for their biochemical activity in an in vitro

continuous spectrofluorometric assay with GGTase and the co-substrate CaaX-peptide dansylGCVLL.

All biochemical assays were performed in our collaborator Dr. Carol Fierke’s

laboratory at the University of Michigan by Elia Wright.
It appears that all of the saturated compounds synthesized display some degree of
substrate activity.

The first set of compounds containing only the α-isoprene unit (3.3a-c)

revealed that GGTase-I can recognize and utilize these compounds as substrates (Figure 3.4);
however, it is evident that the length of the aliphatic carbon chain plays a definite role in the level
of enzyme activity. When the carbon chain length is 14 carbons (3.3a) we notice that the
substrate activity is greatly diminished when compared to GGPP; however, when the carbon
chain length is increased to 16 carbons (3.3c), the same length as GGPP, we see an increase in
substrate activity although it is still much less than GGPP.
In order to determine if any substrate activity could be regained, we synthesized
compounds that contained both the α- and β-isoprene units (3.7a-d). Indeed, replacing the βsubunit of 3.3a (14 carbons long) to generate 3.7b resulted in a moderate increase of substrate
activity (Figure 3.5); however the same modification to 3.3c (16 carbons long) to generate 3.7d
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only led to a minimal increase in substrate activity. Although decreasing the length of the carbon
chain to 13 carbons seemed to hinder substrate activity, increasing the carbon chain from 14 to 16
carbons did not appear to greatly affect the substrate activity.
The next two analogs tested contained only the α- and ω-isoprene units (3.16a-b; Figure
3.6). These compounds were synthesized for two main reasons: (1) could we increase substrate

activity when compared to compounds containing only α-isoprene units and (2) are the two
central isoprene units necessary for substrate activity. In fact, replacing the ω-subunit of 3.3c to
generate 3.16b resulted in an increase in activity. Similar to the α-isoprenoid analogs, we noticed
that by decreasing the length of the carbon chain from 16 carbons (3.16b; the length of GGPP) to
15 carbons (3.16a) resulted in a significant decrease of substrate activity.
The final two compounds analyzed lacked the γ and/or ω isoprene double bonds but
retained the methylene units (3.21 & 3.26). Interestingly, when both the γ and ω double bond are
saturated the substrate activity greatly decreases (Figure 3.7). When compared to other saturated
molecules of the same length (e.g. 3.3a and 3.7d), analog 3.21 is a poorer substrate. One possible
explanation for this observation is that the compound has a chiral carbon at position 7 and was
synthesized as a mixture of isomers. Thus, it is possible that only one isomer is active. A more
likely explanation is molecular geometry. With the double bonds in place, the geometry of the
molecule is planar; however, by removing the double bonds the molecular geometry changes
from planar to tetrahedral. This change in geometry could lead to unfavorable interaction with
the active site of the enzyme and ultimately reduce substrate ability. Analog 3.26 also displayed
substrate activity, but is being retested due to an abnormality at 5µM analog.
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*100 ± 0.73%
*56 ± 2.0%
(Same length as GGPP)
*8.2 ± 7.1%

*23 ± 0.62%

Figure 3.4. Bar graphs of substrate activity represented in RFI of saturated GGPP analogs 3.3a-c
versus GGPP (+ control) with 5 µM dansyl-GCVLL and 50 nM GGTase-I. Error bars represent
mean ± SD (n = 3). *Values give are for 10 µM analog at time 1.5 hours.

*63± 3.3%
(Same length
as GGPP)

*100 ± 0.73%
*59 ± 1.6%
6

†

22 ± 1.7%

OPP

8

7

OPP

OPP

*46 ± 3.4%
5

OPP

Figure 3.5. Bar graphs of substrate activity represented in RFI of saturated GGPP analogs 3.7a-d
versus GGPP (+ control) with 5 µM dansyl-GCVLL and 50 nM GGTase-I. Error bars represent
mean ± SD (n = 3). Values give are for †5µM or *10 µM analog at time 1.5 hours.
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OPP
10

*100 ± 0.73%
*88 ± 1.6%
(Same length as GGPP)

OPP
9

*16 ± 1.1%

Figure 3.6. Bar graphs of substrate activity represented in RFI of saturated GGPP analogs 3.16ab versus GGPP (+ control) with 5 µM dansyl-GCVLL and 50 nM GGTase-I. Error bars represent
mean ± SD (n = 3). * Values give are for 10 µM analog at time 1.5 hours.

*27 ± 0.84%

*100 ± 0.73%

*22 ± 6.2%
OPP

Figure 3.7. Bar graphs of substrate activity represented in RFI of saturated GGPP analogs 3.21
& 3.26 versus GGPP (+ control) with 5 µM dansyl-GCVLL and 50 nM GGTase-I. Error bars
represent mean ± SD (n = 3). * Values give are for 10 µM analog at time 1.5 hours.

1 µM Analog

5 µM Analog
1.0
GGPP

GGPP

0.3

3.3a

3.3a

0.8

3.3b

3.3b

3.3c

3.3c

0.2

3.7c

RFI

RFI

3.7b

3.7a

0.6

3.7a

3.7b
3.7c
3.7d

0.4

3.16a

3.7d

0.1

3.16b

3.16a
3.16b

0.0
0.5

1.0

1.5

2.0

2.5

3.21
3.26

0.2

3.21
3.26

0.0
0.5

Time (hr)

1.0

1.5

2.0

2.5

Time (hr)
-0.2

10 µM Analog
1.0

GGPP
3.3a
3.3b
3.3c
3.7a

0.5

RFI

3.7b

Figure 3.8. Monitoring continuous changes in fluorescence of saturated
GGPP analogs versus GGPP (+ control) at various concentrations (1 µM,
5µM, & 10µM) with 5 µM dansyl-GCVLL and 50 nM GGTase-I. 0.0
Experiments were performed in triplicate and data points represent the mean.
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3.4

Conclusions

The goal of this chapter was to focus on the synthesis of a small library of saturated
GGPP analogs in order to determine the isoprene requirements of the enzyme GGTase-I. While
various types of FPP and GGPP analogs have been synthesized in the past (Figure 1.9), it was
unknown if all of the isoprene units were required for enzyme recognition and activity.
This aim was centered on designing synthetic routes that would enable us to rapidly
develop our small library of compounds.

Although our laboratory has employed Negishi

couplings in the past to generate FPP analogs, this reaction is highly sensitive to moisture and air.
Therefore, we wished to develop alternative synthetic routes that utilized less sensitive coupling
procedures such as Suzuki couplings.
Considering the number of commercially available alkynes, Negishi’s ZACA reaction
was an appealing method for the facile generation of various isoprenoid units. Through the
utilization of the ZACA reaction, we were able to synthesize the α-containing analogs 3.3a-c and
the vinyl iodides 3.5a-d which underwent Suzuki couplings to produce the α/β-containing
analogs 3.7a-d. In order to synthesize the α/ω- containing analogs, an alternative approach was
needed. Thus, by utilizing Swern and Wittig reactions we could generate the alkyl halides 3.9
and 3.12 which were converted to organoboranes and subjected to Suzuki coupling to afford
3.16a-b.

The synthesis of the of the tetrahydro-GGPP analog 3.21 was accomplished using similar
chemistry as discussed in Chapter 1; however, a different approach was needed to yield the
dihydro-GGPP analog 3.24 due to an increase in SN2’ product resulting from a decrease in the
steric bulk of the Grignard reagent. Instead, a Cu(I)-mediated THP-ether displacement by a
Grignard reagent was utilized.

69
Upon in vitro biochemical testing, it was revealed that all analogs displayed some degree
of substrate activity. Generally, if we increase the number of carbons in the chain it results in
greater substrate activity. Interestingly, it became evident that the α-isoprene unit is sufficient to
warrant enzyme recognition and catalysis; however, increasing the carbon length from 14 to 16
greatly added to the analogs substrate ability. Replacing the β-isoprene unit seems to have the
greatest effect on analogs that are shorter than GGPP (less than 16 carbons). For instance,
replacing the β-isoprene of 3.3a (14 carbons long) to generate 3.7b had a much greater effect on
substrate ability than the same modification of 3.3c (16 carbons long) to generate 3.7d.
When replacing the terminal isoprene to generate α/ ω-containing analogs it appears that
chain length is essential. Having just one carbon unit short of the length of GGPP is detrimental
to the analog’s substrate ability (3.16a); however, with the proper chain length (3.16b), the data
suggest that this modification is the most advantageous resulting in an analog comparable to
GGPP. By examining the data in Figure 3.8, it appears that analog 3.16b is turned over more
quickly than GGPP. That is to say, analog 3.16b reaches its fluorescence maximum more quickly
than GGPP. Many of the other compounds seem to turn over more slowly than GGPP or have a
lower affinity for the enzyme. Unfortunately, the analogs were tested at only three concentrations
(1, 5, & 10 µM) and many of the reactions did not reach completion at 10 µM of analog. In order
to determine accurate kcat and Km values, these analogs are currently being retested at more
concentrations.
We have successfully synthesized a library of saturated GGPP compounds in which one
or more of the isoprene units has been removed from the molecule. The preliminary biochemical
evaluation revealed several intriguing results. At a later date, these compounds will be screened
with an expansive library of dansyl-GCaaX peptides to determine if these analogs globally or
selectively geranylgeranylate proteins. In addition, these compounds ranged in length between
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GGPP and FPP; therefore, we will also be testing these compounds with FTase to determine their
ability to be recognized and utilized by one enzyme over another.
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3.5

Experimental Procedures Utilized for the Synthesis & Biochemical Evaluation of Saturated
Geranylgeranyl Pyrophosphate Analogs

General Experimental Procedures: All reactions were performed with oven-dried or flame-

dried glassware and under dry argon gas. All commercial reagents and solvents were used
directly without subsequent purification. For the organmetallic coupling reactions, anhydrous
THF was freshly distilled from sodium and benzophenone. All other anhydrous solvents were
purchased from Acros Organics as extra dry solvents and were bottled over molecular sieves.
Reactions were monitored by thin layer chromatography and visualized with one or more of the
following:

UV

light,

iodine,

vanillin

solution,

potassium

permanganate

dinitrophenylhydrazine solution, and/or phosphomolybdic acid solution.

solution,

All products were

purified using flash chromatography silica gel 60 M purchased from Macherey-Nagel.

All

reactions involving either triphenyl phosphine or triphenyl phosphine oxide were first dry-loaded
with sodium sulfated before column purification. NOTE: *Dry glassware is critical for the
organometallic reactions in this publication.

This was accomplished by taking oven-dried

glassware (dried for at least 24 hr and then cooled under argon) and flame drying the round
bottom flask under vacuum.
temperature.

The flask was then purged with argon and cooled to room

This process was repeated 3 times to produce a completely water free

environment.* **Deoxygenated solvents are extremely crucial for successful organometallic
reactions in this publication. In order to achieve completely deoxygenated solutions, the solvent
was placed in a flame-dried round bottom and under vacuum was sonicated for 30 seconds and
then purged with argon for 30 seconds. This process was repeated 3 times to yield completely
deoxygenated solvents.** All NMR spectra were taken either on a 300 MHz Bruker ARX300 or
a 500 MHz Bruker DRX500 spectrometer. Low-resolution MS (EI/CI) were recorded with a
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Hewlett Packard Engine and low-resolution MS (ESI) were taken on a Thermoquest LCQ. All
high-resolution mass spectra were recorded on a FinniganMAT XL95.

Representative procedure for the synthesis of vinyl alcohols 3.2a-c:

OH

(E)-3-methyltetradec-2-en-1-ol (3.2a):
Cp2ZrCl2 (0.25 eq, 0.38 mmol) was dissolved in dichloromethane (1.5 mL) and the
solution was cooled to 0°C, where AlMe3 solution (2.0 M in heptanes, 2.5eq, 4.5 mmol, 2.25 mL)
was added dropwise. After stirring the reaction mixture at 0°C for 30 minutes, 1-tridecyne (1.0
eq, 1.5 mmol) was diluted in dichloromethane (1.0 mL) and added to the reaction mixture
dropwise. The reaction mixture was allowed to slowly warm to room temperature and stirred an
additional 12 hours. Next, the reaction mixture was cooled to 0°C, where (CH2O)n (5 eq, 4.5
mmol, 135 mg) was added in several portions. The reaction continued to stir for 3 hours after
which it was slowly poured into an ice-cold 10% HCl(aq) solution. The solution was then filtered
over a pad of Celite 545, extracted with 3 × 10 mL dichloromethane, washed with brine, dried
with magnesium sulfated, filtered, and concentrated.

Column chromatography (10% Ethyl

acetate in Hexanes) afforded 3.2 in 50% yield. 1H NMR (300 MHz, CDCl3) δ 5.41 – 5.30 (m,
1H), 4.11 (d, J = 6.9 Hz, 2H), 2.01 – 1.91 (m, 2H), 1.62 (s, 3H), 1.23 (s, 18H), 0.84 (t, J = 6.6 Hz,
3H); 13C NMR (75 MHz, Chloroform-d) δ 140.31, 123.26, 59.53, 39.76, 32.12, 29.88, 29.84,
29.82, 29.75, 29.56, 29.53, 27.89, 22.89, 16.34, 14.31. MS (EI) m/z 226 [M+].; MS (CI) m/z 227
[M++H].
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OH

(E)-3-methylpentadec-2-en-1-ol (3.2b):
Yield (58%); 1H NMR (300 MHz, Chloroform-d) δ 5.49 – 5.24 (m, 1H), 4.13 (d, J = 7.0
Hz, 2H), 1.98 (t, J = 7.5 Hz, 2H), 1.64 (d, J = 1.3 Hz, 3H), 1.24 (d, J = 4.1 Hz, 20H), 0.86 (t, J =
6.3 Hz, 3H). 13C NMR (75 MHz, Chloroform-d) δ 140.52, 123.25, 59.64, 39.79, 32.15, 29.94,
29.91, 29.87, 29.84, 29.77, 29.59, 29.55, 27.91, 22.92, 16.40, 14.36. MS (EI) m/z 222 [M+-H2O].;
MS (CI) m/z 241 [M++H].

OH

(E)-3-methylhexadec-2-en-1-ol (3.2c):

Yield (56%); 1H NMR (300 MHz, Chloroform-d) δ 5.38 (ddt, J = 7.0, 5.6, 1.5 Hz, 1H),
4.13 (d, J = 7.0 Hz, 2H), 1.98 (t, J = 7.5 Hz, 2H), 1.64 (d, J = 1.3 Hz, 3H), 1.24 (d, J = 3.8 Hz,
22H), 0.85 (t, J = 6.3 Hz, 3H). 13C NMR (75 MHz, Chloroform-d) δ 140.53, 123.24, 59.65, 39.79,
32.15, 29.94, 29.91, 29.88, 29.84, 29.77, 29.59, 29.55, 27.91, 22.92, 16.40, 14.36. MS (EI) m/z
236 [M+-H2O].; MS (CI) m/z 253 [M+-H].

Representative procedure for the synthesis of vinyl iodides 3.5a-d:
I

(E)-1-iodo-2-methyloct-1-ene (3.5a):
Cp2ZrCl2 (0.25 eq, 0.75 mmol) was dissolved in dichloromethane (3 mL) and the solution
was cooled to 0°C, where a Me3Al solution (2.0 M in heptanes, 2.5eq, 9 mmol) was added
dropwise. After stirring the reaction mixture at 0°C for 30 minutes, 1-octyne (1.0 eq, 3 mmol)
was diluted in dichloromethane (1.5 mL) and added to the reaction mixture dropwise. The
reaction mixture was allowed to slowly warm to room temperature and stirred an additional 12
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hours. Next, the reaction mixture was cooled to 0°C, where I2 (2.5 eq, 7.5 mmol) was added in
several portions. The reaction continued to stir for 3 hours after which it was slowly poured into
an ice-cold 10% HCl(aq) solution. The solution was then filtered over a pad of Celite 545,
extracted with 3 × 20 mL dichloromethane, washed with saturated Na2S2O3 × 2, washed with
brine, dried with magnesium sulfated, filtered, and concentrated to afford 3.5 a in 55% yield.
NMR: 1H NMR (300 MHz, Chloroform-d) δ 5.97 – 5.56 (m, 1H), 2.17 (t, J = 7.5 Hz, 2H), 1.80
(s, 3H), 1.53 – 1.07 (m, 8H), 0.86 (t, J = 6.1 Hz, 3H).

13

C NMR (75 MHz, Chloroform-d) δ

148.55, 74.53, 39.82, 31.82, 28.94, 27.89, 24.04, 22.79, 14.31.
I

(E)-1-iodo-2-methylnon-1-ene (3.5b):
Yield (63%); 1H NMR (300 MHz, Chloroform-d) δ 5.83 (s, 1H), 2.17 (t, J = 7.5 Hz, 2H),
1.80 (s, 3H), 1.24 (s, 10H), 0.86 (dt, 3H).

13

C NMR (75 MHz, Chloroform-d) δ 104.96, 74.52,

39.82, 31.99, 29.28, 29.23, 27.92, 24.04, 22.86, 14.32.
I

(E)-1-iodo-2-methyldec-1-ene (3.5c):
Yield (75%); 1H NMR (300 MHz, CDCl3) δ 5.85 – 5.81 (m, 1H), 2.22 – 2.11 (m, 2H),
1.80 (d, J = 1.0 Hz, 3H), 1.24 (s, 12H), 0.86 (t, J = 6.6 Hz, 3H).

13

C NMR (75 MHz, Chloroform-

d) δ 148.50, 74.54, 39.82, 32.08, 29.58, 29.45, 29.27, 27.92, 24.03, 22.89, 14.34.
I

(E)-1-iodo-2-methylundec-1-ene (3.5d):

Yield (81%); 1H NMR (300 MHz, CDCl3) δ 5.95 – 5.63 (m, 1H), 2.23 – 2.10 (m, 2H),
1.80 (s, 3H), 1.24 (s, 14H), 0.86 (t, J = 6.6 Hz, 3H).

13

C NMR (75 MHz, CDCl3) δ 148.54, 74.53,

39.82, 32.10, 29.74, 29.62, 29.53, 29.27, 27.93, 24.04, 22.90, 14.35.
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Representative Procedure for the Synthesis of Suzuki Couplings:

OTHP

2-(((2E,6E)-3,7-dimethylhexadeca-2,6-dien-1-yl)oxy)tetrahydro-2H-pyran:
An oven-dried round-bottom flask containing powdered molecular sieves was charged
with (E)-2-((5-bromo-3-methylpent-2-en-1-yl)oxy)tetrahydro-2H-pyran (stored over sieves; 2.0
eq, 4 mmol) which was dissolved in 13 mL of anhydrous Et2O and cooled to -78°C. Next, t-BuLi
(1.7M in pentane; 3.0 eq, 6.0 mmol, 3.53 mL) was slowly added to the reaction flask and stirred
for 1 hour at -78°C. Afterward, β-MeO-9-BBN (1.0M in Hexanes; 3.8 eq, 7.6 mmol) was slowly
added to the reaction vessel and the mixture was stirred for 16 hours slowly warming to room
temperature.
In a scintillation vial, (E)-1-iodo-2-methyldec-1-ene (1.0 eq, 2.0 mmol) and Pd(dppf)Cl2
(0.15 eq, 0.3 mmol) are dissolved in 7 mL of DMF. Next, K3PO4 (3 M in H2O, 3.0 eq, 6.0 mmol,
3mL) is added to the vial and after deoxygenating the solvent, the vinyl-iodide solution is added
to the round-bottom flask containing the newly formed organoborane. The reaction mixture is
allowed to stir for an additional 16 hours at 85°C after which it is poured into a separatory funnel
containing water and Et2O and the aqueous layer was extracted 3 × 30 mL Et2O. The organic
layers were combined and washed with water then brine, dried with magnesium sulfate, and
concentrated. The crude reaction product was purified by column chromatography using 5%
Diethyl ether/Hexanes as the mobile phase to afford THP-protected alcohol in 70% yield.

1

H

NMR (300 MHz, CDCl3) δ 5.32 (t, J = 7.0 Hz, 1H), 5.05 (t, J = 6.7 Hz, 1H), 4.58 (t, J = 3.2 Hz,
1H), 4.19 (dd, J = 12.0, 6.4 Hz, 1H), 3.98 (dd, J = 12.0, 7.4 Hz, 1H), 3.85 (td, J = 8.7, 6.5, 2.6 Hz,
1H), 3.61 – 3.39 (m, 1H), 2.03 (dd, J = 11.6, 6.0 Hz, 3H), 1.95 – 1.66 (m, 3H), 1.63 (s, 3H), 1.59
– 1.25 (m, 10H), 1.22 (s, 12H), 0.98 – 0.71 (m, 3H).

13

C NMR (75 MHz, CDCl3) δ 140.34,
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135.70, 123.74, 120.74, 97.82, 63.73, 62.35, 39.84, 39.82, 32.08, 30.87, 29.79, 29.74, 29.53,
29.46, 28.13, 26.40, 25.68, 22.86, 19.77, 16.54, 16.04, 14.27.

OTHP

2-(((2E,6E)-3,7-dimethylpentadeca-2,6-dien-1-yl)oxy)tetrahydro-2H-pyran:
Yield (47%); 1H NMR (300 MHz, CDCl3) δ 5.39 – 5.27 (m, 1H), 5.05 (dd, J = 7.1, 6.1
Hz, 1H), 4.59 (t, J = 3.4 Hz, 1H), 4.20 (dd, J = 11.9, 6.4 Hz, 1H), 3.99 (dd, J = 11.9, 7.3 Hz, 1H),
3.86 (ddd, J = 11.1, 7.2, 3.6 Hz, 1H), 3.47 (dt, J = 10.7, 5.3 Hz, 1H), 2.05 (d, J = 11.0 Hz, 3H),
1.90 (d, J = 7.9 Hz, 2H), 1.86 – 1.66 (m, 2H), 1.64 (s, 3H), 1.52 (dd, J = 10.0, 5.6 Hz, 7H), 1.39 –
1.11 (m, 11H), 0.88 – 0.78 (m, 5H). 13C NMR (75 MHz, Chloroform-d) δ 140.47, 135.79, 123.76,
120.71, 97.90, 63.79, 62.43, 39.87, 34.89, 32.10, 30.89, 29.72, 29.52, 29.48, 28.16, 26.42, 25.69,
22.87, 19.80, 16.58, 16.09, 14.31.

OTHP

2-(((2E,6E)-3,7-dimethyltetradeca-2,6-dien-1-yl)oxy)tetrahydro-2H-pyran:
Yield (35%); 1H NMR (300 MHz, CDCl3) δ 5.32 (dd, J = 10.1, 3.7 Hz, 1H), 5.06 (dd, J
= 6.6, 5.8 Hz, 1H), 4.59 (t, J = 3.4 Hz, 1H), 4.27 – 3.40 (m, 4H), 2.14 – 1.66 (m, 7H), 1.64 (s,
3H), 1.61 – 1.14 (m, 18H), 0.85 (dd, J = 7.7, 5.7 Hz, 4H). 13C NMR (75 MHz, CDCl3) δ 140.44
(s), 135.78 (s), 123.76 (s), 120.73 (s), 97.90 (s), 63.79 (s), 62.42 (s), 39.86 (s), 32.07 (s), 30.90
(s), 29.44 (s), 28.16 (s), 26.42 (s), 25.70 (s), 22.87 (s), 19.81 (s), 16.58 (s), 16.08 (s), 14.30 (s).

OTHP

2-(((2E,6E)-3,7-dimethyltrideca-2,6-dien-1-yl)oxy)tetrahydro-2H-pyran:
Yield (23 % based on NMR). Compound co-eluted with an impurity after column
chromatography (5% Diethyl ether/Hexanes). Impure compound was taken on and deprotected in
the next step.
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Representative procedure for the synthesis of alcohols 3.6a-d:

(2E,6E)-3,7-dimethylhexadeca-2,6-dien-1-ol (3.6d):
In a scintillation vial, 2-(((2E,6E)-3,7-dimethylhexadeca-2,6-dien-1-yl)oxy)tetrahydro2H-pyran (1.0 eq, 1.4 mmol) was dissolved in 7.5 mL of absolute EtOH and PPTS (0.1 eq, 0.14
mmol) was added to the vial. The reaction mixture was heated to 60°C and stirred for 12 hours.
Next, the reaction was cooled to room temperature where it was poured into a separator funnel
containing water and Et2O and the aqueous layer was extracted 3 × 10 mL Et2O. The organic
layers were combined and washed with water then brine, dried with magnesium sulfate, and
concentrated. The crude reaction product was purified by column chromatography using 10%
Ethyl Acetate/Hexanes as the mobile phase to afford 3.6d in 76% yield (mg). NMR: 1H NMR
(300 MHz, CDCl3) δ 5.38 (t, J = 6.9 Hz, 1H), 5.06 (t, J = 6.7 Hz, 1H), 4.11 (d, J = 6.8 Hz, 2H),
2.13 – 1.97 (m, 3H), 1.92 (t, J = 7.5 Hz, 2H), 1.64 (s, 3H), 1.55 (s, 3H), 1.43 – 1.05 (m, 15H),
0.98 – 0.66 (m, 3H).

13

C NMR (75 MHz, CDCl3) δ 139.85, 135.91, 123.66, 123.52, 59.50, 39.86,

39.77, 32.10, 29.81, 29.77, 29.55, 29.48, 28.17, 26.46, 22.89, 16.43, 16.06, 14.30. MS (EI) m/z
266 [M+-].; MS (CI) m/z 265 [M+-H].

OH

(2E,6E)-3,7-dimethylpentadeca-2,6-dien-1-ol (3.6c):
Yield (56%): NMR: 1H NMR (300 MHz, CDCl3) δ 5.42 (td, J = 6.9, 1.2 Hz, 1H), 5.08
(dt, J = 6.7, 3.4 Hz, 1H), 4.15 (d, J = 6.9 Hz, 2H), 2.17 – 1.99 (m, 4H), 1.95 (t, J = 7.4 Hz, 2H),
1.68 (s, 3H), 1.58 (s, 3H), 1.42 (s, 1H), 1.40 – 1.29 (m, 2H), 1.26 (s, 10H), 0.88 (t, J = 6.7 Hz,
3H).

13

C NMR (75 MHz, CDCl3) δ 140.06 (s), 135.98 (s), 123.56 (d, J = 14.2 Hz), 77.65 (s),

77.23 (s), 76.81 (s), 59.60 (s), 39.84 (d, J = 7.4 Hz), 32.12 (s), 29.87 – 29.37 (m), 28.19 (s), 26.46
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(s), 22.89 (s), 16.48 (s), 16.11 (s), 14.34 (s). MS (EI) m/z 236 [M+-H2O].; MS (CI) m/z 235
[(M++H)-H2O].

(2E,6E)-3,7-dimethyltetradeca-2,6-dien-1-ol (3.6b):
Yield (66%); NMR: 1H NMR (300 MHz, CDCl3) δ 5.38 (td, J = 6.9, 1.2 Hz, 1H), 5.11 –
5.00 (m, 1H), 4.11 (d, J = 6.9 Hz, 2H), 2.14 – 1.96 (m, 4H), 1.92 (t, J = 7.4 Hz, 2H), 1.64 (s, 3H),
1.55 (s, 3H), 1.48 – 1.11 (m, 12H), 0.85 (dd, J = 8.4, 5.0 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ
139.90 (s), 135.92 (s), 123.66 (s), 123.50 (s), 59.53 (s), 39.86 (s), 39.77 (s), 32.07 (s), 29.43 (s),
29.43 (s), 28.17 (s), 26.45 (s), 22.87 (s), 16.44 (s), 16.07 (s), 14.30 (s). MS (EI) m/z 238 [M+].;
MS (CI) m/z 237 [M+-H].

(2E,6E)-3,7-dimethyltrideca-2,6-dien-1-ol (3.6a):
Yield (52%; 12% from coupling step). 1H NMR (300 MHz, Chloroform-d) δ 5.42 (td, J
= 7.5, 6.9, 1.2 Hz, 0H), 5.09 (t, J = 6.5 Hz, 0H), 4.15 (dd, J = 7.1, 2.9 Hz, 1H), 2.07 (ddt, J =
13.7, 9.1, 4.2 Hz, 1H), 1.95 (t, J = 7.5 Hz, 0H), 1.68 (s, 1H), 1.58 (s, 1H), 1.43 – 1.16 (m, 2H),
0.88 (t, J = 6.7 Hz, 1H). 13C NMR (75 MHz, Chloroform-d) δ 140.08, 135.98, 123.67, 123.50,
59.63, 39.89, 39.80, 32.01, 29.17, 28.15, 26.47, 22.88, 16.48, 16.12, 14.34. MS (EI) m/z 224 [M+H2O].; MS (CI) m/z 223 [M++H].

HO

I

10-iododecan-1-ol:
To an oven dried round bottom flask cooled under Argon is added decane-1,10-diol (1.3
eq, 39 mmol) dissolved in 50 mL of anhydrous dichloromethane. The reaction flask is cooled to
0°C where PPh3 (1.0 eq, 30 mmol) followed by imidazole (1.5 eq, 45mmol) are added to the
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reaction vessel. After stirring at 0°C for 10 minutes, iodine (1.0 eq, 30 mmol) is added to the
reaction portion wise; after complete addition, the reaction is stirred for 3.5 hours at room
temperature. The reaction was then quenched with 10% NH4Cl(aq) and the aqueous layer was
extracted 3 × 100 mL of hexanes. The organic layers were combined, dried with sodium sulfate,
and concentrated. The crude reaction product was purified column chromatography by dryloading with sodium sulfate and using 30% Ethyl Acetate/Hexanes as the mobile phase to afford
title compound in 45% yield. 1H NMR (300 MHz, CDCl3) δ 3.61 (t, J = 6.2 Hz, 2H), 3.16 (t, J =
7.0 Hz, 2H), 1.85 – 1.71 (m, 2H), 1.52 (dd, J = 13.7, 6.8 Hz, 2H), 1.42 – 1.11 (m, 14H). 13C NMR
(75 MHz, CDCl3) δ 77.65 (s), 77.23 (s), 76.81 (s), 63.25 (s), 33.73 (s), 32.97 (s), 30.69 (s), 29.81
– 29.40 (m), 28.71 (s), 25.92 (s), 7.62 (s).

O

I

10-iododecanal (3.8):
An oven dried multi-neck round bottom flask is equipped with an oven dried addition
funnel and cooled under Argon. The flask is charged with (COCl)2 (1.2 eq, 16 mmol) dissolved
in 16 mL of dichloromethane and cooled to -78°C. Next, DMSO (2.4 eq, 32 mmol) is dissolved
in 2.2 mL of dichloromethane, added to the addition funnel, and slowly added to the reaction
vessel over a 20 minute period at -78°C. The reaction is allowed to stir at this temperature for 30
minutes after which 11-iodoundecan-1-ol (1.0 eq, 13.34 mmol) diluted with 26 mL of
dichloromethane is added slowly to the reaction mixture. The reaction is allowed to stir for an
additional 1.5 hours at -78°C followed by the addition of Et3N (5.0 eq, 66.7 mmol). After
allowing the reaction to come to room temperature, it is quenched by adding 10% NH4Cl(aq) and
the aqueous layer was extracted 3 × 75 mL of DCM. The organic layers were combined, washed
with brine, dried with magnesium sulfate, filtered, and concentrated. The crude reaction product
was purified column chromatography using 5% Ethyl Acetate/Hexanes as the mobile phase to
afford 3.8 in 81% yield. 1H NMR (300 MHz, CDCl3) δ 9.67 (t, J = 1.5 Hz, 1H), 3.09 (t, J = 7.0
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Hz, 2H), 2.33 (td, J = 7.3, 1.7 Hz, 2H), 1.71 (dd, J = 14.4, 7.1 Hz, 2H), 1.59 – 1.47 (m, 2H), 1.21
(s, 10H).

13

C NMR (75 MHz, Chloroform-d) δ 202.74, 43.88, 33.49, 30.44, 29.24, 29.19, 29.09,

28.45, 22.03, 7.43.

Br

O
11-bromoundecanal (3.11):

Yield (75%); 1H NMR (300 MHz, CDCl3) δ 9.74 (d, J = 1.5 Hz, 1H), 3.38 (t, J = 6.8 Hz,
2H), 2.40 (t, J = 7.3 Hz, 2H), 1.81 (dd, J = 14.3, 7.2 Hz, 2H), 1.68 – 1.53 (m, 2H), 1.38 (d, J = 6.9
Hz, 2H), 1.26 (s, 12H).

13

C NMR (75 MHz, CDCl3) δ 203.16 (s), 77.65 (s), 77.23 (s), 76.80 (s),

44.12 (s), 34.28 (s), 33.01 (s), 29.46 (t, J = 8.0 Hz), 28.93 (s), 28.35 (s), 22.26 (s).

Representative procedure of the Wittig reaction:

I

12-iodo-2-methyldodec-2-ene (3.9):
An oven dried round bottom flask is charged with isopropyl triphenylphosphine iodide
(1.5eq, mmol) and THF. The flask is cooled to 0°C where n-BuLi (2.5 M in Hexanes, 1.5 eq,
mmol) is added dropwise to give a red solution. The reaction mixture is stirred for 30 minutes at
0°C, after which 10-iododecanal (1.0 eq, mmol) dissolved in mL of THF is added dropwise to the
reaction. The reaction is allowed to stir for an additional 4 hours at room temperature. Upon
completion of the reaction, the reaction mixture is quenched by adding 10% NH4Cl(aq) and the
aqueous layer was extracted 3 × mL of Et2O. The organic layers were combined, washed with
brine, dried with magnesium sulfate, filtered, and concentrated. The crude reaction product was
purified with column chromatography by dry-loading with sodium sulfate and using hexanes as
the mobile phase to afford 3.9 in 58% yield. 1H NMR (300 MHz, CDCl3) δ 5.13 – 5.04 (m, 1H),
3.15 (t, J = 7.1 Hz, 2H), 1.92 (t, J = 6.5 Hz, 2H), 1.78 (dd, J = 14.5, 7.1 Hz, 2H), 1.66 (d, J = 0.9
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Hz, 3H), 1.57 (s, 3H), 1.42 – 1.31 (m, 2H), 1.26 (s, 11H).

13

C NMR (75 MHz, CDCl3) δ 131.19,

125.03, 33.74, 30.69, 30.05, 29.66, 29.59, 29.46, 28.73, 28.20, 25.92, 17.85, 7.35.
Br

13-bromo-2-methyltridec-2-ene (3.10):
Yield (63%);

1

H NMR (300 MHz, CDCl3) δ 5.14 – 5.04 (m, 1H), 3.39 (t, J = 6.9 Hz,

2H), 1.92 (t, J = 6.6 Hz, 2H), 1.88 – 1.77 (m, 2H), 1.66 (d, J = 0.9 Hz, 3H), 1.58 (s, 3H), 1.53 (s,
1H), 1.46 – 1.34 (m, 2H), 1.25 (s, 14H).

13

C NMR (75 MHz, Chloroform-d) δ 131.37, 125.13,

34.32, 33.06, 30.11, 29.75, 29.66, 29.54, 29.00, 28.40, 28.26, 25.96, 17.89.
OTBS

(but-2-yn-1-yloxy)(tert-butyl)dimethylsilane:
To a round bottom flask is added but-2-yn-1-ol (1.0 eq, 12 mmol) dissolved in DCM.
Next, DIEA (1.3 eq, 15.6 mmol) followed by TBDMSCl (1.3 eq, 15.6 mmol) is added to the
reaction vessel and stirred for 6 hours at room temperature. Upon completion of the reaction, the
reaction mixture is quenched by adding 10% NH4Cl(aq) and the aqueous layer was extracted 3 ×
50 mL of Et2O. The organic layers were combined, washed with brine, dried with magnesium
sulfate, filtered, and concentrated.

The crude reaction product was purified column

chromatography using 2% ethyl acetate/hexanes as the mobile phase to afford the title compound
in 95% yield. 1H NMR (300 MHz, CDCl3) δ 4.23 (q, J = 2.3 Hz, 1H), 1.79 (t, J = 2.4 Hz, 1H),
0.87 (s, 5H), 0.07 (s, 3H).
-5.00.

13

C NMR (75 MHz, CDCl3) δ 81.02, 77.92, 52.14, 26.05, 18.54, 3.77,
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(E)-tert-butyl((3-iodobut-2-en-1-yl)oxy)dimethylsilane (3.14):
To an oven dried round bottom flask, which was also flame dried under vacuum and
cooled with Argon three times, is added Cp2ZrCl2 (1.5 eq, 17 mmol) in anhydrous THF(39 mL)
and cooled to 0°C. DIBAL (1.0 M in Toluene, 1.5 eq, 17 mmol) is then slowly added to afford a
milky yellow solution which is stirred 30 minutes at 0°C. Next, (but-2-yn-1-yloxy)(tert-butyl)
dimethylsilane dissolved in THF (6 mL) is slowly added and the reaction mixture is allowed to
war to room temperature where it is stirred until a homogeneous solution results (~1 hour).
Finally, the reaction is cooled to -78°C and I2 dissolved in THF (17 mL) is added slowly and the
mixture is allowed to stir for an additional 30 minutes at -78°C. The reaction mixture is quenched
by pouring into a beaker containing 10% HCl(aq) and the aqueous layer was extracted 3 × 50 mL
of Et2O. The organic layers were combined, washed with saturated Na2S2O3, saturated NaHCO3,
and brine. The organic layer is dried with magnesium sulfate, filtered, and concentrated. The
crude reaction product was purified column chromatography using 2% ethyl acetate/hexanes as
the mobile phase to afford 3.14 in 40% yield. 1H NMR (300 MHz, Chloroform-d) δ 6.26 (td, J =
6.3, 1.5 Hz, 1H), 4.09 (d, J = 6.5 Hz, 3H), 2.38 (d, J = 1.4 Hz, 4H), 0.86 (s, 12H), 0.04 (s, 7H).
13

C NMR (75 MHz, Chloroform-d) δ 140.70, 96.11, 60.77, 28.22, 26.00, 18.44, -5.07.
OTBS

(E)-tert-butyl((3,14-dimethylpentadeca-2,13-dien-1-yl)oxy)dimethylsilane:

(E)-tert-butyl((3-iodobut-2-en-1-yl)oxy)dimethylsilane

and 12-iodo-2-methyldodec-2-

ene were coupled using the same procedure as 2-(((2E,6E)-3,7-dimethylhexadeca-2,6-dien-1yl)oxy)tetrahydro-2H-pyran.

The

crude reaction

product

was

purified

by column

chromatography using 5% ethyl acetate/hexanes as the mobile phase to afford the title compound
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in 86% yield. 1H NMR (300 MHz, Chloroform-d) δ 5.27 (t, J = 6.4 Hz, 1H), 5.14 – 5.03 (m, 1H),
4.17 (d, J = 6.3 Hz, 2H), 1.94 (q, J = 8.0 Hz, 5H), 1.66 (s, 4H), 1.57 (s, 10H), 1.24 (s, 15H), 0.88
(s, 15H), 0.05 (s, 8H). 13C NMR (75 MHz, Chloroform-d) δ 137.52, 131.29, 125.16, 124.33,
60.56, 39.77, 30.13, 29.85, 29.82, 29.78, 29.57, 28.28, 27.90, 26.25, 26.20, 25.95, 17.88, 16.47, 4.81.

OTBS

(E)-tert-butyl((3,15-dimethylhexadeca-2,14-dien-1-yl)oxy)dimethylsilane:
13-bromo-2-methyltridec-2-ene and 12-iodo-2-methyldodec-2-ene were coupled using
the same procedure as 2-(((2E,6E)-3,7-dimethylhexadeca-2,6-dien-1-yl)oxy)tetrahydro-2H-pyran.
The crude reaction product was purified by column chromatography using 5% ethyl
acetate/hexanes as the mobile phase to afford the title compound in 66% yield. 1H NMR (300
MHz, CDCl3) δ 5.29 (tq, J = 6.4, 5.1, 1.3 Hz, 1H), 5.11 (tq, J = 7.3, 5.8, 2.9, 1.5 Hz, 1H), 4.19
(dd, J = 6.4, 0.9 Hz, 2H), 1.96 (q, J = 8.2 Hz, 4H), 1.69 (d, J = 1.4 Hz, 3H), 1.60 (dd, J = 2.8, 1.3
Hz, 6H), 1.27 (d, J = 2.7 Hz, 16H), 0.91 (s, 9H), 0.07 (s, 6H).13C NMR (75 MHz, CDCl3) δ
137.51, 131.27, 125.16, 124.34, 60.55, 39.77, 30.14, 29.88, 29.82, 29.78, 29.59, 29.56, 28.28,
27.90, 26.24, 25.94, 18.65, 17.87, 16.46, -4.82.

Representative procedure for TBDMS deprotection:
OH

(E)-3,14-dimethylpentadeca-2,13-dien-1-ol (3.15a):
In a scintillation vial equipped with a magnetic stirrer was added (E)-tert-butyl((3,14dimethylpentadeca-2,13-dien-1-yl)oxy)dimethylsilane (1.0 eq, 1.32 mmol) in THF (2 mL) and
cooled to 0°C. Next, TBAF (1.5 eq, 1.97 mmol) was added to the vial and the reaction mixture
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was allowed to stir for 2 hours coming to room temperature. The reaction mixture was quenched
by adding 10% NH4Cl(aq) and the aqueous layer was extracted 3 × mL of Et2O. The organic
layers were combined, washed with brine, dried with magnesium sulfate, filtered, and
concentrated. The crude reaction product was purified by column chromatography using hexanes
as the mobile phase to afford 3.15 in 26% yield. 1H NMR (300 MHz, CDCl3) δ 5.37 (t, J = 7.0
Hz, 1H), 5.09 (t, J = 7.4 Hz, 1H), 4.12 (d, J = 7.0 Hz, 2H), 2.04 – 1.85 (m, 4H), 1.64 (d, J = 7.0
Hz, 6H), 1.57 (s, 3H), 1.24 (s, 14H).

13

C NMR (75 MHz, Chloroform-d) δ 140.39, 131.30,

125.13, 123.25, 59.57, 39.76, 30.10, 29.79, 29.79, 29.74, 29.55, 29.52, 28.25, 27.89, 25.92, 17.85,
16.36. MS (EI) m/z 234 [M+-H2O].

OH

(E)-3,15-dimethylhexadeca-2,14-dien-1-ol (3.15b):
Yield (64%); 1H NMR (300 MHz, CDCl3) δ 5.45 – 5.29 (m, 1H), 5.14 – 4.99 (m, 1H),
4.12 (d, J = 7.1 Hz, 2H), 2.02 – 1.86 (m, 4H), 1.66 (s, 3H), 1.63 (s, 3H), 1.57 (s, 3H), 1.23 (s,
16H).

13

C NMR (75 MHz, Chloroform-d) δ 140.38, 131.29, 125.14, 123.26, 59.57, 39.77, 30.11,

29.86, 29.82, 29.80, 29.75, 29.56, 29.52, 28.25, 27.90, 25.93, 17.85, 16.36. MS (EI) m/z 248 [M+H2O].

(2E,6E)-2,6-dimethyl-8-((tetrahydro-2H-pyran-2-yl)oxy)octa-2,6-dien-1-yl

diethyl

phosphate

(3.18):

To an Erlenmeyer flask charged with t-BuOOH (2.0 eq, 49 mmol, 70% in water) and 65
mL of CH2Cl2 is added MgSO4. The solution was then filtered into a round bottom flask
equipped with a magnetic stir bar. Next, SeO2 (0.12 eq, 2.94 mmol) and salicylic acid (0.1 eq, 2.5
mmol) were added to the reaction mixture. While the solution stirred, THP-protected geraniol
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(1.0 eq, 24.5 mmol) dissolved in 10 mL of CH2Cl2 was added dropwise to the reaction vessel.
The reaction mixture was allowed to stir for 12 hours. The CH2Cl2 was removed and the
resulting residue was resuspended in Et2O. Next, 10% NaOH was added to solution, the organic
layer was removed, and the aqueous layer was extracted 3 × Et2O (40 mL). The organic layers
are combined, washed with brine, dried with MgSO4, filtered, and concentrated. In an oven-dried
round bottom flask, the crude reaction product was diluted with 80 mL of ethanol and NaBH4 (1.0
eq, 24.5 mmol) was added in several portions to the reaction vessel. The reaction was allowed to
stir for 1 hour and then diluted with 200 mL of water. The aqueous layer was extracted 3 × Et2O
(40 mL) and the organic layers were combined, washed with brine, dried with MgSO4, filtered,
and concentrated. The crude reaction product was purified by column chromatography using 20%
Ethyl Acetate/Hexanes as the mobile phase to afford (2E,6E)-2,6-dimethyl-8-((tetrahydro-2Hpyran-2-yl)oxy)octa-2,6-dien-1-ol in 27% yield.
To a separate round bottom flask equipped with a magnetic stir bar was added (2E,6E)2,6-dimethyl-8-((tetrahydro-2H-pyran-2-yl)oxy)octa-2,6-dien-1-ol (1.0 eq, 5.15 mmol) in 10 mL
of dichloromethane. Next, pyridine (2.5 eq, 12.9 mmol) was added to the reaction vessel and the
mixture was cooled to 0°C, where diethyl chlorophosphate (1.5 eq, 7.7 mmol) was added
dropwise to the reaction. The reaction was allowed to warm to room temperature and stirred for
12 hours. Next, 10% NaOH was added to solution, the organic layer was removed, and the
aqueous layer was extracted 3 × EtOAc (20 mL). The organic layers are combined, washed with
brine, dried with MgSO4, filtered, and concentrated. The crude reaction product was purified by
column chromatography using 80% Ethyl Acetate/Hexanes as the mobile phase to afford diethyl
phosphpate 3.18 in 76% yield. 1H NMR (300 MHz, Chloroform-d) δ 5.44 (t, J = 6.8 Hz, 1H),
5.31 (t, J = 6.7 Hz, 1H), 4.68 – 4.50 (m, 1H), 4.34 (d, J = 7.0 Hz, 2H), 4.18 (dd, 1H), 4.05 (dp,
4H), 3.98 (dd, J = 7.4 Hz, 1H), 3.89 – 3.77 (m, 1H), 3.55 – 3.37 (m, 1H), 2.13 (q, J = 7.7, 7.3 Hz,
2H), 2.02 (dd, J = 9.4, 6.2 Hz, 2H), 1.86 – 1.66 (m, 1H), 1.63 (s, 6H), 1.59 – 1.40 (m, 5H), 1.34 –
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1.22 (m, 6H).

13

C NMR (75 MHz, Chloroform-d) δ 139.67, 130.87, 129.52, 121.12, 98.06, 73.31

(d, J = 5.5 Hz), 63.79 (d, J = 5.6 Hz). 63.78, 62.47, 39.02, 30.85, 26.15, 25.63, 19.78, 16.58,
16.35, 16.26, 13.74.

31

P NMR (202 MHz, Chloroform-d) δ -0.32.

(2E,6E)-3,7,11,15-tetramethylhexadeca-2,6-dien-1-ol (3.20):
To an oven-dried round bottom flask equipped with a magnetic stir bar was added
magnesium powder (18 eq, 20 mmol) and 6 mL of anhydrous Et2O and an iodide chip was added
to the round bottom and the mixture was stirred for 5 minutes.

Next, 1-bromo-3,7-

dimethyloctane (4.5 eq, 4.5 mmol) in 2 mL of Et2O was added dropwise to the reaction vessel
over a 10 minute period and the reaction mixture was stirred for 4 hours. After the allotted time,
the reaction mixture was cooled to 0°C where diethyl phosphate 3.18 (1.0 eq, 1.0 mmol)
dissolved in 6 mL of THF was added dropwise to the mixture and the reaction was allowed to stir
for 12 hours. The reaction was quenched with 10% NH4Cl, the organic layer was removed, and
the aqueous layer was extracted 3 × Et2O (5 mL). The organic layers are combined, washed with
brine, dried with MgSO4, filtered, and concentrated. The crude reaction product was purified by
column chromatography using 3% Ethyl Acetate/Hexanes as the mobile phase to afford 3.19 in
15% yield.
In a scintillation vial equipped with a magnetic stir bar, 3.19 (1.0 eq, 0.155 mmol) was
dissolved in 5.0 mL of absolute EtOH and PPTS (0.1 eq, 0.016 mmol) was added to the vial. The
reaction mixture was heated to 75°C and stirred for 12 hours. Next, the reaction was cooled to
room temperature where it was poured into a separator funnel containing water and Et2O and the
aqueous layer was extracted 3 × 5 mL Et2O. The organic layers were combined and washed with
water then brine, dried with magnesium sulfate, and concentrated. The crude reaction product
was purified by column chromatography using 10% Ethyl Acetate/Hexanes as the mobile phase
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to afford 3.20 in 70% yield. 1H NMR (300 MHz, Chloroform-d) δ 5.39 (t, J = 7.4 Hz, 1H), 5.07
(t, J = 6.2 Hz, 1H), 4.12 (d, J = 6.9 Hz, 2H), 2.17 – 1.97 (m, 4H), 1.91 (t, J = 7.3 Hz, 2H), 1.65 (s,
3H), 1.56 (s, 3H), 1.55 – 1.42 (m, 2H), 1.29 – 0.98 (m, 10H), 0.84 (d, J = 6.5 Hz, 6H), 0.81 (d, J
= 5.5 Hz, 3H).

13

C NMR (75 MHz, Chloroform-d) δ 140.00, 135.96, 123.71, 123.49, 59.56,

40.17, 39.79, 39.54, 37.48, 36.85, 32.86, 28.17, 26.48, 25.58, 25.01, 22.92, 22.83, 19.91, 16.47,
16.10. MS (EI) m/z 294 [M+] and 276 [M+-H2O]; MS (CI) 293 [M-H]+ and 295 [M+H]+.

(2E,6E,10E)-12-hydroxy-3,7,11-trimethyldodeca-2,6,10-trien-1-yl acetate (3.22):
Compound 3.21 was synthesized using the same method as compound 2.2 with the
exception that acetyl-protected farnesol was utilized instead of THP-protected farnesol. Yield
(28%). 1H NMR (300 MHz, Chloroform-d) δ 5.37 – 5.16 (m, 2H), 5.13 – 4.85 (m, 1H), 4.50 (d, J
= 7.1 Hz, 2H), 3.89 (s, 2H), 2.10 – 1.72 (m, 13H), 1.62 (s, 3H), 1.57 (s, 3H), 1.52 (s, 3H).

13

C

NMR (75 MHz, Chloroform-d) δ 171.30, 142.24, 135.17, 134.82, 125.75, 123.89, 118.34, 68.77,
61.47, 39.51, 39.34, 26.24, 26.17, 21.07, 16.49, 16.05, 13.71.

(2E,6E,10E)-3,7,11-trimethyl-12-((tetrahydro-2H-pyran-2-yl)oxy)dodeca-2,6,10-trien-1-ol
(3.23):

To a round bottom flask equipped with a magnetic stir bar was added 3.21 (1.0 eq, 5.62
mmol) and 30 mL of dichloromethane.

Next, 3,4-dihydro-2H-pyran (2.0 eq, 11.24 mmol)

followed by pyridinium p-toluenesulfonate (0.15 eq, 0.84 mmol) was added to the reaction flask
and the reaction was allowed to stir for 12 hours. Saturated NaHCO3(aq) was added to the reaction
flask and organic layer was isolated. The aqueous layer was further extracted 3 × DCM (25 mL)
and the organic layers were combined, washed with brine, dried with MgSO4, filtered, and
concentrated. In a round bottom flask, the crude product was redissolved in a saturated solution
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of K2CO3 in MeOH (30 mL) and stirred for 12 hours. After the allotted time, water (150 mL) and
Et2O (30 mL) were added to the reaction mixture and the organic layer was isolated. The
aqueous layer was further extracted 3 × Et2O (25 mL) and the organic layers were combined,
washed with brine, dried with MgSO4, filtered, and concentrated. The crude reaction product was
purified by column chromatography using 15% Ethyl Acetate/Hexanes as the mobile phase to
afford 3.22 in 74% yield. 1H NMR (300 MHz, Chloroform-d) δ 5.40 (t, J = 6.9 Hz, 2H), 5.10 (t, J
= 6.4 Hz, 1H), 4.64 – 4.56 (m, 1H), 4.14 (d, J = 6.9 Hz, 2H), 4.08 (d, J = 11.6 Hz, 1H), 3.94 –
3.78 (m, 2H), 3.59 – 3.40 (m, 1H), 2.07 (dp, J = 27.1, 7.4 Hz, 8H), 1.92 – 1.78 (m, 1H), 1.66 (s,
3H), 1.64 (s, 3H), 1.59 (s, 3H), 1.65 – 1.46 (m, 6H).

13

C NMR (75 MHz, Chloroform-d) δ

139.55, 135.11, 131.90, 127.98, 124.16, 123.59, 97.48, 73.07, 62.28, 59.46, 39.61, 39.34, 30.77,
26.37, 26.36, 25.61, 19.63, 16.39, 16.09, 14.19.

(2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10-trien-1-ol (3.25):
To an oven-dried round bottom flask equipped with a magnetic stir bar was added
magnesium powder (14.5 eq, 14.5 mmol) and 5 mL of anhydrous THF and an iodide chip was
added to the round bottom and the mixture was stirred for 5 minutes.

Next, 1-bromo-3-

methylbutane (10 eq, 10mmol) in 3 mL of Et2O was added dropwise to the reaction vessel over a
10 minute period and the reaction mixture was stirred for 4 hours to produce Grignard 3.24.
In a separate oven-dried round bottom flask was added THP-ether 3.23 (1.0 eq, 1mmol)
and dissolved in 5 mL of anhydrous THF and the solution was cooled to -35°C. Next, Cu(I)Br
(1.5 eq, 1.5 mmol) was added in one portion followed by the dropwise addition of the newly
formed Grignard reagent. The reaction was stirred for 1 hour at -35°C and allowed to warm to 10°C where it was stirred for 48 hours. The reaction mixture is quenched with 10% NH4Cl(aq) and
the aqueous layer was extracted 3 × 15 mL of Et2O. The organic layers were combined, washed
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with brine, dried with magnesium sulfate, filtered, and concentrated. The crude reaction product
was purified column chromatography using 15% ethyl acetate/hexanes as the mobile phase to
afford 3.25 in 17% yield. 1H NMR (300 MHz, Chloroform-d) δ 5.39 (t, J = 6.9 Hz, 1H), 5.07 (q,
J = 6.8, 6.3 Hz, 2H), 4.12 (d, J = 6.9 Hz, 2H), 1.98 (ddt, J = 31.0, 15.2, 6.8 Hz, 10H), 1.65 (s,
3H), 1.58 (s, 3H), 1.55 (s, 3H), 1.55 – 1.40 (m, 1H), 1.42 – 1.27 (m, 3H), 1.16 – 1.01 (m, 2H),
0.84 (d, J = 6.6 Hz, 6H).

13

C NMR (75 MHz, Chloroform-d) δ 40.10, 39.92, 39.75, 38.79, 28.09,

26.77, 26.51, 25.94, 22.85, 16.47, 16.20, 16.08. MS (EI) m/z 274 [M+-H2O]; MS (CI) m/z 293
[M-H]+.

Representative procedure for the synthesis of pyrophosphates:

(E)-3-methyltetradec-2-en-1-yl diphosphate (3.3a):
To an oven-dried round bottom flask equipped with a magnetic stir bar was added NCS
(2.5 eq, 0.44 mmol) in 1 mL of CH2Cl2 and cooled to -30°C where dimethyl sulfide (2.5 eq, 0.44
mmol) was added dropwise to the reaction. Following the addition, the mixture is then placed in
a 0°C ice bath and stirred for 5 minutes before being re-cooled back to -30°C. Next, alcohol 3.2a
(1 eq, 0.22 mmol) is dissolved in CH2Cl2 (0.44 mL) and added dropwise to the reaction mixture.
The mixture is then placed in a 0°C ice bath and stirred for 2.5 hours coming to room
temperature. After the allotted time, brine is added to the reaction mixture and the organic layer
was extracted. The aqueous layer was further extracted 3 × 5 mL CH2Cl2 and the organic layers
were combined, dried with magnesium sulfate, and concentrated. The crude reaction product was
used immediately in the following step.
To another oven-dried round bottom flask equipped with a magnetic stir bar was added
tris (tetrabutylammonium) hydrogen pyrophosphate (3.0eq, 0.66 mmol) dissolved in 3 mL of
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acetonitrile. Next, a solution of crude allylic chloride dissolve in 2 mL of acetonitrile was added
dropwise to the reaction vessel. The reaction was stirred for 3 hours at room temperature and
then the solvent was removed by rotary evaporation at 34°C. The residue was the dissolve in a
minimal amount of ion exchange NH3HCO3 buffer (700mg NH3HCO3, 1 L of deionized H2O, 20
mL of isopropanol) and the resulting solution was passed through a Dowex AG 50 × 8 ion
exchange column (2 × 8 cm) using the NH3HCO3 buffer as an eluent and 25 mL was collected in
a flask. The resulting solution was lyophilized for 3-5 hours. The resulting residue was then
redissolved in deionized watered and purified by cellulose flash column chromatography (3 × 15
cm) using isopropanol:deionized H2O:acetonitrile: NH3HCO3 buffer (500 mL : 250 mL : 250 mL
: 4 g) as the eluent. In a beaker was collected 40 mL of eluent, then twenty-four 2.5 mL fractions
were collected. Typically, fractions 12-18 were collected and the organic solvents were removed
by rotary evaporation at 34°C.

The resulting solution was then lyophilized to afford

pyrophosphate (3.3a) as a white fluffy solid in 57% yield. 1H NMR (500 MHz, Chloroform-d) δ
5.44 – 5.23 (m, 1H), 4.34 (s, 2H), 1.92 (s, 2H), 1.62 (d, J = 24.3 Hz, 3H), 1.20 (s, 18H), 0.98 –
0.70 (m, 3H).

31

P NMR (202 MHz, Deuterium Oxide) δ -9.96 (d, J = 15.9 Hz), -13.61 (d, J =

22.1 Hz). HRMS 385.1548 [M+2H]-, calculated 385.1545 (C15H31O7P2).

(E)-3-methylpentadec-2-en-1-yl diphosphate (3.3b):
Yield (64%). 1H NMR (300 MHz, Deuterium Oxide) δ 5.43 (t, 1H), 4.44 (s, 2H), 2.03 (s,
2H), 1.68 (s, 3H), 1.25 (s, 20H), 0.83 (t, J = 5.8 Hz, 3H).

31

P NMR (122 MHz, Chloroform-d) δ -

10.43, -14.05. HRMS 399.1701 [M+2H]-, calculated 399.1702 (C16H33O7P2).
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(E)-3-methylhexadec-2-en-1-yl diphosphate (3.3c):
Yield (83%). 1H NMR (500 MHz, Deuterium Oxide) δ 5.37 (s, 1H), 4.39 (s, 2H), 2.04 –
1.93 (m, 2H), 1.65 (s, 3H), 1.25 (d, J = 7.4 Hz, 22H), 0.91 (t, J = 7.4 Hz, 3H).

31

P NMR (202

MHz, Deuterium Oxide) δ -9.99 (d, J = 19.2 Hz), -13.70 (d, J = 20.9 Hz). HRMS 413.1852
[M+2H]-, calculated 413.1858 (C17H35O7P2).

(2E,6E)-3,7-dimethyltrideca-2,6-dien-1-yl diphosphate (3.6a):
Yield (91%). 1H NMR (500 MHz, Deuterium Oxide) δ 5.38 (t, J = 6.9 Hz, 1H), 5.10 (d,
J = 6.4 Hz, 1H), 4.40 (d, J = 7.3 Hz, 2H), 2.16 – 2.02 (m, 2H), 2.03 – 1.94 (m, 2H), 1.89 (t, J =
7.8 Hz, 2H), 1.66 (s, 3H), 1.54 (s, 3H), 1.21 (s, 8H), 0.82 (t, J = 6.4 Hz, 3H).

31

P NMR (202

MHz, Deuterium Oxide) δ -10.01, -13.74 (d, J = 15.5 Hz). HRMS 383.1391 [M+2H]-, calculated
383.1389 (C15H29O7P2).

(2E,6E)-3,7-dimethyltetradeca-2,6-dien-1-yl diphosphate (3.6b):
Yield (49%). 1H NMR (500 MHz, Deuterium Oxide) δ 5.52 – 5.32 (m, 1H), 5.08 (d, J =
7.1 Hz, 1H), 4.41 (s, 2H), 2.05 (s, 2H), 2.02 – 1.94 (m, 2H), 1.91 (d, J = 8.0 Hz, 2H), 1.68 (d, J =
16.2 Hz, 3H), 1.60 – 1.49 (m, 3H), 1.24 (s, 10H), 0.84 (d, J = 6.9 Hz, 3H).

31

P NMR (202 MHz,

Deuterium Oxide) δ -11.27 (d, J = 14.8 Hz), -13.98 (d, J = 15.3 Hz). HRMS 397.1547 [M+2H]-,
calculated 397.1545 (C16H31O7P2).
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(2E,6E)-3,7-dimethylpentadeca-2,6-dien-1-yl diphosphate (3.6c):
Yield (58%). 1H NMR (500 MHz, Deuterium Oxide) δ 5.38 (d, J = 5.9 Hz, 1H), 5.23 –
4.99 (m, 1H), 4.67 – 4.36 (m, 2H), 2.09 – 2.01 (m, 2H), 2.00 – 1.94 (m, 2H), 1.94 – 1.83 (m, 2H),
1.65 (s, 3H), 1.54 (s, 3H), 1.24 (s, 12H), 0.84 (t, J = 6.4 Hz, 3H).

31

P NMR (202 MHz,

Deuterium Oxide) δ -12.53 (d, J = 19.6 Hz), -16.19 (d, J = 17.9 Hz). HRMS 411.1698 [M+2H]-,
calculated 411.1702 (C17H33O7P2).

(2E,6E)-3,7-dimethylhexadeca-2,6-dien-1-yl diphosphate (3.6d):
Yield (70%). 1H NMR (300 MHz, Deuterium Oxide) δ 5.39 (s, 1H), 5.09 (s, 1H), 4.43 (s,
2H), 1.93 (t, J = 19.3 Hz, 6H), 1.70 (d, J = 10.3 Hz, 3H), 1.56 (d, J = 7.1 Hz, 3H), 1.26 (d, J = 8.2
Hz, 14H), 0.88 (t, J = 5.9 Hz, 3H).

31

P NMR (122 MHz, Chloroform-d) δ -15.06, -16.83. HRMS

425.1860 [M+2H]-, calculated 425.1858 (C18H35O7P2).

(E)-3,14-dimethylpentadeca-2,13-dien-1-yl diphosphate (3.16a):
Yield (86%). 1H NMR (500 MHz, Chloroform-d) δ 5.37 (s, 1H), 5.03 (s, 1H), 4.41 (s,
2H), 1.90 (s, 4H), 1.69 – 1.45 (m, 9H), 1.24 (s, 14H). 31P NMR (202 MHz, Deuterium Oxide) δ 10.09 (d, J = 19.2 Hz), -13.78 (d, J = 25.9 Hz). HRMS 411.1707 [M+2H]-, calculated 411.1702
(C17H33O7P2).
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(E)-3,15-dimethylhexadeca-2,14-dien-1-yl diphosphate (3.16 b):
Yield (69%). 1H NMR (500 MHz, Deuterium Oxide) δ 5.38 (s, 1H), 5.06 (s, 1H), 4.42 (s,
2H), 1.96 (d, J = 37.9 Hz, 4H), 1.67 (s, 3H), 1.61 (s, 3H), 1.53 (s, 3H), 1.27 (s, 16H).

31

P NMR

(202 MHz, Deuterium Oxide) δ -14.26 (d, J = 18.7 Hz), -16.53 (d, J = 17.6 Hz). HRMS
425.1859 [M+2H]-, calculated 425.1858 (C18H35O7P2).

(2E,6E)-3,7,11,15-tetramethylhexadeca-2,6-dien-1-yl diphosphate (3.21):
Yield (52%). 1H NMR (500 MHz, Chloroform-d) δ 5.40 (s, 1H), 5.10 (s, 1H), 4.41 (s,
2H), 2.06 (s, 2H), 1.98 (s, 2H), 1.91 (s, 2H), 1.68 (s, 3H), 1.57 (s, 3H), 1.25 (s, 10H), 0.85 (s, 3H),
0.84 (s, 6H).

31

P NMR (202 MHz, Deuterium Oxide δ -9.88 (d J = 16.2 Hz), -13.59 (d, J = 18.3

Hz). HRMS 453.2174 [M+2H]-, calculated 453.2171 (C20H39O7P2).

(2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10-trien-1-yl diphosphate (3.24):
Yield (28%). 1H NMR (500 MHz, Deuterium Oxide) δ 5.42 (s, 1H), 5.05 (s, 2H), 4.43 (s,
2H), 2.13 – 1.76 (m, 10H), 1.68 (s, 3H), 1.65 – 1.39 (m, 7H), 1.32 (s, 3H), 1.14 – 1.01 (m, 2H),
0.82 (s, 6H).

31

P NMR (202 MHz, Deuterium Oxide) δ -10.16, -14.05. HRMS 451.2022

[M+2H]-, calculated 451.2014 (C20H39O7P2).

General procedure for in vitro biochemical substrate screening:

All biochemical evaluations were performed in our collaborator Dr. Carol Fierke’s
laboratory at the University of Michigan by Elia Wright.

Preliminary evaluation of all

pyrophosphate analogs were performed using GGPP analog (1, 5, or 10 µM), the peptide dansyl-
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GCVLL (5 µM), recombinant mammalian GGTase-I (50 nM), 50 nM HEPPSO pH 7.8, 5 mM
tris(2carboxyethyl)phosphine (TCEP), and 5 mM MgCl2 at 25°C in 96 well plates (Corning).
Protein prenylation was determined by monitoring the dansylated peptide using a continuous
spectrofluorometic assay and all assays were performed in triplicate. Upon prenylation of the
peptide, the activity was measured by an increase in fluorescence intensity of the dansyl group
(λex = 340 nm, λem = 520 nm) in a POLARstar Galaxy plate reader. Peptide in assay buffer was
utilized as a negative control and the baseline fluorescence of the peptide was subtracted from the
reaction signal.
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CHAPTER 4. SYNTHESIS & BIOCHEMICAL EVALUATION OF FRAME-SHIFTED
GERANYLGERANYL PYROPHOSPHATE ANALOGS

4.1

Introduction

Isoprenoids are found in almost all life forms and are the largest and most structurally
diverse class of natural products.123,

124

As such, they are responsible for a multitude of

biochemical functions including their use as hormones (e.g. steroids, gibberellins, and abscisic
acid) and roles in cell membrane structure (e.g. cholesterol), electron transfer (e.g. quinones), and
photosynthesis (e.g. carotenoids).125 As precursors to a myriad of lipid moieties, isoprenoids are
important biosynthetic intermediates that lead to the production of sterols, triterpenes (e.g.
squalene), carotenoids, and hopanoids.125 Isoprenoids can also serve as lipid anchors for proteins
and carbohydrates.4,

126

Perhaps the most interesting and complex group of isoprenoid

biosynthetic products is the vast set of cyclic terpene natural products such as monoterpenes,
sesquiterpenes, and diterpenes.124,

127

Due to the extensive diversity of isoprenoid natural

products, it is not surprising that many promising and effective pharmaceuticals such as Taxol
(cancer), artemisinin (malaria), vinblastine (cancer), and prostratin (HIV) have been
discovered.125 Not only are cyclic isoprenoids of importance to the pharmaceutical industry, but
they are also of great interest in the materials, chemical, and fuel industries.128 Therefore, there is
significant interest in generating novel isoprenoid diphosphate analogs to use as chemical tools to
further explore these multifarious processes.
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Our lab has a long-standing interest in the design and synthesis of novel FPP and GGPP
analogs as chemical tools to explore the enzyme specificity and requirements of FTase. Recently,
Dr. Andrew Placzek developed a method for the preparation of a small library of frame-shifted
FPP analogs (Figure 4.1).75 These analogs were designed to increase and/or decrease the carbon
spacers of the FPP backbone in order to examine the relevance of the length and flexibility of the
isoprenoid chain and how this pertains to FTase activity. Preliminary evaluation revealed that
four of the eight FPP frame-shifted analogs are substrates of FTase (2,2,1,1-OPP; 1,2,1-OPP;
1,3,1-OPP, 3,1,1-OPP; Figure 4.1, Blue solid box). The numbering scheme refers to the number
of carbon spacers between the double bonds or between the first isoprene double bond and the
pyrophosphate group. While three of these compounds have an overall comparable length to that
of FPP, the surprising result was the ability of 2,2,1,1-OPP (an analog that is only one CH2 unit
shorter than GGPP) to act as a substrate of FTase. Moreover, it appears that conformationally
restricting the last isoprene unit leads to very poor or non-substrates. With this information in
hand, we decided to construct 1,2,2,1-OPP (4.21). This analog is of same overall length as
2,2,1,1-OPP and also incorporates the conformationally restrictive 1E,4E-pentadiene structural
motif; thus, it would be interesting to see how these features translate into biochemical activity in
FTase and GGTase-I binding. Additionally, in the case of 3,1,1-OPP and 2,2,1,1-OPP, it appeared
that deletion of a methylene group from between the α and β isoprenoids led to good substrates
with comparable kcat/KM to FPP; however, the kcat and KM values were ~10-fold lower than FPP.
Of the four analogs that did not behave as substrates, a preliminary inhibitory potency
assay revealed that one analog, homofarnesyl diphosphate (2,2,2-OPP), was an inhibitor of FTase
with an IC50 below 1 µM (Figure 4.1, Purple dashed box). This inhibitory activity is believed to
be attributed to the lower nucleophilicity at the now non-allylic C1 (the C attached to the –OPP).
To see if this holds true in GGTase-I binding as well, we synthesized a nonallylic GGPP analog,
homogeranylgeranyl pyrophosphate (2,2,2,2-OPP; 4.32).
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With the preliminary data in hand, our goal was to expand upon this theme and develop
novel frame-shifted analogs in an effort to explore the enzyme specificity and requirements of
GGTase-I versus FTase.

The target compounds were 3,3,1-OPP; 2,3,1-OPP; 1,2,2,1-OPP;

2,2,2,2-OPP; 3,2,1-OPP; 4,2,1-OPP; 5,2,1-OPP; and 6,2,1-OPP (Figure 4.2).

Unlike the

previously synthesized frame-shifted analogs, these analogs are much more flexible and vary
greatly in length between FPP and GGPP. Additionally, 6,2,1-OPP is essentially the same as
GGPP with the exception that the third (γ) isoprene unit has been removed. We believe that
increased flexibility may aid in binding ability.
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A)

B)

Figure 4.1. Frame-shifted analog numbering scheme & previously synthesized FPP analogs. (A)
General numbering scheme. (B) Previously synthesized frame-shifted FPP analogs by Andrew
Plazcek. Green box indicated substrates; red box indicates inhibitor. Green circle indicates
methylene unit added; Red square represents methylene unit removed; Blue solid box represents
substrates; Purple dashed box represents inhibitor; TC = total carbons; l = carbon chain length.
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Figure 4.2. Newly synthesized frame-shifted analogs. Green circle indicates methylene unit
added; Red square represents methylene unit removed; Blue solid box represents substrates;
Purple dashed box represents inhibitor; TC = total carbons; l = carbon chain length.
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4.2

Synthesis of Frame-Shifted Geranylgeranyl Pyrophosphate Analogs

The synthesis began with the preparation of 3,3,1-OPP (Scheme 4.1). To begin, 4pentyn-1-ol (4.1) was transformed into the corresponding iodide (4.2) which underwent Negishi’s
ZACA reaction and quenched with paraformaldehyde to afford iodo-alcohol 4.3.114 Similarly, 5hexyn-1-ol (4.5) underwent a ZACA reaction and was quenched with iodide to yield the vinyliodide 4.6. To install the last isoprene unit, 4.6 was subjected to Swern oxidation conditions
followed by a Wittig reaction to generate vinyl-iodide 4.8. Following THP-protection of alcohol
4.3, alkyl iodide 4.4 could be converted into the organoborane and then coupled with vinyl-iodide
4.8 under Suzuki cross-coupling conditions to afford 3,3,1-OTHP (4.9), which was then

deprotected to yield 4.10.120 Pyrophosphorylation was accomplished in a similar manner as
described by Davisson et al. to produce 4.11 (3,3,1-OPP).112, 113
To synthesize 2,3,1-OH (Scheme 4.2), we first needed to synthesize bishomogeranyl
iodide, 4.14. This could be accomplished by employing a method described by Kuwajima & Doi
and later used in our laboratory.129, 130 Briefly, LDA was added to an equimolar amount of ethyl
acetate in the presence of Cu(I)I at -110°C. The solution was then allowed to slowly warm to 30°C at which point geranyl bromide (4.12) was added to the reaction to give ester 4.13 in 34%
yield.

The ester was then subjected to DIBAL reduction followed by iodination to afford

bishomogeranyl iodide 4.15. Utilizing Suzuki coupling, vinyl-iodide 3.14 and alkyl-iodide 4.15
were coupled. Following deprotection of the TBS-group with TBAF, 4.16 (2,3,1-OH) was
produced in 38% yield. Subsequent chlorination and pyrophosphorylation resulted in compound
4.17.

The strategy for the synthesis of 1,2,2,1-OH was based on the displacement of allylic
diethyl phosphates with Grignard reagents utilized by Snyder and colleagues (Scheme 4.3).111
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Displacement of the phosphate group by Grignard 4.18 followed by THP-deportation produced
4.20 (1,2,2,1-OH). Subsequent chlorination and pyrophosphorylation resulted in compound 4.21.

In the synthesis of 3,2,1-OH (Scheme 4.4), iodide 4.25 was obtained by first converting
the THP ether of farnesol to epoxide 4.22 via a bromohydrin intermediate. Epoxide 4.22 was
then converted to aldehyde 4.23 using periodic acid which was later reduced to alcohol 4.24 via a
borohydride reduction. Following iodination, iodide 4.22 was obtained and subjected to THPdeprotection to afford iodo-alcohol 4.26. Employing a method originally developed by DerguiniBoumechal & Linstrumelle, vinyl-Grignard 4.18 can be used to substitute the alkyl iodide of 4.26
when done in the presence of Cu(I)I to produced 3,2,1,-OH (4.27).75, 131 Subsequent chlorination
and pyrophosphorylation resulted in compound 4.28.
One compound targeted for synthesis was a GGPP analog containing a nonallylic
diphosphate (4.32). Previously, homofarnesyl pyrophosphate (2,2,2-OPP) was synthesized in our
lab as part of an FTase screen.

The significant decrease in nucleophilicity at C1 of the

homoallylic diphosphate lead to the hypothesis that 2,2,2-OPP would behave as a non-substrate.
In fact, homofarnesyl pyrophosphate displayed inhibitory activity with an IC50 below 1µM. Thus,
we hypothesis that homogeranylgeranyl pyrophospahte will behave in a similar manner as the
farnesyl derivative. In order to synthesized homogeranylgeranyl pyrophospahte (2,2,2,2-OPP,
4.32), we utilized a synthetic route similar to the one our laboratory used to synthesized

geranylgeraniol (Scheme 4.5). Briefly, farnesyl chloride (4.29) is subjected to the TMS-propynyl
anion, displacing the chloride.

Following TMS-deprotection with TBAF, alkyne 4.30 can

undergo a ZACA reaction which is subsequently quenched with oxirane to produce
homogeranylgeraniol (3.31).132,

133

Attempts to chlorinate alcohol 4.31 via NCS lead to poor

yields which may be contributed to the less reactive homoallylic position. To avoid this problem,
the alcohol was first converted into the mesylate and subsequently pyrophosphorylated to yield
compound 4.32.112, 113

102
With the above alcohols in hand, we turned to synthesizing the remaining three alcohols
(Scheme 4.6). Commercially available bromo-alkylesters (4.33) were easily converted into the
corresponding iodoalkenes (4.34a-c) with a series of Finkelstein, DIBAL reduction, and Wittig
reactions. In order to complete the unique transformation of 4.34 to 4.37, we employed a strategy
utilized previously in our laboratory which was first developed by Wenkert and colleagues and
later used by Kocienski and colleagues.75, 134-136 In order to transform the carbon-oxygen bonds
into carbon-carbon bonds, this method relies upon the nickel-catalyzed ring opening of
dihydrofurans (or dihydropyrans) with Grignard reagents to produces stereo-defined trisubstituted
alkenes. First, iodides 4.34a-c underwent alkylation with 5-lithio-2,3-dihydrofuran (4.36) using a
modified procedure of Placzek and coworkers.75 We found that increasing the equivalents of 4.36
from 0.95 to 3.0 equivalents resulted in higher yields when applied to our compounds. The newly
prepared alkylated dihydrofuran was immediately reacted with MeMgBr in the presence of
NiCl2(PPh3)2 to produce alcohols 4.37a-c. The corresponding iodides (4.48a-c) were converted
into their organoborane derivatives. Suzuki cross-coupling of these organoboranes with vinyl
iodide 3.14 followed by TBS-deprotection with TBAF afforded alcohols 4.39a-c. Subsequent
chlorination and pyrophosphorylation produced compounds 4.40a-c.
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Scheme 4.1. Synthesis of 3,3,1-OPP. (a) I2, PPh3, Imidazole, DCM, 0°C, 4 hr; (b) Me3Al,
Cp2ZrCl2, DCM, 0°C, 18 hr then (CH2O)n, 3 hr (52%; 2 steps); (c) PPTS, DHP, DCM (86%); (d)
Me3Al, Cp2ZrCl2, DMC 0°C, 18 hr then I2, 3 hr (25%); (e) (COCl)2, DMSO, DCM, -78C, 1hr
then Et3N (67%); (f) i-PrPPh3I, n-BuLi, THF, -78°C, 4 hr (65%); (g) i. t-BuLi, Et2O, -78°C, ii. βMeO-9-BBN, THF, -78°C warming to RT o/n, iii. K3PO4, PdCl2(dppf), DMF, 18 hr; (h) PPTS,
MeOH, 60°C (25%-2 Steps); (i) NCS, DMS, DCM, 0°C to rt, 2.5 hr; (j) (NBu4)3HP2O7, ACN, 2.5
hr (70% - 2 steps).

Scheme 4.2. Synthesis of 2,3,1-OPP. (a) Ethyl Acetate, Cu(I)I, LDA, THF, -110°C (34%) (b)
DIBAL, THF, 0°C; (c) I2, PPh3, Imidazole, DCM, 0°C (68% - 2 Steps); (d) i. t-BuLi, Et2O, 78°C, ii. β-MeO-9-BBN, THF, -78°C warming to RT o/n, iii. K3PO4, PdCl2(dppf), DMF, 85°C,
18 hr; (e) TBAF, THF, 0°C (56% - 2 Steps); (f) NCS, DMS, DCM, 0°C to rt, 2.5 hr; (g)
(NBu4)3HP2O7, ACN, 2.5 hr (43% - 2 steps).
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Scheme 4.3. Synthesis of 1,2,2,1-OPP. (a) 4.18, THF, o/n (52%); (b) PPTS, EtOH, 70°C. (71%);
(c) NCS, DMS, DCM, 0°C to rt, 2.5 hr; (d) (NBu4)3HP2O7, ACN, 2.5 hr (69% - 2 steps).

Scheme 4.4. Synthesis of 3,2,1-OPP. (a) i. NBS, THF:H2O (2:1); ii. K2CO3, MeOH (46% - 2
Steps); (b) i.H5IO6, THF, Et2O; (c) NaBH4, EtOH; (d) PPh3, I2, imidazole, DCM (55%-3 steps);
(e) PPTS, EtOH, 65°C (68%); (f) 4.18, Cu(I)I, THF, -30°C (29%); (g) NCS, DMS, DCM, 0°C to
rt, 2.5 hr; (h) (NBu4)3HP2O7, ACN, 2.5 hr (73% - 2 steps).
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Scheme 4.5. Synthesis of 2,2,2,2-OPP. (a) i. TMS-propyne, n-BuLi, THF, -78°C; ii. TBAF,
THF, 0°C (73%); (b) i. Cp2ZrCl2, Me3Al, DCM, 0°C to r.t., 16 hr; ii. n-BuLi, 0.5 hr, -78°C; iii.
oxirane, 4 hr, -78°C to r.t. (18%); (c) MsCl, DMAP, DCM, 0°C to rt, 2.5 hr; (d) (NBu4)3HP2O7,
ACN, 2.5 hr (71% - 2 steps).

Scheme 4.6. Synthesis of 4,2,1-OPP. 5,2,1-OPP, & 6,2,1-OPP. (a) i. KI, Acetone, Reflux; ii.
DIBAL, DCM, -78°C; iii. i-PrPPh3I, n-BuLi, THF, 0°C; (b) t-BuLi, Et2O, -78°C; (c) i. 4.35, THF,
-78°C to r.t., 16 hr; ii. NiCl2(PPh3)2, MeMgBr, PhH, 75°C; (d) Imidazole, PPh3, I2, 0°C; (e) i. tBuLi, Et2O, -78°C; ii. β-MeO-9-BBN, THF, -78°C to r.t., 16 hr; iii. 3.14, K3PO4, PdCl2(dppf),
DMF, 85°C, 16 hr; (f) TBAF, THF, 0°C; (g) NCS, DMS, DCM, 0°C to rt, 2.5 hr; (h)
(NBu4)3HP2O7, ACN, 2.5 hr.
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4.3

Biochemical Evaluation of Frame-Modified Geranylgeranyl Pyrophosphate Analogs

Previously, Dr. Andrew Placzek of our laboratory synthesized a small library of frameshifted FPP analogs. Upon evaluation of these analogs, it was revealed that four behaved as
substrates while one was shown to be an inhibitor of FTase. Based on these results, our goal was
to synthesize a small library of similar compounds ranging in length between FPP and GGPP.
These frame-shifted analogs (4.11, 4.17, 4.21, 4.28, 4.32, 4.40a-c) were evaluated for their
biochemical activity in an in vitro continuous spectrofluorometric assay with GGTase and the cosubstrate CaaX-peptide dansyl-GCVLL.

All biochemical assays were performed in our

collaborator Dr. Carol Fierke’s laboratory at the University of Michigan by Elia Wright.
Upon in vitro evaluation, it was evident that seven of the eight frame-shifted analogs
(4.11, 4.17, 4.21, 4.28, 4.40a-c) were substrates of GGTase-I. While the data in Figure 4.3 may
not appear to indicate that 4.11 and 4.17 are substrates, an endpoint assay monitored 1 µM
analog, 5 µM peptide, and 50 nM GGTase-I for 3 hours and revealed these analogs do get turned
over by the enzyme, albeit very slowly (Figure 4.5); however, further investigation of these
analogs as potential inhibitors should be considered.
Once again, the chain length of our analogs plays a crucial role in determining substrate
activity; however, by comparing analogs of 13 carbons in chain length (4.17 and 4.28), an
additional feature seems to hinder substrate activity (Figure 4.3 & 4.4). Compounds 4.17 and
4.28 differ only in the position of the β-isoprene unit; by adding an extra methylene group

between the α- and β-isoprene units, substrate activity is decreased. This trend is also apparent
when comparing analogs of 14 carbons in chain length (4.11 and 4.40a; Figures 4.3-4.5). One
possible reason for this observation could be that extending the β-isoprene into the binding pocket
of GGTase could result in unfavorable interactions between the analog and the enzyme and/or
peptide substrate; however, further structural studies are needed. Hence, the β-isoprene unit is
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not required for substrate recognition and activation as demonstrated in Chapter 3; however, if it
is present, its location/orientation in the molecule appears to be crucial.
When comparing compounds of 15 carbons in length (4.21 and 4.40b), it becomes
apparent that chain length plays a much larger role in determining substrate activity rather than
flexibility (Figures 4.3-4.5). The only difference between these two analogs is that 4.40b lacks
the γ-isoprene unit of 4.21; however, both analogs have very similar substrate abilities. Thus, the
lack of flexibility in the ω-isoprene of 4.21 seems not to be an important factor. The similarity
between these two compounds also indicates that the γ-isoprene has no added benefit to the
substrate activity. Addtionally, chain length of molecules containing the ω-isoprene is critical for
substrate activity.
By examining the length of analogs 4.28 and 4.40a-b (Figure 4.4), it appears that
increasing the length of the carbon chain from 13 to 15 carbons has minimal effects on substrate
activity. Thus, having three isoprene units attenuates the effects of increased chain length when
the number of carbons is less than GGPP; however, when the carbon length is increased to that of
GGPP (4.40c), we notice a significant jump in substrate ability. In fact, analog 4.40c exhibited
substrate activity comparable to GGPP. Analog 4.40c also reveals that the γ-isoprene unit of
GGPP is not needed for enzyme recognition.
Not surprisingly, our homo-GGPP analog (4.32) displayed no substrate activity. This
analog was originally synthesized to determine if it would act as an inhibitor of GGTase-I.
Reactions with 1 µM or 5 µM analog with 10 µM GGPP displayed no increase in fluorescence
(Figure 4.6). A preliminary inhibitor assay (Figure 4.6) suggests that analog 4.32 is an inhibitor
of GGTase; a more extensive evaluation is currently underway.
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Figure 4.3. Bar graphs of substrate activity represented in RFI of 4.11, 4.17, 4.21, 4.32, &
1,2,2,1-OPP versus GGPP (+ control) with 5 µM dansyl-GCVLL and 50 nM GGTase-I.. Error
bars represent mean ± SD (n = 3). *Values shown are for 10 µM analog at 1.5 hours.
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Figure 4.4. Bar graphs of substrate activity represented in RFI of 4.28 & 4.40a-c versus GGPP
(+ control) with 5 µM dansyl-GCVLL and 50 nM GGTase-I. Error bars represent mean ± SD (n
= 3). *Values shown are for 10 µM analog at 1.5 hours.
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Figure 4.5. Monitoring continuous changes in fluorescence of frame-shifted GGPP analogs versus GGPP (+ control) at various
concentrations (1 µM, 5µM, & 10µM) with 5 µM dansyl-GCVLL and 50 nM GGTase-I. Experiments were performed in triplicate and data
points represent the mean. Endpoint assays of 4.11 & 4.17 are also included.
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Figure 4.6. Preliminary inhibitor assay results for 4.32 with 50 nM GGTase-I. Raw fluorescence
was not subtracted from background. Reactions with inhibitor were not above background
peptide fluorescence. Experiment was performed in triplicate and data represents the mean.
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4.4

Conclusions

The goal of this chapter was to focus on the synthesis of a small library of frame-shifted
GGPP analogs in order to determine the isoprene requirements of the enzyme GGTase-I.
Previously, our lab synthesized a library of frame-shifted FPP analogs that displayed interesting
result in vivo. Therefore, our laboratory aimed to expand this library to include analogs in length
between FPP and GGPP.
This aim was centered on designing synthetic routes that would enable us to generate our
small library of eight compounds to use as chemical tools to probe the tolerance of the GGTase-I
binding pocket. Unfortunately, no one synthetic route could be utilized for all frame-shifted
compounds. The synthesis of 4.11 was dependent upon the availability of the alkynyl-alcohols
4.1 and 4.5 (Scheme 4.1). This route could not be utilized for the other analogs for multiple

reasons. First, various attempts to oxidize iodo-alcohols shorter than 4.6 resulted in low yields or
unstable aldehydes. Second, longer alkynyl-alcohols of 4.5 needed in the synthesis of 4.40a-c
were not commercially available. Therefore, in order to synthesize 4.17 we utilized a method
originally developed by Kuwajima & Doi and was later used in our laboratory to generate
bishomogeraniol.129 The synthesis of 4.21 was accomplished in a similar manner as employed in
Chapter 2 to generate the aryl-modified analogs.

To generate 4.28, we employed a method

developed by Derguini-Boumechal & Linstrumell to substitute an alkyl iodide with a vinylGrignard reagent.131 This method was later used by Andrew Placzek in the synthesis of the
frame-shifted FPP analogs.75 Homogeranylgeraniol could easily be synthesized utilizing the
ZACA reaction. By simply substituting oxirane for paraformaldehyde we could generate a
homoallylic alcohol which was then converted into 4.32. The remaining analogs 4.40a-c were
synthesized using a modified method as employed by Andrew Placzek to generate the frameshifted FPP analogs.75 This method was originally developed by Wenkert and colleagues and was
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used to synthesize the intermediates (4.37a-c).134 The original method called for 0.95 equivalents
of dihydrofuran 4.35; however, this produced very low yields (< 20%). By increasing the
equivalents to 3 resulted in much higher yielding transformations.
The biochemical evaluation of these compounds revealed several interesting trends. The
first observation was that by increasing or decreasing the number of carbons between the α- and
β-isoprenes by one methylene result in a significant decrease in substrate activity. These analogs
could be selective substrates; thus, while these analogs are poor co-substrates with DansylGCVLL, they could potentially be great co-substrates with other CaaX sequences. Alternatively,
these modifications could hinder product release from the enzyme, which is dependent on the
movement of the isoprene chain into an exit groove; however, further structural analyses are
needed. The second observation is that the length of the carbon chain appears to be more
important than flexibility (4.21 vs 4.39b). Moreover, when the analog has three or more isoprene
units and two carbons between the α- and β-isoprene units, increasing the carbon chain length
from 13 to15 carbons has a minimal effect; however, increasing the length to 16 carbons (4.39c)
has a substantial effect on enzyme activity. Additionally, the γ-isoprene appears to be irrelevant;
by removing this isoprene unit we generated an analog that displays substrate activity comparable
to GGPP. The preliminary data suggests the homoallylic analog (4.32) is an inhibitor of GGTaseI. Further analysis is underway to determine the IC50 value of this analog.
We have successfully generated a small library of frame-shifted GGPP analogs designed
to probe the GGPP binding pocket of GGTase-I. Data shown in Figure 4.5 indicates our frameshifted molecules are either turned over more slowly than GGPP or display a lower affinity for
the enzyme than GGPP. Unfortunately, the analogs were tested at only three concentrations (1, 5,
& 10 µM) and none of the reactions reached completion at 5 or 10 µM of analog in the time they
were monitored. In order to determine accurate kcat and Km values, these analogs are currently
being retested at more concentrations and longer reaction times. Our preliminary results are very
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promising and we anticipate doing more extensive in vitro screening with a large library of
dansyl-GCaaX sequences to determine the selectivity of our analogs. Additionally, we also
expect to test the analogs that demonstrated poor or no substrate activity as inhibitors. These
compounds range in length between GGPP and FPP; therefore, at a later date, we will also be
testing these compounds with FTase to determine their ability to be recognized and utilized by
one enzyme over another.
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4.5

Experimental Procedures Utilized for the Synthesis & Biochemical Evaluation of FrameShifted Geranylgeranyl Pyrophosphate Analogs

General Experimental Procedures: All reactions were performed with oven-dried or flame-

dried glassware and under dry argon gas. All commercial reagents and solvents were used
directly without subsequent purification. For the organmetallic coupling reactions, anhydrous
THF was freshly distilled from sodium and benzophenone. All other anhydrous solvents were
purchased from Acros Organics as extra dry solvents and were bottled over molecular sieves.
Reactions were monitored by thin layer chromatography and visualized with one or more of the
following:

UV

light,

iodine,

vanillin

solution,

potassium

permanganate

dinitrophenylhydrazine solution, and/or phosphomolybdic acid solution.

solution,

All products were

purified using flash chromatography silica gel 60 M purchased from Macherey-Nagel.

All

reactions involving either triphenyl phosphine or triphenyl phosphine oxide were first dry-loaded
with sodium sulfated before column purification. NOTE: *Dry glassware is critical for the
organometallic reactions in this publication.

This was accomplished by taking oven-dried

glassware (dried for at least 24 hr and then cooled under argon) and flame drying the round
bottom flask under vacuum.
temperature.

The flask was then purged with argon and cooled to room

This process was repeated 3 times to produce a completely water free

environment.* **Deoxygenated solvents are extremely crucial for successful organometallic
reactions in this publication. In order to achieve completely deoxygenated solutions, the solvent
was placed in a flame-dried round bottom and under vacuum was sonicated for 30 seconds and
then purged with argon for 30 seconds. This process was repeated 3 times to yield completely
deoxygenated solvents.** All NMR spectra were taken either on a 300 MHz Bruker ARX300 or
a 500 MHz Bruker DRX500 spectrometer. Low-resolution MS (EI/CI) were recorded with a
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Hewlett Packard Engine and low-resolution MS (ESI) were taken on a Thermoquest LCQ. All
high-resolution mass spectra were recorded on a FinniganMAT XL95.

(E)-6-iodo-3-methylhex-2-en-1-ol (4.3):
To a round bottom flask was added pent-4-yn-1-ol (1 eq, 8 mmol), PPh3 (1.3 eq, 10.4
mmol) and imidazole (1.7 eq, 13.6 mmol) dissolved in dichloromethane (10 mL). Next, the
solution was cooled to 0°C with and ice-bath and I2 (1.3 eq, 10.4 mmol) was added to the reaction
flask. The reaction was allowed to stir 0.5 hr at 0°C then allowed to warm to room temperature
and stirred for an additional 1.5 hr. Upon completion of the reaction, 10% Na2S2O3 was added to
the flask and stirred for 20 minutes. The organic layer was isolated and the aqueous layer was
extracted 1 × DCM (10 mL). Due to the volatility of 5-iodopent-1-yne, it was used in the next
step with purification and was not concentrated.
Cp2ZrCl2 (0.25 eq, 2.0 mmol) was dissolved in dichloromethane (8.0 mL) and the
solution was cooled to 0°C, where AlMe3 solution (2.0 M in heptanes, 2.5 eq, 24 mmol, 12.0 mL)
was added dropwise. After stirring the reaction mixture at 0°C for 30 minutes, 5-iodopent-1-yne
(1.0 eq, 8.0 mmol) was diluted in dichloromethane (20 mL) and added to the reaction mixture
dropwise. The reaction mixture was allowed to slowly warm to room temperature and stirred an
additional 12 hours. Next, the reaction mixture was cooled to 0°C, where (CH2O)n (5 eq, 40.0
mmol) was added in several portions. The reaction continued to stir for 3 hours after which it
was slowly poured into an ice-cold 10% HCl(aq) solution. The solution was then filtered over a
pad of Celite 545, extracted with 3 × 30 mL dichloromethane, washed with brine, dried with
magnesium sulfated, filtered, and concentrated. Column chromatography (30% Ethyl acetate in
Hexanes) afforded 4.3a in 52% yield over 2-steps. 1H NMR: (300 MHz, CDCl3) δ 5.44 (ddd, J =
8.1, 5.7, 1.3 Hz, 1H), 4.13 (d, J = 6.8 Hz, 2H), 3.14 (t, J = 6.9 Hz, 2H), 2.11 (t, J = 7.3 Hz, 2H),
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1.98 – 1.87 (m, 2H), 1.65 (s, 3H).

13

C NMR (75 MHz, CDCl3) δ 137.81 (s), 124.84 (s), 59.50 (s),

40.12 (s), 31.48 (s), 16.41 (s), 6.51 (s).

(E)-2-((6-iodo-3-methylhex-2-en-1-yl)oxy)tetrahydro-2H-pyran (4.4):
A round bottom flask was charged with (E)-6-iodo-3-methylhex-2-en-1-ol (1.0 eq, 4.13
mmol) dissolved in DCM (10 mL). Next, 3,4-dihydro-2H-pyran (3.0 eq, 12.40 mmol) and
pyridinium p-toluenesulfonate (0.1 eq, 0.413 eq) were added to the reaction flask. The reaction
was stirred at room temperature for 1 hour and then concentrated. The residue was loaded
directly onto a silica column and column chromatography (7.5% Ethyl acetate in Hexanes)
afforded 4.4a in 86% yield. 1H NMR (300 MHz, Chloroform-d) δ 5.32 (t, J = 6.3 Hz, 1H), 4.53
(s, 1H), 4.04 (ddd, J = 64.9, 11.9, 6.9 Hz, 2H), 3.79 (dd, J = 12.8, 5.6 Hz, 1H), 3.68 – 3.32 (m,
1H), 3.08 (t, J = 6.9 Hz, 2H), 2.05 (t, J = 7.3 Hz, 2H), 1.86 (p, J = 7.0 Hz, 2H), 1.81 – 1.69 (m,
1H), 1.59 (s, 3H), 1.54 – 1.37 (m, 5H).

13

C NMR (75 MHz, Chloroform-d) δ 137.95, 122.02,

97.85, 63.52, 62.28, 40.02, 31.33, 30.70, 25.50, 19.62, 16.37, 6.45.

(E)-6-iodo-5-methylhex-5-en-1-ol (4.6):
Cp2ZrCl2 (0.25 eq, 4.0 mmol) was dissolved in dichloromethane (16.0 mL) and the
solution was cooled to 0°C, where AlMe3 solution (2.0 M in heptanes, 2.5 eq, 48 mmol, 24.0 mL)
was added dropwise. After stirring the reaction mixture at 0°C for 30 minutes, 5-hexyn-1-ol (1.0
eq, 16.0 mmol) was diluted in dichloromethane (8 mL) and added to the reaction mixture
dropwise. The reaction mixture was allowed to slowly warm to room temperature and stirred an
additional 12 hours. Next, the reaction mixture was cooled to 0°C, where I2 (3.5 eq, 56.0 mmol)
was added in several portions. The reaction continued to stir for 3 hours after which it was
slowly poured into an ice-cold 10% HCl(aq) solution. The solution was then filtered over a pad of
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Celite 545, extracted with 3 × 50 mL dichloromethane, washed with brine, dried with magnesium
sulfated, filtered, and concentrated. Column chromatography (15% Ethyl acetate in Hexanes)
afforded 4.6 in 25% yield. 1H NMR (300 MHz, CDCl3) δ 5.86 (dd, J = 2.2, 1.1 Hz, 1H), 3.63
(dd, J = 7.2, 5.0 Hz, 2H), 2.24 – 2.17 (m, 2H), 1.81 (d, J = 1.0 Hz, 3H), 1.54 – 1.47 (m, 5H). 13C
NMR (75 MHz, Chloroform-d) δ 148.00, 75.01, 62.83, 39.46, 32.23, 24.06, 23.96.

(E)-6-iodo-5-methylhex-5-enal (4.7):
An oven-dried multi-neck round bottom flask and addition funnel are assembled while
hot and cooled down under argon. The flask is then charged with (COCl)2 (1.2 eq, 4.84mmol)
dissolved in 5 mL of anhydrous DCM. The flask is then cooled down to -78°C and DMSO (2.4
eq, 9.67 mmol) diluted in 2 mL of anhydrous DCM is added dropwise to the reaction mixture
over the course of 20 minutes via the addition funnel and stirred for an additional 30 minutes at 78°C. Next, (E)-6-iodo-5-methylhex-5-en-1-ol (1.0 eq, 4.03 mmol) is dissolved in 8 mL of
anhydrous DCM and slowly added to the reaction mixture via the addition funnel.

Upon

complete addition of the alcohol, the reaction is stirred for an additional 1.5 hr at -78°C. Finally,
Et3N (5.0 eq, 20.15 mmol) is added to the reaction; the mixture is removed from the cooling bath
and is allowed to stir until it warms to room temperature. The reaction is then quenched by the
addition of 10% NH4Cl and extracted 3 × 50 mL DCM. The organic layers were combined
washed brine, dried with magnesium sulfate, and concentrated. The crude reaction product was
purified by column chromatography (30% Et2O/Hexanes) to afford 4.7 in 67% yield. 1H NMR
(300 MHz, Chloroform-d) δ 9.69 (q, J = 1.2 Hz, 1H), 5.84 (t, 1H), 2.36 (tt, J = 7.2, 1.2 Hz, 2H),
2.17 (t, J = 7.5 Hz, 2H), 1.75 (t, J = 1.1 Hz, 3H), 1.74 – 1.67 (m, 2H).

13

C NMR (75 MHz,

CDCl3) δ 201.83 (s), 146.97 (s), 75.72 (s), 42.87 (s), 38.64 (s), 23.71 (s), 19.95 (s).
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(E)-1-iodo-2,7-dimethylocta-1,6-diene (4.8):
To an oven-dried round bottom flask is added (i-Pr)Ph3PI (1.3 eq, 3.51 mmol) dissolved
in 17.5 mL of anhydrous THF. The mixture is cooled to 0°C where n-BuLi (2.5 M in hexanes,
1.3 eq, 3.51 mmol) is added dropwise. The resulting orange solution is stirred for 1 hr at 0°C.
Next, E)-1-iodo-2,7-dimethylocta-1,6-diene (1.0 eq, 2.7 mmol) is diluted in 1.2 mL of anhydrous
THF and added dropwise to the reaction mixture, which is allowed to stir for 4 hours coming to
room temperature. Upon completion of the reaction, saturated NH4Cl(aq) is added to the reaction
vessel and stirred for 15 minutes. Following extraction with 3 × 50 mL hexanes, the organic
layers were combined, washed with brine, dried with magnesium sulfate, and concentrated. The
crude reaction product was purified by column chromatography (100% Hexanes) to afford 4.8 in
65% yield. 1H NMR (300 MHz, Chloroform-d) δ 5.84 (dd, J = 2.2, 1.1 Hz, 1H), 5.06 (t, J = 7.2
Hz, 1H), 2.18 (t, 2H), 1.93 (q, J = 7.3 Hz, 2H), 1.80 (d, J = 1.0 Hz, 3H), 1.67 (d, J = 0.9 Hz, 3H),
1.57 (s, 3H), 1.50 – 1.39 (m, 2H). 13C NMR (75 MHz, CDCl3) δ 148.21 (s), 132.13 (s), 124.11
(s), 74.75 (s), 39.28 (s), 28.01 (s), 27.50 (s), 25.94 (s), 24.01 (s), 17.95 (s).

2-(((2E,7E)-3,8,13-trimethyltetradeca-2,7,12-trien-1-yl)oxy)tetrahydro-2H-pyran (4.9):
An oven-dried round-bottom flask containing powdered molecular sieves was charged
with (E)-2-((6-iodo-3-methylhex-2-en-1-yl)oxy)tetrahydro-2H-pyran (stored over sieves; 2.11 eq,
3.55 mmol) which was dissolved in 3.5 mL of anhydrous Et2O and cooled to -78°C. Next, t-BuLi
(1.7 M in pentane; 4.22 eq, 7.1 mmol) was slowly added to the reaction flask and stirred for 1
hour at -78°C. Afterward, β-MeO-9-BBN (1.0M in Hexanes; 4 eq, 6.72mmol) was slowly added
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to the reaction vessel and the mixture was stirred for 16 hours slowly warming to room
temperature.
In a scintillation vial, (E)-1-iodo-2,7-dimethylocta-1,6-diene (1.0 eq, 1.68 mmol) and
Pd(dppf)Cl2 (0.1 eq, 0.17 mmol) are dissolved in 8 mL of DMF. Next, K3PO4 (3.0 eq, 5.0 mmol)
is added to the vial and after deoxygenating the solvent, the vinyl-iodide solution is added to the
round-bottom flask containing the newly formed organoborane. The reaction mixture is allowed
to stir for an additional 16 hours at 85°C after which it is poured into a separatory funnel
containing water and Et2O and the aqueous layer was extracted 3 × 50 mL Et2O. The organic
layers were combined and washed with water then brine, dried with magnesium sulfate, and
concentrated.

The crude reaction product was purified by column chromatography (5%

Et2O/Hexanes) to afford 4.9 in 38% yield. 1H NMR (300 MHz, Chloroform-d) δ 5.32 (t, J = 7.0
Hz, 1H), 5.08 (t, J = 7.1 Hz, 2H), 4.60 (t, J = 3.5 Hz, 1H), 4.10 (ddd, J = 62.6, 11.9, 6.8 Hz, 2H),
3.86 (td, J = 7.6, 3.8 Hz, 1H), 3.47 (dd, J = 11.0, 5.1 Hz, 1H), 2.06 – 1.85 (m, 8H), 1.66 (s, 3H),
1.63 (s, 3H), 1.56 (s, 3H), 1.54 (s, 3H), 1.53 – 1.28 (m, 10H).

(2E,7E)-3,8,13-trimethyltetradeca-2,7,12-trien-1-ol (4.10):
In

a

scintillation

vial,

2-(((2E,7E)-3,8,13-trimethyltetradeca-2,7,12-trien-1-

yl)oxy)tetrahydro-2H-pyran (1.0 eq, 0.63 mmol) was dissolved in 5.0 mL of absolute EtOH and
PPTS (0.1 eq, 0.07 mmol) was added to the vial. The reaction mixture was heated to 60°C and
stirred for 12 hours. Next, the reaction was cooled to room temperature where it was poured into
a separator funnel containing water and Et2O and the aqueous layer was extracted 3 × 5 mL Et2O.
The organic layers were combined and washed with water then brine, dried with magnesium
sulfate, and concentrated. The crude reaction product was purified by column chromatography
using 10% Ethyl Acetate/Hexanes as the mobile phase to afford 4.10 in 67% yield.

1

H NMR
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(300 MHz, Chloroform-d) δ 5.38 (dd, J = 7.9, 6.2 Hz, 1H), 5.13 – 5.01 (m, 2H), 4.12 (d, J = 6.8
Hz, 2H), 1.95 (ddd, J = 13.1, 9.4, 6.0 Hz, 8H), 1.66 (s, 3H), 1.64 (s, 3H), 1.57 (s, 3H), 1.55 (s,
3H), 1.41 (ddt, J = 15.0, 12.8, 7.5 Hz, 4H). 13C NMR (75 MHz, Chloroform-d) δ 140.25, 135.63,
131.53, 124.89, 124.37, 123.42, 59.60, 39.53, 39.34, 28.38, 28.09, 27.84, 27.71, 25.94, 17.89,
16.39, 16.15. MS (EI) m/z 250; MS (CI) m/z 249.

(E)-ethyl 5,9-dimethyldeca-4,8-dienoate (4.13):
A round bottom flask charged with Cu(I)I (4.0 eq, 12 mmol) and placed in a drying oven
for 1.5 hr, after which it is cooled to room temperature under argon. Anhydrous EtOAc (2.05 eq,
24.6 mmol, 2.42 mL) and anhydrous THF (90 mL) are added to the round bottom flask, which is
then cooled to -107°C utilizing an isooctane/N2(liq) bath. To this mixture is added LDA (2.0 M in
heptanes/THF/ethyl benzene, 2.05 eq, 24.6 mmol) dropwise. The reaction is allowed to slowly
warm to -30°C over 2 hr, at which point geranyl bromide (1.0 eq, 12 mmol) is dissolved in 15 mL
of THF and added slowly to the reaction mixture. Upon complete addition of geranyl bromide,
the reaction is stirred an additional 1 hr at -30°C, allowed to warm to 0°C and quenched with
saturated NH4Cl (80 mL). The aqueous layer was extracted with 30 mL Et2O × 3, the organic
layers were pooled together, washed with brine, dried with MgSO4, filtered and concentrated.
Purification by flash chromatography using 3% EtOAc/Hexanes as the eluent afforded the title
compound in 34% yield. 1H NMR (300 MHz, Chloroform-d) δ 5.13 – 5.01 (m, 2H), 4.10 (q, J =
7.1 Hz, 2H), 2.29 (d, J = 3.1 Hz, 4H), 2.10 – 1.88 (m, 4H), 1.65 (s, 3H), 1.59 (s, 3H), 1.57 (s,
3H), 1.23 (t, J = 7.2 Hz, 3H).

13

C NMR (75 MHz, Chloroform-d) δ 191.48, 136.71, 131.54,

124.30, 122.45, 60.35, 39.78, 34.69, 26.76, 25.82, 23.71, 17.82, 16.13, 14.40.
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(E)-5,9-dimethyldeca-4,8-dien-1-ol (4.14):
To an oven-dried round bottom flask is added (E)-ethyl 5,9-dimethyldeca-4,8-dienoate
(1.0 eq, 4.034 mmol) dissolved in 15 mL of toluene which is then cooled to -78°C. DIBAL (1.0
M in toluene, 4.0 eq) was added dropwise to the reaction mixture and allowed to stir for 4 hours.
The reaction mixtures was then slowly poured into an ice-cold 10% HCl(aq) solution and then
filtered over a pad of Celite 545. The aqueous layer was extracted with 30 mL Et2O × 3, the
organic layers were pooled together, washed with brine, dried with MgSO4, filtered and
concentrated. Purification by flash chromatography using 15% EtOAc/Hexanes as the eluent
afforded the title compound in 38% yield (Yield given is for 2-steps from geranyl bromide). 1H
NMR (300 MHz, Chloroform-d) δ 5.09 (t, J = 7.6 Hz, 1H), 5.03 (t, J = 7.0 Hz, 1H), 3.56 (t, J =
6.6 Hz, 2H), 2.36 (s, 1H), 2.08 – 1.87 (m, 6H), 1.63 (s, 3H), 1.61 – 1.49 (m, 8H). 13C NMR (75
MHz, Chloroform-d) δ 135.76, 131.46, 124.38, 123.92, 62.57, 39.84, 32.82, 26.77, 25.79, 24.36,
17.77, 16.05.

(Z)-10-iodo-2,6-dimethyldeca-2,6-diene (4.15):
To a round bottom flask was added (E)-5,9-dimethyldeca-4,8-dien-1-ol (1 eq, 4.6 mmol),
PPh3 (1.3 eq, 6.0 mmol) and imidazole (1.7 eq, 7.8 mmol) dissolved in dichloromethane (15 mL).
Next, the solution was cooled to 0°C with and ice-bath and I2 (1.3 eq, 6.0 mmol) was added to the
reaction flask. The reaction was allowed to stir 0.5 hr at 0°C then allowed to warm to room
temperature and stirred for an additional 1.5 hr. Upon completion of the reaction, 10% Na2S2O3
was added to the flask and stirred for 20 minutes. The organic layer was isolated and the aqueous
layer was extracted 3 × DCM (10 mL). The organic layers were pooled together, washed with
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brine, dried with MgSO4, filtered and concentrated. Purification by flash chromatography using
hexanes as the eluent afforded the title compound in 68% yield.

1

H NMR (300 MHz,

Chloroform-d) δ 5.04 (td, J = 7.4, 6.7, 3.9 Hz, 2H), 3.16 (t, J = 6.9 Hz, 2H), 2.14 – 1.92 (m, 6H),
1.84 (p, J = 7.0 Hz, 2H), 1.66 (s, 3H), 1.61 (s, 3H), 1.58 (s, 3H).

13

C NMR (75 MHz,

Chloroform-d) δ 136.94, 131.64, 124.38, 122.46, 39.91, 33.81, 28.79, 26.77, 25.94, 17.92, 16.42,
7.06.

(2E,7E)-3,8,12-trimethyltrideca-2,7,11-trien-1-ol (4.16):
An oven-dried round-bottom flask containing powdered molecular sieves was charged
with (Z)-10-iodo-2,6-dimethyldeca-2,6-diene (stored over sieves; 2.0 eq) which was dissolved in
4.6 mL of anhydrous Et2O and cooled to -78°C. Next, t-BuLi (1.7M in pentane; 3.0 eq, 2.06
mmol) was slowly added to the reaction flask and stirred for 1 hour at -78°C. Afterward, β-MeO9-BBN (1.0M in Hexanes; 3.8 eq, 2.6 mmol) was slowly added to the reaction vessel and the
mixture was stirred for 16 hours slowly warming to room temperature.
In a scintillation vial, (E)-tert-butyl((3-iodobut-2-en-1-yl)oxy)dimethylsilane (1.0 eq,
0.69 mmol) and Pd(dppf)Cl2 (0.15 eq, 0.10 mmol) are dissolved in 6.6 mL of DMF. Next, K3PO4
(3.0 eq, 2.06 mmol) is added to the vial and after deoxygenating the solvent, the vinyl-iodide
solution is added to the round-bottom flask containing the newly formed organoborane. The
reaction mixture is allowed to stir for an additional 16 hours at 85°C after which it is poured into
a separatory funnel containing water and Et2O and the aqueous layer was extracted 3 × 50 mL
Et2O.

The organic layers were combined and washed with water then brine, dried with

magnesium sulfate, and concentrated. The crude reaction product was run through a silica
column (3% EtOAc/Hexanes) to remove most of the impurities and any oxidizing species.
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In a scintillation vial, the semi-crude product was dissolved in 5.0 mL of THF, cooled to
0°C, and TBAF (1.0 M in THF, 2.0 eq, 1.15 mmol) was added to the vial. The reaction was
allowed to stir for 4 hours and then quenched with 10% NH4Cl(aq). Next, the organic layer was
removed, and the aqueous layer was extracted 3 × Et2O (10 mL). The organic layers are
combined, washed with brine, dried with MgSO4, filtered, and concentrated. The crude reaction
product was purified by column chromatography using 15% Ethyl Acetate/Hexanes as the mobile
phase to afford 4.16 in 56% yield. 1H NMR (300 MHz, Chloroform-d) δ 5.35 (t, J = 7.0 Hz, 1H),
5.07 (q, J = 7.3 Hz, 2H), 4.09 (d, J = 6.9 Hz, 2H), 1.95 (h, J = 7.0 Hz, 8H), 1.64 (s, 3H), 1.62 (s,
3H), 1.56 (s, 3H), 1.55 (s, 3H), 1.42 (p, J = 7.5 Hz, 2H).

13

C NMR (75 MHz, Chloroform-d) δ

140.15, 135.40, 131.47, 124.53, 124.46, 123.43, 59.55, 39.92, 39.28, 28.03, 27.67, 26.87, 25.89,
17.87, 16.37, 16.19. MS (EI) m/z 236; MS (CI) m/z 235.

2-(((2E,6E,10E)-3,7,11,14-tetramethylpentadeca-2,6,10,13-tetraen-1-yl)oxy)tetrahydro-2H-pyran
(4.19):

In an oven-dried round bottom flask is added 2.3 (1.0 eq, 0.5 mmol) dissolved in 2.5 mL
of anhydrous THF. The mixture is cooled to 0°C where 2-methyl-1-propenylmagnesium bromide
(0.5 M in THF, 10 eq, 5 mmol) is added dropwise. The mixture is allowed to stir for 12 hours
and quenched by the addition of 10% NH4Cl(aq) solution. The mixture was then poured into a
separator funnel and the aqueous layer was extracted 3 × 10 mL Et2O. The organic layers were
combined and washed with water then brine, dried with magnesium sulfate, and concentrated.
The crude reaction product was purified by column chromatography using 3% Ethyl
Acetate/Hexanes as the mobile phase to afford 4.19 in 52% yield.

1

H NMR (300 MHz,

Chloroform-d) δ 5.40 – 5.30 (m, 1H), 5.19 – 4.97 (m, 3H), 4.60 (dd, J = 4.3, 2.7 Hz, 1H), 4.21
(dd, J = 11.9, 6.4 Hz, 1H), 4.00 (dd, J = 11.9, 7.4 Hz, 1H), 3.95 – 3.79 (m, 1H), 3.59 – 3.44 (m,
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1H), 2.61 (d, J = 7.5 Hz, 2H), 2.22 – 1.88 (m, 8H), 1.69 (d, J = 1.5 Hz, 3H), 1.66 (d, J = 1.3 Hz,
4H), 1.61 – 1.46 (m, 14H).

13

C NMR (75 MHz, Chloroform-d) δ 140.49, 135.42, 134.74, 132.57,

124.22, 124.10, 122.86, 120.73, 97.96, 63.84, 62.47, 39.91, 39.85, 38.43, 30.92, 26.87, 26.50,
26.01, 25.71, 19.83, 17.86, 16.64, 16.36, 16.23.

(2E,6E,10E)-3,7,11,14-tetramethylpentadeca-2,6,10,13-tetraen-1-ol (4.20):
In a scintillation vial, 1,2,2,1-OTHP (1.0 eq, 0.258 mmol) was dissolved in 5.0 mL of
absolute EtOH and PPTS (0.1 eq, 0.026 mmol) was added to the vial. The reaction mixture was
heated to 75°C and stirred for 12 hours. Next, the reaction was cooled to room temperature
where it was poured into a separator funnel containing water and Et2O and the aqueous layer was
extracted 3 × 5 mL Et2O. The organic layers were combined and washed with water then brine,
dried with magnesium sulfate, and concentrated. The crude reaction product was purified by
column chromatography using 10% Ethyl Acetate/Hexanes as the mobile phase to afford 4.20 in
71% yield. 1H NMR (300 MHz, Chloroform-d) δ 5.48 – 5.36 (m, 1H), 5.22 – 5.04 (m, 3H), 4.12
(d, J = 7.0 Hz, 2H), 2.61 (d, J = 7.4 Hz, 2H), 2.19 – 1.86 (m, 9H), 1.68 (s, 3H), 1.65 (s, 3H), 1.59
(s, 3H), 1.57 (s, 3H), 1.54 (s, 3H).

13

C NMR (75 MHz, Chloroform-d) δ 139.94, 135.53, 134.76,

132.58, 124.17, 123.97, 123.49, 122.84, 59.55, 39.88, 39.74, 38.40, 26.84, 26.49, 25.99, 17.84,
16.47, 16.35, 16.19. MS (EI) m/z 258 [M+-H2O]; MS (CI) m/z 259 [M++H-H2O].

2-(((2E,6E)-9-(3,3-dimethyloxiran-2-yl)-3,7-dimethylnona-2,6-dien-1-yl)oxy)tetrahydro-2Hpyran (4.22):
A suspension of THP-protected farnesol (1.0 eq, 5.55 mmol) in 50 mL THF/H2O (2:1)
was added to a round bottom flask and cooled to 0°C. THF was carefully added dropwise to the
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mixture to discharge the turbidity. Next, NBS (1.1 eq, 6.1 mmol) was added and the reaction
mixture was allowed to warm to room temperature. After 3 hr of stirring, the THF is evaporated
and the aqueous layer is extracted 3 × 20 mL hexanes. The organic layers were pooled, washed
with brine, dried with MgSO4, and concentrated. The bromo-hydrin was taken on cured in the
following step by dissolving it in MeOH (70 mL) and adding K2CO3 (2.0 eq, 11.1 mmol) to the
mixture. The reaction was allowed to stir for 1 hr then the MeOH was removed. Water (50 mL)
and Et2O (20 mL) were added to the concentrated solution. The Et2O layer was collected and the
aqueous layer was further extracted with 20 mL Et2O × 2, the organic layers were pooled
together, washed with brine, dried with MgSO4, filtered and concentrated. Purification by flash
chromatography using 10% EtOAc/Hexanes as the eluent afforded the title compound in 46%
yield. 1H NMR (300 MHz, Chloroform-d) δ 5.31 (t, J = 6.3 Hz, 1H), 5.11 (t, J = 6.2 Hz, 1H),
4.58 (t, J = 3.4 Hz, 1H), 4.08 (ddd, J = 66.2, 11.9, 6.9 Hz, 2H), 3.85 (ddd, J = 11.1, 7.3, 3.4 Hz,
1H), 3.46 (dt, J = 10.5, 4.8 Hz, 1H), 2.65 (t, J = 6.2 Hz, 1H), 2.03 (dq, J = 13.6, 7.1, 5.8 Hz, 6H),
1.95 – 1.39 (m,14H), 1.25 (s, 3H), 1.21 (s, 3H).

13

C NMR (75 MHz, CDCl3) δ 140.24 (s), 134.49

(s), 124.69 (s), 120.81 (s), 97.97 (s), 64.34 (s), 63.80 (s), 62.44 (s), 58.50 (s), 39.70 (s), 36.46 (s),
30.87 (s), 27.59 (s), 26.43 (s), 25.66 (s), 25.07 (s), 19.79 (s), 18.92 (s), 16.60 (s), 16.18 (s).

4E,8E)-4,8-dimethyl-10-((tetrahydro-2H-pyran-2-yl)oxy)deca-4,8-dien-1-ol (4.25):
To an oven-dried round bottom flask is added H5IO6 (1.2 eq, 3.05 mmol) in 2.5 mL of
THF and cooled to 0°C where 4.22 (1.0 eq, 2.54 mmol) in 13 mL of Et2O was added rapidly to
the reaction flask. The reaction was allowed to stir for 30 minutes and quenched by the addition
of 40mL of saturated Na2S2O3(aq). The Et2O layer was collected and the aqueous layer was further
extracted with 20 mL Et2O × 3, the organic layers were pooled together, washed with brine, dried
with MgSO4, filtered, concentrated, and taken on crude.
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To an oven-dried round bottom flask was added 4.23 (1.0 eq, 2.54 mmol) in 30 mL of
absolute EtOH and cooled to 0°C. Next, NaBH4 (2.0 eq, 5.1 mmol) was added to the reaction
vessel in several portions and the reaction was allowed to stir for 1 hour. The reaction was then
quenched by the addition of 50 mL of water and extracted with 20 mL Et2O × 3, the organic
layers were pooled together, washed with brine, dried with MgSO4, filtered, concentrated, and
again taken on crude.
To a round bottom flask was added alcohol 4.24 (1.0 eq, 2.54 mmol), PPh3 (1.3 eq, 3.3
mmol) and imidazole (1.7 eq, 4.23 mmol) dissolved in dichloromethane (10 mL). Next, the
solution was cooled to 0°C with and ice-bath and I2 (1.3 eq, 3.3 mmol) was added to the reaction
flask. The reaction was allowed to stir 0.5 hr at 0°C then allowed to warm to room temperature
and stirred for an additional 1.5 hr. Upon completion of the reaction, 10% Na2S2O3 was added to
the flask and stirred for 20 minutes. The organic layer was isolated and the aqueous layer was
extracted 3 × DCM (10 mL). The organic layers were pooled together, washed with brine, dried
with MgSO4, filtered and concentrated.

Purification by flash chromatography using 5%

EtOAc/hexanes as the eluent afforded the title compound in 55% yield over 3 steps.

1

H NMR

(300 MHz, Chloroform-d) δ 5.37 – 5.29 (m, 1H), 5.13 (t, J = 6.2 Hz, 1H), 4.59 (t, J = 3.5 Hz,
1H), 4.10 (ddd, J = 66.0, 11.9, 6.9 Hz, 2H), 3.91 – 3.79 (m, 1H), 3.58 – 3.39 (m, 1H), 3.10 (t, J =
6.9 Hz, 2H), 2.16 – 1.67 (m, 10H), 1.64 (s, 3H), 1.60 – 1.43 (m, 7H).

13

C NMR (75 MHz,

CDCl3) δ 140.15 (s), 133.28 (s), 125.61 (s), 120.92 (s), 97.98 (s), 63.81 (s), 62.46 (s), 40.15 (s),
39.66 (s), 31.67 (s), 30.89 (s), 26.36 (s), 25.67 (s), 19.80 (s), 16.57 (s), 16.01 (s), 6.91 (s).

(2E,6E)-10-iodo-3,7-dimethyldeca-2,6-dien-1-ol (4.26):
In

a

scintillation

vial,

2-(((2E,6E)-10-iodo-3,7-dimethyldeca-2,6-dien-1-

yl)oxy)tetrahydro-2H-pyran (1.0 eq, 0.88 mmol) was dissolved in 5.0 mL of absolute EtOH and
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PPTS (0.1 eq, 0.09 mmol) was added to the vial. The reaction mixture was heated to 75°C and
stirred for 12 hours. Next, the reaction was cooled to room temperature where it was poured into
a separator funnel containing water and Et2O and the aqueous layer was extracted 3 × 5 mL Et2O.
The organic layers were combined and washed with water then brine, dried with magnesium
sulfate, and concentrated. The crude reaction product was purified by column chromatography
using 10% Ethyl Acetate/Hexanes as the mobile phase to afford 4.26 in 68% yield.

1

H NMR

(300 MHz, Chloroform-d) δ 5.37 (t, J = 6.9 Hz, 1H), 5.13 (t, J = 6.7 Hz, 1H), 4.11 (d, J = 7.0 Hz,
2H), 3.10 (t, J = 6.9 Hz, 2H), 2.04 (dd, J = 13.7, 6.2 Hz, 6H), 1.92 – 1.77 (m, 2H), 1.63 (s, 3H),
1.55 (s, 3H).

13

C NMR (75 MHz, Chloroform-d) δ 139.49, 133.32, 125.51, 123.71, 59.49, 40.06,

39.55, 31.57, 26.33, 16.40, 15.98, 6.95.

(2E,6E)-3,7,12-trimethyltrideca-2,6,11-trien-1-ol (4.27):
To an oven-dried round bottom flask is added (2E,6E)-10-iodo-3,7-dimethyldeca-2,6dien-1-ol (1.0 eq, 0.6 mmol) and dissolved in 2.2 mL of anhydrous THF. Next, Cu(I)I (0.5 eq,
0.3 mmol) is added to the flask and the mixture is cooled to

-40°C, where 2-methyl-1-

propenylmagnesium bromide (0.5 M in THF, 5.0 eq, 3.0 mmol, 6 mL) is slowly added dropwise
to the reaction. The reaction is rapidly warmed to 0°C and stirred for 9 hr. Warming to room
temperature, the reaction is allowed to stir for an additional 9 hr then slowly poured into beaker
containing 30 mL of 10% NH4Cl(aq) and 10 mL of Et2O. The organic layer was isolated and the
aqueous layer was extracted 3 × Et2O (10 mL). The organic layers were pooled together, washed
with brine, dried with MgSO4, filtered and concentrated. Purification by flash chromatography
using 25% EtOAc/hexanes as the eluent afforded the title compound in 29% yield. 1H NMR (300
MHz, Chloroform-d) δ 5.44 – 5.33 (m, 1H), 5.22 – 4.94 (m, 2H), 4.12 (d, J = 6.9 Hz, 2H), 2.15 –
1.97 (m, 4H), 1.91 (dt, J = 13.7, 7.3 Hz, 4H), 1.66 (d, J = 2.8 Hz, 6H), 1.56 (s, 6H), 1.38 (p, J =
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7.6 Hz, 2H).

13

C NMR (75 MHz, Chloroform-d) δ 139.96, 135.71, 131.58, 124.86, 123.89,

123.53, 59.60, 39.77, 39.47, 28.33, 27.81, 26.46, 25.94, 17.89, 16.47, 16.12. MS (EI) m/z 236.

(5E,9E)-6,10,14-trimethylpentadeca-5,9,13-trien-1-yne (4.30):
An oven-dried round bottom flask is cooled under argon and charged with TMS-propyne
(1.3 eq, 6.5 mmol) and 8 mL of anhydrous THF then cooled to -78°C. Next, n-BuLi (2.5 M in
hexanes, 1.3 eq, 6.5 mmol) is added dropwise. The reaction mixture is allowed to stir for 1.5 hr,
after which farnesyl chloride (1.0 eq, 5 mmol) is dissolved in THF (2 mL) and added slowly to
the reaction mixture at -78°C. The reaction is allowed to stir 16 hr and is then quenched by the
addition of 10% NH4Cl(aq). The organic layer was isolated and the aqueous layer was extracted 3
× Et2O (25 mL). The organic layers were pooled together, washed with brine, dried with MgSO4,
filtered and concentrated. The crude TMS-protected alkyne was used directly in the next step
without purification.
In a round bottom flask was added trimethyl((5E,9E)-6,10,14-trimethylpentadeca-5,9,13trien-1-yn-1-yl)silane (1.0 eq, 5 mmol) and 20 mL of THF and cooled to 0°C. Next, TBAF (1.0
M in THF, 1.5 eq, 7.5 mmol) is added to the reaction flask and allowed to stir for 2 hours. Upon
completion of the reaction, 30 mL of 10% NH4Cl(aq) and 15 mL Et2O are added and the organic
layer was isolated. The aqueous layer was further extracted 3 × Et2O (20 mL). The organic
layers were pooled together, washed with brine, dried with MgSO4, filtered and concentrated.
The crude reaction product was purified by column chromatography using 1% Ethyl
Acetate/Hexanes as the mobile phase to afford 4.30 in 73% yield (yield given is for 2 steps). 1H
NMR (300 MHz, Chloroform-d) δ 5.15 (t, J = 7.0 Hz, 1H), 5.08 (q, J = 6.4 Hz, 2H), 2.26 – 2.12
(m, 4H), 2.12 – 1.93 (m, 8H), 1.92 (d, J = 2.4 Hz, 1H), 1.66 (s, 3H), 1.61 (s, 3H), 1.58 (s, 6H).

129
13

C NMR (75 MHz, Chloroform-d) δ 136.90, 135.20, 131.44, 124.57, 124.26, 122.65, 84.71,

68.30, 39.92, 39.83, 27.39, 26.95, 26.70, 25.91, 19.12, 17.88, 16.32, 16.21.

(3E,7E,11E)-4,8,12,16-tetramethylheptadeca-3,7,11,15-tetraen-1-ol (4.31):
Cp2ZrCl2 (0.25 eq, 0.81 mmol) was dissolved in dichloromethane (3.5 mL) and the
solution was cooled to 0°C, where Me3Al solution (2.0 M in heptanes, 2.5 eq, 8.1 mmol) was
added dropwise. After stirring the reaction mixture at 0°C for 30 minutes, (5E,9E)-6,10,14trimethylpentadeca-5,9,13-trien-1-yne (1.0 eq, 3.22 mmol) was diluted in dichloromethane (1.6
mL) and added to the reaction mixture dropwise. The reaction mixture was allowed to slowly
warm to room temperature and stirred an additional 12 hours. Next, the reaction mixture was
cooled to -78°C and n-BuLi (2.5 M in hexanes, 1.5 eq, 4.8 mmol) was added dropwise and the
reaction was stirred for 1 hr. After 1 hr, ethylene oxide (1.4 M in toluene, 3.0 eq, 9.7 mmol) was
slowly added dropwise to the reaction at -78°C. The reaction continued to stir for 5 hours, slowly
warming to room temperature. The reaction mixture was then slowly poured into an ice-cold
10% HCl(aq) solution. The solution was then filtered over a pad of Celite 545, extracted with 3 ×
50 mL dichloromethane, washed with brine, dried with magnesium sulfated, filtered, and
concentrated. Column chromatography (15% acetone/hexanes) afforded 4.31 in 41% yield. 1H
NMR (300 MHz, Chloroform-d) δ 5.09 (q, J = 7.7 Hz, 4H), 3.59 (t, J = 6.5 Hz, 2H), 2.26 (q, J =
6.8 Hz, 2H), 2.14 – 1.86 (m, 12H), 1.65 (s, 3H), 1.62 (s, 3H), 1.57 (s, 9H).

13

C NMR (75 MHz,

Chloroform-d) δ 139.12, 135.49, 135.13, 131.47, 124.57, 124.37, 124.17, 120.03, 62.60, 40.01,
39.93, 39.90, 31.68, 26.95, 26.82, 26.69, 25.91, 17.89, 16.42, 16.23, 16.20. MS (EI) m/z 304; MS
(CI) m/z 305.
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Representative procedure for the synthesis of alkyl-iodides 4.34a-c:

7-iodo-2-methylhept-2-ene (4.34a):
To a round bottom flask was added ethyl 5-bromovalerate (1.0 eq, 20 mmol) and acetone
(30 mL). Next, KI (2.0 eq, 40 mmol) was to the flask and the reaction was reluxed at 65°C for 20
hr. The acetone was the removed and the crude iodide was used directly without purification.
To an oven-dried round bottom flask cooled under argon was added ethyl 5-iodovalerate
(1.0 eq, 20 mmol) dissolved in 100 mL of anhydrous toluene. The solution was then cooled to 78°C where DIBAL (1.1 eq, 22 mmol) was added dropwise. The reaction was allowed to stir for
5 hours at -78°C and then was poured into an ice-cold 10% HCl(aq) solution. The mixture was
then filtered over a pad of Celite 545, extracted with 3 × 50 mL Et2O, washed with brine, dried
with magnesium sulfated, filtered, and concentrated. The crude aldehyde was used directly
without purification.
To an oven-dried round bottom flask is added (i-Pr)Ph3PI (1.1 eq, 22 mmol) dissolved in
80 mL of anhydrous THF. The mixture is cooled to 0°C where n-BuLi (2.5 M in hexanes, 1.1 eq,
22 mmol,) is added dropwise. The resulting orange solution is stirred for 1 hr at 0°C. Next, 5iodopentanal (1.0 eq, 20 mmol) is diluted in 9 mL of anhydrous THF and added dropwise to the
reaction mixture, which is allowed to stir for 16 hours coming to room temperature. Upon
completion of the reaction, saturated NH4Cl(aq) is added to the reaction vessel and stirred for 15
minutes. Following extraction with 3 × 50 mL hexanes, the organic layers were combined,
washed with brine, dried with magnesium sulfate, and concentrated. The crude reaction product
was purified by column chromatography (100% Hexanes) to afford 4.34a in 64% yield. 1H NMR
(300 MHz, Chloroform-d) δ 5.07 (tt, J = 8.7, 5.8, 1.4 Hz, 1H), 3.16 (t, J = 7.1 Hz, 2H), 1.96 (q,
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2H), 1.80 (p, J = 14.6, 7.1 Hz, 2H), 1.66 (s, 3H), 1.57 (s, 3H), 1.40 (p, J = 7.4 Hz, 2H).

13

C NMR

(75 MHz, Chloroform-d) δ 132.17, 124.06, 33.32, 30.87, 27.08, 25.92, 17.90, 7.35.

8-iodo-2-methyloct-2-ene (4.34b):
Yield (30%). 1H NMR (300 MHz, Chloroform-d) δ 5.09 (dddt, J = 7.2, 5.8, 2.9, 1.5 Hz,
1H), 3.18 (t, J = 7.1 Hz, 2H), 1.98 (q, J = 6.4, 6.0 Hz, 2H), 1.82 (p, J = 7.1 Hz, 2H), 1.68 (s, 3H),
1.60 (s, 3H), 1.47 – 1.27 (m, 4H).

13

C NMR (75 MHz, Chloroform-d) δ 131.79, 124.52, 33.71,

30.37, 28.97, 27.97, 25.94, 17.91, 7.42.

9-iodo-2-methylnon-2-ene (4.34c):
Yield (47%). 1H NMR (300 MHz, Chloroform-d) δ 5.12 – 4.82 (m, 1H), 3.16 (t, J = 7.0
Hz, 2H), 1.94 (q, J = 6.8 Hz, 2H), 1.80 (p, J = 7.0 Hz, 2H), 1.66 (s, 3H), 1.57 (s, 3H), 1.43 – 1.23
(m, 6H). 13C NMR (75 MHz, Chloroform-d) δ 131.54, 124.77, 33.75, 30.62, 29.82, 28.37, 28.08,
25.94, 17.89, 7.49.
Representative procedure for the synthesis of homo-allylic alcohols 4.37 a-c:

(E)-4,12-dimethyltrideca-3,11-dien-1-ol (4.37c):
To an oven-dried round bottom flask is added powdered molecular sieves and is cooled
under argon. The round bottom was then flamed-dried under vacuum and cooled under argon;
this process was repeated 3 times. Next, 3 mL of anhydrous THF was added to the round bottom
flask which was sonicated under vacuum for 30 seconds and then the atmosphere was replaced
with argon for 30 seconds; this process was also repeated 3 times. Next, 2,3-dihydrofuran (stored
over molecular sieves, 3.0 eq, 18 mmol) was added to the reaction vessel and the solution was
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cooled to -78°C where t-BuLi (1.7 M in heptanes, 3.0 eq, 18 mmol) was slowly added dropwise
over 5 – 10 minutes. The reaction was stirred at -78°C for 10 minutes then placed in a 0°C ice
bath and continued to stir for 1 hr. Next, the reaction mixture was cooled back -78°C and 9-iodo2-methylnon-2-ene (1.0 eq, 5.7 mmol) in 2.5 mL of anhydrous THF (also sonicated as described
above) was added to the reaction vessel. The reaction was stirred for 20 hr slowly coming to
room temperature and then poured into a beaker containing ice-cold 20 mL of saturated NH4Cl(aq)
and 2 mL of NH4OH. The mixture was allowed to stir for 20 minutes and then extracted with 3 ×
20 mL Et2O, the organic layers were combined, washed with brine, dried with magnesium sulfate,
concentrated (at room temperature), and used immediately in the next step.
To an oven-dried round bottom flask is added NiCl2(PPh3)2 (0.05 eq, 0.3 mmol) dissolved
in anhydrous benzene (17 mL). The round bottom flask was sonicated under vacuum for 30
seconds and then the atmosphere was replaced with argon for 30 seconds; this process was
repeated 3 times. Next, MeMgBr (3.0 M in Et2O, 2.9 eq, 17.4 mmol) was added slowly to the Nicatalyst solution and stirred for 30 minutes at room temperature. Next, a solution of the newly
alkylated-furan (1.0 eq, 5.7 mmol) was dissolved in benzene (15 mL) and deoxygenated by
sonication as previously described. After deoxygenation, the alkylated-furan solution was added
slowly to the Ni-catalyst solution and the reaction was refluxed at 80°C for 12 hours. The
reaction is then cooled to room temperature and poured into a beaker containing 250 mL of
saturated NH4Cl(aq) and 100 mL of Et2O. The organic layer was isolated and the aqueous layer
was extracted 3 × Et2O (50 mL). The organic layers were pooled together, washed with brine,
dried with MgSO4, filtered and concentrated. Purification by flash chromatography using 20%
EtOAc/hexanes as the eluent afforded the title compound in 69% yield.

1

H NMR (300 MHz,

Chloroform-d) δ 5.18 – 4.94 (m, 2H), 3.59 (t, J = 6.5 Hz, 2H), 2.26 (q, J = 6.8 Hz, 2H), 1.95 (q, J
= 7.4 Hz, 4H), 1.66 (s, 3H), 1.60 (s, 3H), 1.57 (s, 3H), 1.31 – 1.14 (m, 8H).

13

C NMR (75 MHz,
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Chloroform-d) δ 139.46, 131.37, 125.06, 119.65, 62.70, 40.02, 31.68, 30.05, 29.45, 29.41, 28.22,
28.13, 25.93, 17.86, 16.34.

(E)-4,11-dimethyldodeca-3,10-dien-1-ol (4.37b):
Yield (72%). 1H NMR (300 MHz, Chloroform-d) δ 5.08 (ddt, J = 7.1, 2.9, 1.5 Hz, 2H),
3.58 (t, 2H), 2.25 (q, J = 6.6 Hz, 2H), 1.95 (h, J = 7.1 Hz, 4H), 1.66 (s, 3H), 1.60 (s, 3H), 1.56 (s,
3H), 1.43 – 1.17 (m, 6H).

13

C NMR (75 MHz, Chloroform-d) δ 139.36, 131.40, 125.00, 119.69,

62.66, 39.98, 31.67, 29.94, 29.16, 28.18, 28.05, 25.91, 17.84, 16.30.

(E)-4,10-dimethylundeca-3,9-dien-1-ol (4.37a):
Yield (33%). 1H NMR (300 MHz, Chloroform-d) δ 5.08 (q, J = 6.3, 5.5 Hz, 2H), 3.58 (t,
J = 6.6 Hz, 2H), 2.25 (q, J = 6.6 Hz, 2H), 1.95 (dt, J = 13.2, 6.7 Hz, 4H), 1.65 (s, 3H), 1.60 (s,
3H), 1.57 (s, 3H), 1.45 – 1.19 (m, 4H).

13

C NMR (75 MHz, Chloroform-d) δ 139.29, 131.48,

124.89, 119.73, 62.67, 39.89, 31.66, 29.69, 28.08, 27.74, 25.91, 17.85, 16.28.
Representative procedure for the synthesis of homo-allylic iodides 4.38a-c:

(E)-11-iodo-2,8-dimethylundeca-2,8-diene (4.38a):
To a round bottom flask was added 4.37a (1 eq, 1.93 mmol), PPh3 (1.3 eq, 2.51 mmol)
and imidazole (1.7 eq, 3.28 mmol) dissolved in dichloromethane (14 mL). Next, the solution was
cooled to 0°C with and ice-bath and I2 (1.3 eq, 2.51 mmol) was added to the reaction flask. The
reaction was allowed to stir 0.5 hr at 0°C then allowed to warm to room temperature and stirred
for an additional 1.5 hr. Upon completion of the reaction, 10% Na2S2O3 was added to the flask
and stirred for 20 minutes. The organic layer was isolated and the aqueous layer was extracted 3
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× DCM (mL). The organic layers were pooled together, washed with brine, dried with MgSO4,
filtered and concentrated. Purification by flash chromatography using hexanes as the eluent
afforded the title compound in 61% yield. 1H NMR (300 MHz, Chloroform-d) δ 5.08 (dtt, J =
8.3, 5.8, 1.3 Hz, 2H), 3.09 (t, J = 7.4 Hz, 2H), 2.56 (q, J = 7.3 Hz, 2H), 2.08 – 1.85 (m, 4H), 1.67
(d, 3H), 1.58 (s, 6H), 1.47 – 0.98 (m, 4H).

13

C NMR (75 MHz, Chloroform-d) δ 138.63, 131.48,

124.93, 122.94, 39.71, 32.60, 29.65, 28.10, 27.60, 25.96, 17.91, 16.39, 6.42.

(E)-12-iodo-2,9-dimethyldodeca-2,9-diene (4.38b):
Yield (82%). 1H NMR (300 MHz, Chloroform-d) δ 5.22 – 4.68 (m, 2H), 3.09 (t, J = 7.4
Hz, 2H), 2.56 (q, J = 7.3 Hz, 2H), 1.95 (q, 4H), 1.67 (s, 3H), 1.57 (s, 6H), 1.45 – 1.13 (m, 6H).
13

C NMR (75 MHz, Chloroform-d) δ 138.67, 131.39, 125.04, 122.91, 39.79, 32.58, 29.96, 29.11,

28.22, 27.88, 25.96, 17.90, 16.39, 6.43.

(E)-13-iodo-2,10-dimethyltrideca-2,10-diene (4.38c):
Yield (76%). 1H NMR (300 MHz, Chloroform-d) δ 5.16 – 4.98 (m, 2H), 3.09 (t, J = 7.4
Hz, 2H), 2.56 (q, J = 7.3 Hz, 2H), 2.04 – 1.85 (m, 4H), 1.66 (s, 3H), 1.57 (s, 6H), 1.45 – 1.13 (m,
8H).

13

C NMR (75 MHz, Chloroform-d) δ 138.68, 131.34, 125.08, 122.87, 39.81, 32.58, 30.07,

29.41, 29.37, 28.24, 27.93, 25.95, 17.89, 16.40, 6.42.
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Representative procedure for the synthesis of frame-shifted alcohols 4.39a-c;

(2E,6E)-3,7,13-trimethyltetradeca-2,6,12-trien-1-ol (4.39a):
An oven-dried round-bottom flask containing powdered molecular sieves was charged
with (E)-11-iodo-2,8-dimethylundeca-2,8-diene (stored over sieves; 2.0 eq, 1.38 mmol) which
was dissolved in 5 mL of anhydrous Et2O and cooled to -78°C. Next, t-BuLi (1.7 M in pentane;
3.0 eq, 2.06 mmol) was slowly added to the reaction flask and stirred for 1 hour at -78°C.
Afterward, β-MeO-9-BBN (1.0M in Hexanes; 3.8 eq, 2.62 mmol) was slowly added to the
reaction vessel followed by 2 mL of THF and the mixture was stirred for 16 hours slowly
warming to room temperature.
In a scintillation vial, (E)-tert-butyl((3-iodobut-2-en-1-yl)oxy)dimethylsilane (1.0 eq,
0.69 mmol) and Pd(dppf)Cl2 (0.15 eq, 0.10 mmol) are dissolved in 3mL of DMF. Next, K3PO4
(3.0 eq, 2.06 mmol) is added to the vial and after deoxygenating the solvent, the vinyl-iodide
solution is added to the round-bottom flask containing the newly formed organoborane. The
reaction mixture is allowed to stir for an additional 16 hours at 85°C after which it is poured into
a separatory funnel containing water and Et2O and the aqueous layer was extracted 3 × 5 mL
Et2O.

The organic layers were combined and washed with water then brine, dried with

magnesium sulfate, and concentrated. The crude reaction product was run through a silica
column (1% EtO2/Hexanes) to remove most of the impurities and any oxidizing species.
In a scintillation vial, the semi-crude product was dissolved in 2.0 mL of THF, cooled to
0°C, and TBAF (1.0 M in THF, 2.4 eq, 1.42 mmol) was added to the vial. The reaction was
allowed to stir for 4 hours and then quenched with 10% NH4Cl(aq). Next, the organic layer was
removed, and the aqueous layer was extracted 3 × Et2O (5 mL).

The organic layers are

combined, washed with brine, dried with MgSO4, filtered, and concentrated. The crude reaction
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product was purified by column chromatography using 20% Ethyl Acetate/Hexanes as the mobile
phase to afford 4.39a in 46% yield. 1H NMR (300 MHz, Chloroform-d) δ 5.45 – 5.30 (m, 1H),
5.08 (tdq, J = 7.0, 4.2, 1.4 Hz, 2H), 4.12 (d, J = 6.9 Hz, 2H), 2.19 – 1.76 (m, 8H), 1.66 (dd, J =
2.5, 1.3 Hz, 6H), 1.57 (s, 3H), 1.56 (s, 3H), 1.43 – 1.15 (m, 4H).

13

C NMR (75 MHz,

Chloroform-d) δ 139.99, 135.83, 131.44, 125.01, 123.79, 123.52, 59.60, 39.76, 39.72, 29.65,
28.12, 27.79, 26.45, 25.94, 17.88, 16.47, 16.07. MS (EI) m/z 250; MS (CI) m/z 249.

(2E,6E)-3,7,14-trimethylpentadeca-2,6,13-trien-1-ol (4.39b):
Yield (30% - 2 Steps). 1H NMR (300 MHz, Chloroform-d) δ 5.39 (tq, J = 7.0, 1.3 Hz,
1H), 5.15 – 5.00 (m, 2H), 4.13 (d, J = 7.0 Hz, 2H), 2.16 – 1.97 (m, 4H), 1.92 (t, J = 6.7 Hz, 4H),
1.66 (s, 6H), 1.57 (s, 3H), 1.56 (s, 3H), 1.40 – 1.13 (m, 6H).

13

C NMR (75 MHz, Chloroform-d)

δ 140.04, 135.92, 131.38, 125.08, 123.72, 123.50, 59.62, 39.86, 39.79, 29.98, 29.16, 28.22, 28.11,
26.47, 25.94, 17.87, 16.48, 16.11. MS (EI) m/z 246 [M+-H2O]; MS (CI) m/z 247 [M++H-H2O].

(2E,6E)-3,7,15-trimethylhexadeca-2,6,14-trien-1-ol (4.39c):
Yield (25% - 2 steps). 1H NMR (300 MHz, Chloroform-d) δ 5.39 (tq, J = 6.9, 1.4 Hz,
1H), 5.16 – 5.01 (m, 2H), 4.12 (d, J = 6.9 Hz, 2H), 2.04 (s, 4H), 1.92 (t, J = 7.1 Hz, 4H), 1.65 (s,
6H), 1.57 (s, 3H), 1.55 (s, 3H), 1.45 – 1.06 (m, 8H).

13

C NMR (75 MHz, Chloroform-d) δ

139.94, 135.90, 131.32, 125.09, 123.67, 123.50, 59.54, 39.86, 39.77, 30.06, 29.43, 29.39, 28.23,
28.14, 26.45, 25.92, 17.85, 16.45, 16.09. MS (EI) m/z 278; MS (CI) m/z 277.
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Representative procedure for the synthesis of pyrophosphates 4.11, 4.17, 4.21, 4.28, 4.40a-c:

(2E,7E)-3,8,13-trimethyltetradeca-2,7,12-trien-1-yl diphosphate (4.11):
To an oven-dried round bottom flask equipped with a magnetic stir bar was added NCS
(2.5 eq, 0.25 mmol) in 0.5 mL of CH2Cl2 and cooled to -30°C where dimethyl sulfide (2.5 eq,
0.25 mmol) was added dropwise to the reaction. Following the addition, the mixture is then
placed in a 0°C ice bath and stirred for 5 minutes before being re-cooled back to -30°C. Next,
alcohol 4.9 (1 eq, 0.10 mmol) is dissolved in CH2Cl2 (0.2 mL) and added dropwise to the reaction
mixture. The mixture is then placed in a 0°C ice bath and stirred for 2.5 hours coming to room
temperature. After the allotted time, brine is added to the reaction mixture and the organic layer
was extracted. The aqueous layer was further extracted 3 × 5 mL CH2Cl2 and the organic layers
were combined, dried with magnesium sulfate, and concentrated. The crude reaction product was
used immediately in the following step.
To another oven-dried round bottom flask equipped with a magnetic stir bar was added
tris (tetrabutylammonium) hydrogen pyrophosphate (3.0eq, 0.3 mmol) dissolved in 1.3 mL of
acetonitrile. Next, a solution of crude allylic chloride dissolve in 0.9 mL acetonitrile was added
dropwise to the reaction vessel. The reaction was stirred for 3 hours at room temperature and
then the solvent was removed by rotary evaporation at 34°C. The residue was the dissolve in a
minimal amount of ion exchange NH3HCO3 buffer (700mg NH3HCO3, 1 L of deionized H2O, 20
mL of isopropanol) and the resulting solution was passed through a Dowex AG 50 × 8 ion
exchange column (2 × 8 cm) using the NH3HCO3 buffer as an eluent and 25 mL was collected in
a flask. The resulting solution was lyophilized for 3-5 hours. The resulting residue was then
redissolved in deionized watered and purified by cellulose flash column chromatography (3 × 15
cm) using isopropanol:deionized H2O:acetonitrile: NH3HCO3 buffer (500 mL : 250 mL : 250 mL
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: 4 g) as the eluent. In a beaker was collected 40 mL of eluent, then twenty-four 2.5 mL fractions
were collected. Typically, fractions 12-18 were collected and the organic solvents were removed
by rotary evaporation at 34°C.

The resulting solution was then lyophilized to afford

pyrophosphate (4.11) as a white fluffy solid in 70% yield. 1H NMR (300 MHz, Deuterium Oxide)
δ 5.40 (s, 1H), 5.11 (d, J = 7.4 Hz, 2H), 4.42 (d, J = 7.6 Hz, 2H), 2.08 – 1.79 (m, 8H), 1.65 (d, J =
3.9 Hz, 3H), 1.62 (t, J = 3.0 Hz, 3H), 1.52 (d, J = 6.9 Hz, 6H), 1.47 – 1.28 (m, 4H).

31

P NMR

(122 MHz, D2O) δ -10.16, -13.91. HRMS 409.1548 [M+2H]-, calculated 409.1545 (C17H31O7P2).

(2E,7E)-3,8,12-trimethyltrideca-2,7,11-trien-1-yl diphosphate (4.17):
Yield (43%). 1H NMR (300 MHz, Deuterium Oxide) δ 5.52 – 5.36 (m, 1H), 5.22 – 5.12
(m, 1H), 5.09 – 4.98 (m, 1H), 4.44 (d, J = 7.0 Hz, 2H), 1.97 (td, J = 20.7, 19.5, 10.3 Hz, 8H), 1.70
– 1.52 (m, 12H), 1.36 – 1.28 (m, 2H).

31

P NMR (122 MHz, Deuterium Oxide) δ -10.22 (d, J =

19.5 Hz), -14.05 (d, J = 18.7 Hz). HRMS 395.1389 [M+2H]-, calculated 395.1389 (C16H29O7P2).

(2E,6E,10E)-3,7,11,14-tetramethylpentadeca-2,6,10,13-tetraen-1-yl diphosphate (4.21):
Yield (69%). 1H NMR (500 MHz, Deuterium Oxide) δ 5.38 (s, 1H), 5.17 – 4.97 (m, 3H),
4.43 (s, 2H), 2.66 – 2.51 (m, 2H), 2.02 (d, J = 13.3 Hz, 6H), 1.91 (s, 2H), 1.82 – 1.46 (m,
15H).31P NMR (122 MHz, Deuterium Oxide) δ -12.73 (d, J = 15.4 Hz), -14.42 (d, J = 12.9 Hz).
HRMS 435.1705 [M+2H]-, calculated 435.1702 (C19H33O7P2).

(2E,6E)-3,7,12-trimethyltrideca-2,6,11-trien-1-yl diphosphate (4.28):
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Yield (73%). 1H NMR (500 MHz, Deuterium Oxide) δ 5.40 (s, 1H), 5.13 (d, J = 12.2 Hz,
2H), 4.41 (s, 2H), 2.08 (d, J = 12.2 Hz, 2H), 2.07 – 2.01 (m, 2H), 1.91 (q, J = 8.8, 7.5 Hz, 4H),
1.67 (s, 3H), 1.63 (d, J = 7.5 Hz, 3H), 1.55 (s, 6H), 1.37 (dd, J = 14.8, 7.4 Hz, 2H).

31

P NMR

(202 MHz, Deuterium Oxide) δ -10.19 (d, J = 20.9 Hz), -13.99 (d, J = 22.1 Hz). HRMS
395.1389 [M+2H]-, calculated 395.1389 (C16H29O7P2).

(2E,6E)-3,7,13-trimethyltetradeca-2,6,12-trien-1-yl diphosphate (4.40a):
Yield (60%). 1H NMR (500 MHz, Deuterium Oxide) δ 5.38 (s, 1H), 5.08 (d, J = 7.3 Hz,
2H), 4.40 (s, 2H), 2.04 (s, 2H), 1.97 (s, 2H), 1.90 (s, 4H), 1.66 (d, J = 12.4 Hz, 3H), 1.59 (d, J =
5.9 Hz, 3H), 1.51 (d, J = 8.8 Hz, 6H), 1.22 (s, 4H).

31

P NMR (202 MHz, Deuterium Oxide) δ -

9.86 (d, J = 14.3 Hz), -13.78 (d, J = 12.2 Hz). HRMS 409.1543 [M+2H]-, calculated 409.1545
(C17H31O7P2).

(2E,6E)-3,7,14-trimethylpentadeca-2,6,13-trien-1-yl diphosphate (4.40b):
Yield (59%). 1H NMR (500 MHz, Deuterium Oxide) δ 5.40 (s, 1H), 5.10 (s, 2H), 4.42 (s,
2H), 2.07 (s, 2H), 1.99 (s, 2H), 1.91 (s, 4H), 1.64 – 1.57 (m, 12H), 1.26 – 1.17 (m, 6H).

31

P NMR

(202 MHz, Deuterium Oxide) δ -9.93 (d, J = 37.6 Hz), -13.92 (d, J = 23.5 Hz). HRMS 423.1705
[M+2H]-, calculated 423.1702 (C18H33O7P2).

(2E,6E)-3,7,15-trimethylhexadeca-2,6,14-trien-1-yl diphosphate (4.40c):
Yield (94%).

1

H NMR (500 MHz, Deuterium Oxide) δ 5.37 (d, J = 8.6 Hz, 1H), 5.05

(dd, J = 13.0, 6.5 Hz, 2H), 4.40 (s, 2H), 1.93 (d, J = 29.2 Hz, 8H), 1.66 (s, 3H), 1.60 (s, 3H), 1.54
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(s, 3H), 1.52 (s, 3H), 1.25 (s, 8H).

31

P NMR (202 MHz, Deuterium Oxide) δ -9.81 (d, J = 15.6

Hz), -13.66 (d, J = 13.2 Hz). HRMS 437.1866 [M+2H]-, calculated 437.1858 (C19H35O7P2).

(3E,7E,11E)-4,8,12,16-tetramethylheptadeca-3,7,11,15-tetraen-1-yl diphosphate (4.32):
To an oven-dried round bottom flask equipped with a magnetic stir bar were added
methanesulfonyl chloride (1.3 eq, 0.14 mmol), DMAP (1.5 eq, 0.16 mmol) and 0.6 mL of
dichloromethane. The mixture was cooled to 0°C and a solution of alcohol 4.31 in 0.2 mL of
dichloromethane was added dropwise to the reaction vessel and allowed to stir for 3 hours.
Hexanes were then added to the reaction vessel and the solution was filtered and concentrated.
Next, Et2O was added to the crude product and was again filtered and concentrated. The crude
allylic chloride was then converted to pyrophosphate 4.32 following the same method described
for 4.11. Yield (71%). 1H NMR (500 MHz, Deuterium Oxide) δ 5.06 (ddt, J = 26.0, 13.5, 7.3
Hz, 4H), 3.82 (d, J = 7.3 Hz, 2H), 2.33 (t, J = 9.8 Hz, 2H), 2.18 – 1.82 (m, 12H), 1.61 (s, 3H),
1.59 (s, 3H), 1.53 (s, 3H), 1.51 (s, 6H).

31

P NMR (202 MHz, Deuterium Oxide) δ -12.10 (d, J =

16.2 Hz), -14.13 (d, J = 19.0 Hz). HRMS 463.2017 [M+2H]-, calculated 463.2015 (C21H37O7P2).

General procedure for in vitro biochemical substrate screening:

All biochemical evaluations were performed in our collaborator Dr. Carol Fierke’s
laboratory at the University of Michigan by Elia Wright.

Preliminary evaluation of all

pyrophosphate analogs were performed using GGPP analog (1, 5, or 10 µM), the peptide dansylGCVLL (5 µM), recombinant mammalian GGTase-I (50 nM), 50 nM HEPPSO pH 7.8, 5 mM
tris(2carboxyethyl)phosphine (TCEP), and 5 mM MgCl2 at 25°C in 96 well plates (Corning).
Protein prenylation was determined by monitoring the dansylated peptide using a continuous
spectrofluorometic assay and all assays were performed in triplicate. Upon prenylation of the
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peptide, the activity was measured by an increase in fluorescence intensity of the dansyl group
(λex = 340 nm, λem = 520 nm) in a POLARstar Galaxy plate reader. Peptide in assay buffer was
utilized as a negative control and the baseline fluorescence of the peptide was subtracted from the
reaction signal.

General procedure for in vitro GGTase-I inhibitor screening:

The same assay as described above was used with the exception that 1 or 5 µM of GGPP
analog was added to every well in addition to 10 µM GGPP. All readings were recorded in the
same manner.
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CHAPTER 5. SYNTHESIS & BIOCHEMICAL EVALUATION OF ALKYNYL-TAGGED
GERANYLGERANYL PYROPHOSPHATE ANALOGS

5.1

Introduction

Our laboratory has successfully utilized several alkynyl-FPP analogs as chemical tools to
identify farnesylated proteins in cells (Figure 5.1A).31, 137 These alkynyl substrates can be used
not only to identify farnesylated proteins, but also as a method to evaluate the analog-induced
protein selectivity in cells through proteomic studies.137 While much work has been done to
understand the reaction mechanisms of PTases, a great deal remains unknown about their in vivo
function.138 The proteome is believed to be 100-1000 fold more complex than the genome, which
predicts ~30,000 genes. Thus, identification of prenylated proteins is difficult and the total
number of prenylated proteins remains unknown. There are several techniques available to
confirm prenylation of cellular proteins.139,

140

Unfortunately, these methods suffer from a

number of setbacks such as the need for large samples and heavy sample modification. The
greatest pitfall of these methods is that they do not provide researchers with information about the
modification of individual proteins.

An approach that can afford direct identification of a

protein’s modification is radio-labeling proteins by incorporation of tritiated mevalonate or
tritiated alcohols.140, 141 However, this approach is not readily adaptable to purification and MS
analysis. Another setback is that tritium is a weak emitter resulting in extremely slow detection
via autoradiography (3 weeks – 2 months).140, 141 Therefore, a more direct and high throughput
method would aid in uncovering the proteome’s mysteries.
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To avoid these dilemmas, our laboratory has developed a “tagging-via-substrate” method
that attempts to determine the extent of protein farnesylation in vivo. This involves exposing the
cells to an alkynyl-based FPP substrate that can be subsequently tagged with azido-biotin via
click chemistry.78, 115, 137, 142

The biotinylated proteins can then be detected and identified via

mass spectroscopy and western blotting (Figure 5.1C). Click chemistry has many advantages
such as being able to take place in aqueous media (e.g. the cell lysate) and it needs only mild
reducing conditions in the presence of catalytic Cu(I). These alkynyl-FPP analogs have provided
us with valuable information about what proteins can be farnesylated and have proven to be
valuable biochemical tools.

This tagging-via-substrate method combined with MS analysis

technique was developed and greatly refined in or laboratory by Dr. Jiao Song. By using these
alkynyl-FPP analogs, Dr. Song was able to identify over 190 farnesylated proteins which is by far
the most extensive list to date.
Thus, if the alkynyl-GGPP analogs show similar biochemical profiles to their FPP
counterparts, then we would be able to develop chemical tools analogous to our in vivo FPP-tags
(Figure 5.1B).

Therefore, we envisioned a similar alkynyl-based-tagging approach for

geranylgeranylated proteins. To better understand how the alkynyl-GGPP analogs might bind to
GGTase-I, we overlaid these analogs with GGPP (Figure 5.2).
The corresponding alcohols of the terminal alkynyl-FPP tags (Figure 5.1B , left) have
been previously synthesized by Charron et al.; however, the pyrophosphates were not evaluated
nor were they used in a robust screen such as our laboratory’s.143 While effective in our screens,
the terminal alkynes were less efficient than the 7-substituted alkynyl-tags of FPP (Figure 5.1A,
right).137

Therefore, the terminal alkynyl-GGPP tags were synthesized to compare their

efficiency to the 7-substituted alkynyl-GGPP tags (Figure 5.1B). Although 7-substituted GGPP
analogs have been synthesized previously in the Gibbs laboratory and are able to act as substrates
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of GGTase-I,144 7-substituted alkynyl-analogs had yet to be successfully synthesized and
investigated.
The final class of tags to be synthesized is alkynyl-triazoles (Figure 5.1B). Evidence
suggests that triazole containing analogs can act as substrates in the PTases (unpublished data).
As mentioned previously, the ω-isoprene unit of GGPP is oriented nearly perpendicular to the rest
of the molecule. Triazoles could prove to be useful linkers in the synthesis of GGPP analogs by
potentially allowing for the proper orientation of the alkynyl-tail within GGTase. It is our goal
that these compounds can be utilized to determine the extent of protein geranylgeranylation in
vivo.
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A)

B)

C)

Figure 5.1. Potential alkynyl pyrophosphate cellular probes for proteomic studies. (A) Currently
utilized alkynyl FPP analogs as chemical tools to confirm alternative farnesylation in cells. (B)
Proposed alkynyl GGPP analogs to be synthesized and tested as substrates with GGTase-I. (C)
Utilizing alkynyl-based FPP/GGPP derivatives to tag and identify prenylated proteins.

A)

B)

C)

D)

E)

F)

G)
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Figure 5.2. Structural overlay of alkynyl-GGPP analogs with GGPP. (A) Compound 5.7 (Cyan) & GGPP (Green). (B) Compound 5.6 (Magenta)
& GGPP (Green). (C) Overlay of 5.6, 5.7, & GGPP zoomed in to the terminal isoprene unit. (D) Compound 5.14 (Cyan) &GGPP (Green). (E)
Compound 5.11 (Magenta) & GGPP (Green). (F) Overlay of 5.11, 5.14, & GGPP zoomed in to the terminal isoprene unit. (G) Compound 5.25 &
GGPP. (PDB: 1N4P)
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5.2

Synthesis of Alkynyl-Tagged Geranylgeranyl Pyrophosphate Analogs

The synthesis of the alkynyl analogs began with the synthesis of the two terminal alkynes
5.6 and 5.7 according to the procedures of Charron and colleagues.143 Briefly, alcohol 2.2

underwent a NBS bromination to yield bromide 5.1. Due to the instability of allylic bromides,
bromide 5.1 was quickly purified using a very short silica column and used immediately in the
following steps. Allylic bromide 5.1 was then subjected to a mild copper catalyzed coupling with
TMS-acetylene as described by Bieber et al. to yield the protected product 5.2.145 Although
reported as a single isomer by Charron et al., in our hands a mixture of the desired SN2 product
and the SN2’ byproduct was obtained (7.7:2.3) and could not be separated with standard column
chromatography.

Thus, 5.2 was taken on as a mixture of isomers and underwent THP-

deprotection with PPTS in ethanol followed by TMS-removal with TBAF at 0°C to produce
alcohol 5.3. To obtain the second terminal alkyne 5.5, the aforementioned allylic bromide 5.1
underwent a displacement reaction with the TMS-propyne anion to yield the protected product
5.4. Following the same deprotection procedure used for the conversion of 5.2 to 5.3, 5.4 was

converted in to the free alcohol 5.5. Allylic alcohols 5.3 and 5.5 were then chlorinated via CoreyKim chlorination protocols and converted into pyrophosphates 5.6 and 5.7, respectively, using the
method developed by Davisson et al.112, 113
The second set of alkynyl-GGPP analogs to be synthesized was the triazole containing
analogs 5.11 and 5.14. To assemble these compounds we relied on the vastly used Cu-modified
1,3-dipolar Huisgen cycloaddition (“Click” chemistry) between terminal azides and alkynes to
generate 1,4-disubstituted 1,2,3-triazoles.118 This method has been widely employed in our
laboratory to generate vast libraries of both GGTase-I and Icmt inhibitors.77, 106, 146 To begin the
synthesis, previously synthesized iodide 4.26 was “clicked” with either di-alkyne 5.8 or 5.12.
The triazole products obtained were first deprotected with PPTS to generate the free allylic
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alcohols and further deprotected with TBAF to acquire the free terminal alkynes 5.10 and 5.13.
In the past, our laboratory has had difficulties halogenating triazole-containing compounds.
These difficulties have included low yields due to unwanted halogenations of the triazole-ring.
Thus, in order to convert the allylic alcohols into pyrophosphates we first made the corresponding
mesylates of 5.10 and 5.13.

The crude mesylates were used immediately in the

pyrophosphorylation reaction developed by Davisson et al. to afford analogs 5.11 and 5.14.112, 113
The synthesis of 7-propargyl GGPP (5.25) was accomplished in a similar manner as
described by Placzek for the synthesis of 7-propargyl FPP. First, cyclopropyl methyl ketone
(5.15) was transformed into homoprenyl iodide 5.16 using the method of Biernacki and
colleges.31, 147, 148 With 5.16 in hand, we then could utilize a strategy first developed by Wenkert
et al. and later used in our laboratory for the synthesis of both frame-shifted FPP analogs.134, 149
This unique transformation is based on the transforming carbon-oxygen bonds into carbon-carbon
bonds and was previously discussed in Chapter 4 and utilized for the synthesis of the frameshifted GGPP analogs.

Compound 5.16 was first alkylated with 5-lithio-2,3-dihydrofuran

according to the modified procedure discussed in Chapter 4. Immediately reacting the alkylated
dihydrofuran with NiCl2(PPH3)2 and MeMgBr afforded homogerianol (5.17) in 61% yield.
Homogeraniol was then iodinated using standard Appel reaction conditions to generate homo
allylic iodide 5.18 which underwent a subsequent lithium-halogen exchange in the presence of tBuLi. Following the addition of CuCN to the reaction, organocuprate 5.19 was generated.
Following a modified procedure of Placzek et al., addition of 5-lithio-2,3-dihydrofuran (4.36) to
organocupurate 5.19 lead to a 1,2-metalate rearrangement to produce the higher order
alkenylcuprate 5.20 which was coupled with TMS-propargyl bromide to generated 5.22.31, 150-152
Homoallylic alcohol 5.22 was then iodinated in the same manner as 5.17 to produce iodide 5.23
which was then converted into the organborane and coupled with vinyl-iodide 3.14 via a Suzuki
reaction.120 After removal of the TMS and TBDMS groups with TBAF to generate 5.24, the
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allylic alcohol was converted into the pyrophosphate (5.25) using the same procedure utilized to
generate diphosphates 5.6 and 5.7. It is important to note that only a small quantity of 5.24 was
obtained; thus, the pyrophosphorylation was performed on a small scale and only a crude
NMR could be obtained for this product.

31

P
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Scheme 5.1. Synthesis of terminal alkynyl-GGPP analogs. (a) NBS, DMS, DCM, -40°C (crude
purification) (a) i. TMS-acetylene, K2CO3, Na2SO3, Cu(I)I, DMF (27%-2 steps includes
bromination) (c) i. PPTS, EtOH, 50°C, o/n; ii. TBAF, THF (21%-2 Steps) (d) i. TMS-propyne,
n-BuLi, THF, -78°C, 12 hr (49% - 2 steps includes bromination) (e) i. PPTS, EtOH, 50°C, o/n; ii.
TBAF, THF (53%-2 Steps); (f) NCS, DMS, DCM -30°C to r.t., 2.5 hr; (g) (NBu4)3HP2O7, ACN,
3 hr.
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Scheme 5.2. Synthesis of triazole-containing alkynyl-GGPP analogs. (a) NaN3, Na Ascorbate,
CuSO4×5•H2O, DMF, then 5.6 or 5.9; (b) i. PPTS, EtOH, 50°C, o/n; (c) TBAF, THF; (d) MsCl,
DMAP, DCM, 0°C to r.t., 2.5 hr; (e) (NBu4)3HP2O7, ACN, 3 hr.
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Scheme 5.3. Synthesis of 7-propargyl GGPP. (a) i. MeMgI, Et2O, 0°C, 1 hr; ii. 6M H2SO4(aq),
30 min, 0°C (68%); (b) t-BuLi, Et2O, -78°C; (c) i. 5.16, THF, -78°C to r.t., 16 hr; ii. NiCl2(PPh3)2,
MeMgBr, PhH, 75°C (61%); (d) Imidazole, PPh3, I2, 0°C (61%); (e) i. t-BuLi, Et2O, -78°C to 0°C
then THF; ii) CuCN, Me2S, Et2O, -78°C to 0°C; (f) 4.36; (g) PBu3, Et2O, 5.21, 0°C to r.t.(8%);
(h) Imidazole, PPh3, I2, 0°C (77%); (i) i. t-BuLi, Et2O, -78°C, ii. β-MeO-9-BBN, THF, -78°C
warming to r.t, o/n; iii. 3.14, K3PO4, PdCl2(dppf), DMF, 85°C, 18 hr; (j) TBAF, THF, 0°C; (k) i.
NCS, DMS, DCM, -30°C to r.t., 2.5 hr; ii. (NBu4)3HP2O7, ACN, 3 hr (71%).
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5.3

Biochemical Evaluation of Alkynyl-Tagged Geranylgeranyl Pyrophosphate Analogs

Previously, Dr. Amanda Kryzsiak and Dr. Andrew Placzek of our laboratory synthesized
a small library of alkynyl-FPP analogs (Figure 5.1A).31, 78, 80 Upon evaluation of these analogs, it
was determined that these analogs are substrates of FTase and can farnesylate a wide range of
dansyl-GCaaX peptides.

Dr. Jiao Song then utilized these alkynes in proteomic studies to

identify ~192 farnesylated proteins via mass spectroscopy.137
Based on these results, our goal was to synthesize a small library of alkynyl-GGPP
analogs. These alkynyl analogs (5.6, 5.7, 5.11, 5.14, 5.25; Figure 5.1B) were evaluated for their
biochemical activity in an in vitro continuous spectrofluorometric assay with GGTase and the cosubstrate CaaX-peptide dansyl-GCVLL.

All biochemical assays were performed in our

collaborator Dr. Carol Fierke’s laboratory at the University of Michigan by Elia Wright.
Of the alkynes tested, only the terminal alkynes 5.7 displayed moderate substrate activity.
At 1.5 hours with 10 µM analog, we observed 28 ± 0.004% RFI when compared to GGPP
(Figure 5.3 and 5.4). Terminal alkyne 5.6 also displayed substrate activity; however, it was a
weaker substrate than 5.7. Although analogs 5.11,5.14, and 5.25 do not appear to be substrates
based on the bar graph in Figure 5.3, an endpoint point analysis indicates that these analogs may
indeed be substrates, albeit very slow substrates (Figure 5.5). It is important to note that due to
small amounts of material, only a very crude 31P NMR could be obtained for 5.25. Therefore, it
could be beneficial if this compound is remade, fully characterized, and retested. The saturated
alkynyl compounds have yet to be tested.
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Figure 5.3. Bar graphs of substrate activity represented in RFI of alkynyl-GGPP analogs versus
GGPP (+ control) with 5 µM dansyl-GCVLL and 50 nM GGTase-I. Error bars represent mean ±
SD (n = 3). *Values shown are for 10 µM analog at time 1.5 hours.
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5µM dansyl-GCVLL and 50 nM GGTase-I. Experiments were performed
in triplicate and data points represent the mean.
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5.4

Conclusions

The goal of this chapter was to focus on the synthesis of a small library of alkynyl-GGPP
analogs to utilize as potential chemical tools to evaluate GGTase-I via proteomics. Previously,
our lab synthesized alkynyl- FPP analogs that displayed interesting results in vivo and were later
used to identify over 190 farnesylated proteins.137 Therefore, our laboratory aimed to expand this
concept to include analogs that could aid in identifying geranylgeranylated proteins.
The synthesis of the two terminal alkynes (5.6 and 5.7) was accomplished in accordance
with the procedures of Charron and colleagues.143 The triazole containing alkynes were quickly
generated using the previously synthesized intermediate 4.26 and commercially available
dialkynes. The triazole-containing analogs had to be pyrophosphorylated via the mesylate to
avoid unwanted side reactions with NCS and the triazole ring. The 7-propargyl GGPP analog
(5.25) was more difficult to accomplish. The synthesis was carried out in the same manner as
previously developed by Dr. Andrew Placzek in our laboratory.31 The problematic step in this
synthesis was the coupling of the vinyl-iodide 3.14, which resulted in very poor yields.
We have successfully synthesized a small library of alkynyl-GGPP analogs. Of the
analogs synthesized, only the terminal alkyne, 5.7, showed moderate substrate activity. Terminal
alkyne 5.6 also demonstrated substrate activity, albeit it was a poorer substrate than 5.7. Again,
chain length seems to be an important factor. Although our alkynyl-GGPP analogs did not live
up to our expectations, it is important to keep in mind that our preliminary biochemical testing
utilized only one CaaX sequence, dansyl-GCVLL. It is possible that these analogs are more
selective chemical tools and although most are weak substrates with dansyl-CVLL, they could
potentially be strong co-substrates with other CaaX sequences. In the future, these compounds
will be tested as inhibitors of GGTase-I. If no inhibitor activity is detected, an extensive in vitro
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screening with a large library of dansyl-GCaaX sequences will determine if these analogs are
selective substrates.
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5.5

Experimental Procedures Utilized for the Synthesis & Biochemical Evaluation of AlkynylTagged Geranylgeranyl Pyrophosphate Analogs

General Experimental Procedures: All reactions were performed with oven-dried or flame-

dried glassware and under dry argon gas. All commercial reagents and solvents were used
directly without subsequent purification. For the organmetallic coupling reactions, anhydrous
THF was freshly distilled from sodium and benzophenone. All other anhydrous solvents were
purchased from Acros Organics as extra dry solvents and were bottled over molecular sieves.
Reactions were monitored by thin layer chromatography and visualized with one or more of the
following:

UV

light,

iodine,

vanillin

solution,

potassium

permanganate

dinitrophenylhydrazine solution, and/or phosphomolybdic acid solution.

solution,

All products were

purified using flash chromatography silica gel 60 M purchased from Macherey-Nagel.

All

reactions involving either triphenyl phosphine or triphenyl phosphine oxide were first dry-loaded
with sodium sulfated before column purification. NOTE: *Dry glassware is critical for the
organometallic reactions in this publication.

This was accomplished by taking oven-dried

glassware (dried for at least 24 hr and then cooled under argon) and flame drying the round
bottom flask under vacuum.
temperature.

The flask was then purged with argon and cooled to room

This process was repeated 3 times to produce a completely water free

environment.* **Deoxygenated solvents are extremely crucial for successful organometallic
reactions in this publication. In order to achieve completely deoxygenated solutions, the solvent
was placed in a flame-dried round bottom and under vacuum was sonicated for 30 seconds and
then purged with argon for 30 seconds. This process was repeated 3 times to yield completely
deoxygenated solvents.** All NMR spectra were taken either on a 300 MHz Bruker ARX300 or
a 500 MHz Bruker DRX500 spectrometer. Low-resolution MS (EI/CI) were recorded with a
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Hewlett Packard Engine and low-resolution MS (ESI) were taken on a Thermoquest LCQ. All
high-resolution mass spectra were recorded on a FinniganMAT XL95.
Br

OTHP

2-(((2E,6E,10E)-12-bromo-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)oxy)tetrahydro-2H-pyran
(5.1):

To an oven-dried round bottom flask equipped with a magnetic stir bar was added NBS
(2.0 eq, 2.0 mmol) in 10 mL of CH2Cl2 and cooled to -30°C where dimethyl sulfide (2.0 eq, 2.0
mmol) was added dropwise to the reaction. Following the addition, the mixture is then placed in
a 0°C ice bath and stirred for 5 minutes before being recooled back to -30°C. Next, alcohol 2.2 (1
eq, 1 mmol) is dissolved in 5 mL of CH2Cl2 and added dropwise to the reaction mixture. The
mixture is then placed in a 0°C ice bath and stirred for 2.5 hours coming to room temperature.
After the allotted time, brine is added to the reaction mixture and the organic layer was extracted.
The aqueous layer was further extracted 3 × 10 mL CH2Cl2 and the organic layers were
combined, dried with magnesium sulfate, and concentrated. The crude reaction product was
passed through a short plug of silica gel using 5%-10% EtOAc/hexanes as the eluent. Bromide
5.1 was used immediately in the next step.

OH

(2E,6E,10E)-3,7,11-trimethyltetradeca-2,6,10-trien-13-yn-1-ol (5.3):
To an oven-dried round bottom flask is added powdered molecular sieves and is cooled
under argon. The round bottom was then flamed-dried under vacuum and cooled under argon;
this process was repeated 3 times. Next, ethynyltrimethylsilane (3.0 eq, 4 mmol) and 12 mL of
anhydrous DMF were added to the round bottom flask. To the round bottom flask was added
K2CO3 (1.5 eq, 2.7 mmol), Na2SO3 (1.0 eq, 1.33 mmol), bromide 5.1, and Cu(I)I (0.05 eq,
0.07mmol) sequentially and the reaction was stirred at room temperature for 12 hours. The
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reaction was quenched by the addition of 10% NH4Cl, the organic layer was isolated, and the
aqueous layer was extracted 3 × CH2Cl2 (15 mL). The organic layers were combined, washed
with brine, dried with MgSO4, filtered, and concentrated.

The crude reaction product was

purified by column chromatography using 3% Ethyl Acetate/Hexanes as the mobile phase to
afford 5.2 in 27% yield (2-steps from 2.2).
In a scintillation vial equipped with a magnetic stir bar, 5.2 (1.0 eq, 0.47 mmol) was
dissolved in 5 mL of absolute EtOH and PPTS (0.1 eq, 0.05 mmol) was added to the vial. The
reaction mixture was heated to 75°C and stirred for 12 hours. Next, the reaction was cooled to
room temperature where it was poured into a separator funnel containing water and Et2O and the
aqueous layer was extracted 3 × 10 mL Et2O. The organic layers were combined, washed with
water then brine, dried with magnesium sulfate, and concentrated. The crude reaction product
was then dissolved in 5 mL of THF and cooled to 0°C where TBAF (2.0 eq, 1.0 mmol, 1.0 M in
THF) was added to the reaction flask. The reaction was allowed to stir for 3 hours and then
quenched with 10% NH4Cl(aq). Next, the organic layer was removed, and the aqueous layer was
extracted 3 × Et2O (10 mL). The organic layers are combined, washed with brine, dried with
MgSO4, filtered, and concentrated. The crude reaction product was purified by column
chromatography using 20% Ethyl Acetate/Hexanes as the mobile phase to afford alcohol 5.3 in
21 % yield (7.7:2.3; SN2:SN2’). 1H NMR (300 MHz, Chloroform-d) δ 5.39 (t, J = 7.0 Hz, 2H),
5.09 (t, J = 8.4 Hz, 1H), 4.13 (d, J = 6.5 Hz, 2H), 2.93 – 2.80 (m, 2H), 2.14 – 1.91 (m, 10H), 1.77
(t, J = 1.1 Hz, 1H), 1.66 (d, J = 1.4 Hz, 6H), 1.58 (d, J = 1.4 Hz, 3H). MS (EI) m/z 246; MS (CI)
m/z 229 [M+-H-H2O].
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Trimethyl((5E,9E,13E)-5,9,13-trimethyl-15-((tetrahydro-2H-pyran-2-yl)oxy)pentadeca-5,9,13trien-1-yn-1-yl)silane (5.4):
An oven-dried round bottom flask equipped with a magnetic stir bar was charged with 1(trimethylsilyl)propyne (3.0 eq, 4.2 mmol) dissolved in 5.5 mL of anhydrous THF and cooled to 78°C. Next, n-BuLi (2.5 M in hexanes, 3.0 eq, 4.2 mmol) was slowly added to the mixture and
the reaction was allowed to stir 1.5 hours. After the allotted time, 5.1 (1.0 eq, 1.4 mmol) in 7 mL
of THF was added dropwise to the reaction vessel at -78°C. The reaction was allowed to stir for
an additional 12 hours after which time the reaction was quenched by the addition of 10% NH4Cl.
The organic layer was removed, and the aqueous layer was extracted 3 × Et2O (15 mL). The
organic layers were combined, washed with brine, dried with MgSO4, filtered, and concentrated.
The crude reaction product was purified by column chromatography using 5% Ethyl
Acetate/Hexanes as the mobile phase to afford 5.4 in 49% yield (2-steps from 2.2).

1

H NMR

(300 MHz, CDCl3) δ 5.33 (t, J = 6.4 Hz, 1H), 5.10 (dt, J = 12.8, 6.4 Hz, 2H), 4.60 (t, J = 3.3 Hz,
1H), 4.29 – 3.41 (m, 4H), 2.33 – 1.90 (m, 11H), 1.79 (ddd, J = 20.6, 12.5, 8.6 Hz, 1H), 1.66 (d, J
= 5.7 Hz, 4H), 1.62 – 1.42 (m, 11H), 0.14 – 0.00 (m, 9H).

13

C NMR (75 MHz, Chloroform-d) δ

140.44, 135.30, 133.54, 125.67, 124.15, 120.74, 107.57, 97.94, 84.68, 63.81, 62.44, 39.82, 39.79,
38.84, 30.90, 26.79, 26.48, 25.69, 19.81, 19.43, 16.63, 16.22, 16.01, 0.35.

OH

(2E,6E,10E)-3,7,11-trimethylpentadeca-2,6,10-trien-14-yn-1-ol (5.5):
The same procedure was used as in 5.3. Yield (53%).

1

H NMR (300 MHz, CDCl3) δ

5.40 (td, J = 6.9, 1.1 Hz, 1H), 5.11 (dt, J = 12.5, 6.7 Hz, 2H), 4.13 (d, J = 6.9 Hz, 2H), 2.31 – 1.89
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(m, 13H), 1.66 (s, 3H), 1.58 (s, 6H).

13

C NMR (75 MHz, Chloroform-d) δ 140.04, 135.40,

133.38, 125.71, 124.09, 123.49, 84.66, 68.53, 59.63, 39.75, 39.73, 38.61, 26.75, 26.48, 17.82,
16.5, 16.23, 16.01. MS (EI) m/z 260; MS (CI) m/z 261 [M++H].
Representative procedure for the synthesis of triazole containing alkynyl-GGPP analogs:

1-((4E,8E)-4,8-dimethyl-10-((tetrahydro-2H-pyran-2-yl)oxy)deca-4,8-dien-1-yl)-4-(4(triisopropylsilyl)but-3-yn-1-yl)-1H-1,2,3-triazole (5.9):
To a scintillation vial equipped with a magnetic stir bar was added iodide 4.26 (1.0 eq,
0.5 mmol) and 2.5 mL of DMF. Next, NaN3 (3 eq, 1.5 mmol), sodium ascorbate (0.5 eq,.25
mmol), and CuSO4·H2O (0.25 eq, 0.125 mmol) are added sequentially to the vial. Alkyne 5.8
(3.6 eq, 1.8 mmol) was then dissolved in 1.3 mL of DMF and added to the vial. The reaction was
heated to 70°C and allowed to stir for 36 hours. The reaction was then quenched with 10% NH4Cl
and the aqueous layer was extracted 3 × EtOAC (10 mL). The organic layers were combined,
washed with brine, dried with MgSO4, filtered, and concentrated. The crude reaction product was
purified by column chromatography using 25% Ethyl Acetate/Hexanes as the mobile phase to
afford 5.9 in 70% yield. 1H NMR (300 MHz, Chloroform-d) δ 7.42 (s, 1H), 5.35 (ddd, J = 7.6,
6.1, 1.4 Hz, 1H), 5.21 – 5.04 (m, 1H), 4.61 (dd, J = 4.4, 2.7 Hz, 1H), 4.24 (q, J = 6.4 Hz, 3H),
4.01 (dd, J = 11.9, 7.3 Hz, 1H), 3.88 (ddd, J = 11.2, 7.3, 3.2 Hz, 1H), 3.60 – 3.42 (m, 1H), 2.95 (t,
J = 7.1 Hz, 3H), 2.62 (td, J = 7.1, 4.1 Hz, 3H), 2.18 – 1.90 (m, 8H), 1.91 – 1.69 (m, 3H), 1.67 (s,
3H), 1.59 (s, 3H), 1.52 (dq, J = 8.6, 5.2 Hz, 4H), 1.02 (s, 18H).
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(2E,6E)-10-(4-(but-3-yn-1-yl)-1H-1,2,3-triazol-1-yl)-3,7-dimethyldeca-2,6-dien-1-ol (5.10):
Deprotection was accomplished using the same procedure as 5.3. The crude reaction
product was purified by column chromatography using 50 to 100% Ethyl Acetate/Hexanes as the
mobile phase to afford 5.10 in 62% yield. 1H NMR (300 MHz, Chloroform-d) δ 7.40 (s, 1H), 5.46
– 5.35 (m, 1H), 5.10 (t, J = 6.4 Hz, 1H), 4.26 (t, J = 7.0 Hz, 2H), 4.14 (d, J = 6.8 Hz, 2H), 2.93 (t,
J = 7.1 Hz, 2H), 2.54 (td, J = 7.1, 2.6 Hz, 2H), 2.11 (t, J = 6.6 Hz, 1H), 2.03 (dd, J = 9.4, 6.8 Hz,
2H), 1.97 (dt, J = 5.2, 3.0 Hz, 4H), 1.65 (s, 2H), 1.61 (s, 6H).

13

C NMR (75 MHz, CDCl3) δ

146.23 (s), 138.90 (s), 133.22 (s), 125.79 (s), 124.11 (s), 121.32 (s), 83.69 (s), 69.28 (s), 59.40 (s),
49.61 (s), 39.41 (s), 36.22 (s), 28.19 (s), 26.12 (s), 25.09 (s), 18.90 (s), 16.34 (s), 15.95 (s). MS
(ESI) m/z 302 [M++H].

(2E,6E)-3,7-dimethyl-10-(4-(prop-2-yn-1-yl)-1H-1,2,3-triazol-1-yl)deca-2,6-dien-1-ol (5.13):
Synthesis was accomplished following the same procedures as 5.9 and 5.10 to afford 5.13
in 15% yield (2-steps). 1H NMR (300 MHz, Chloroform-d) δ 7.44 (s, 1H), 5.49 – 5.23 (m, 1H),
5.06 (t, J = 6.5 Hz, 1H), 4.26 – 4.16 (m, 2H), 4.08 (d, J = 6.9 Hz, 2H), 3.84 – 3.55 (m, 2H), 2.11 –
2.01 (m, 3H), 2.01 – 1.87 (m, 6H), 1.59 (d, J = 1.4 Hz, 3H), 1.52 (d, J = 1.5 Hz, 3H).

13

C NMR

(75 MHz, Chloroform-d) δ 143.44, 138.56, 133.07, 125.74, 124.09, 121.67, 80.27, 70.03, 59.18,
49.68, 39.33, 36.12, 28.07, 26.07, 16.32, 16.25, 15.84. MS (EI) m/z 287; MS (CI) m/z 288
[M++H].
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5-iodo-2-methylpent-2-ene (5.16):
An oven-dried round bottom flask equipped with a magnetic stir bar was charged with
MeMgI (3.0 M in Et2O, 1.0 eq, 50.5 mmol) and an additional 150 mL of Et2O. The mixture was
then cooled to 0°C and cyclopropyl methyl ketone, 5.15, (1.0 eq, 50.5 mmol) in 25 mL of Et2O
was added dropwise to the reaction mixture and stirred for 1 hour at room temperature. After the
allotted time, 200 mL of 6 M H2SO4(aq) was cooled to 0°C in a beaker. Next, the reaction mixture
was very slowly poured into the acidic solution and allowed to stir for 45 minutes. Next, the
reaction was poured into a separator funnel and the organic layer was isolated. The aqueous
layer was further extracted 2 × 100 mL Et2O. The organic layers were combined, washed 2 × 100
mL of saturated Na2S2O3, washed 1 × brine, dried with magnesium sulfate, and concentrated.
The crude reaction product was purified by column chromatography 100% hexanes as the mobile
phase to afford iodide 5.16 in 68% yield. 1H NMR (300 MHz, Chloroform-d) δ 5.07 (tq, J = 7.1,
5.7, 2.8, 1.4 Hz, 1H), 3.08 (t, J = 7.4 Hz, 2H), 2.69 – 2.36 (m, 2H), 1.68 (s, 3H), 1.59 (s, 3H).

13

C

NMR (75 MHz, Chloroform-d) δ 134.74, 123.26, 32.72, 25.93, 18.18, 6.36.

(E)-4,8-dimethylnona-3,7-dien-1-ol (5.17):
To an oven-dried round bottom flask is added powdered molecular sieves and is cooled
under argon. The round bottom was then flamed-dried under vacuum and cooled under argon;
this process was repeated 3 times. Next, 10 mL of anhydrous THF was added to the round
bottom flask which was sonicated under vacuum for 30 seconds and then the atmosphere was
replaced with argon for 30 seconds; this process was also repeated 3 times.

Next, 2,3-

dihydrofuran (stored over molecular sieves, 3.0 eq, 51.4 mmol) was added to the reaction vessel
and the solution was cooled to -78°C where t-BuLi (3.0 eq, 51.4 mmol, 1.7 M in heptanes) was
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slowly added dropwise over 5 – 10 minutes. The reaction was stirred at -78°C for 10 minutes
then placed in a 0°C ice bath and continued to stir for 1 hour. Next, the reaction mixture was
cooled back -78°C and 5.16 (1.0 eq, 17.14 mmol) in 7 mL of anhydrous THF (also sonicated as
described above) was added to the reaction vessel. The reaction was stirred for 20 hours slowly
coming to room temperature and then poured into a beaker containing ice-cold 50 mL of
saturated NH4Cl(aq) and 5 mL of NH4OH. The mixture was allowed to stir for 20 minutes and
then extracted with 3 × 50 mL Et2O, the organic layers were combined, washed with brine, dried
with magnesium sulfate, concentrated (at room temperature), and used immediately in the next
step.
To an oven-dried round bottom flask is added NiCl2(PPh3)2 (0.05 eq, 1.72 mmol)
dissolved in anhydrous benzene (100 mL). The round bottom flask was sonicated under vacuum
for 30 seconds and then the atmosphere was replaced with argon for 30 seconds; this process was
repeated 3 times. Next, MeMgBr (3.0 M in Et2O, 2.9 eq, 99.4 mmol) was added slowly to the Nicatalyst solution and stirred for 30 minutes at room temperature. Next, a solution of the newly
alkylated-furan (1.0 eq, 17.14 mmol) was dissolved in benzene (50 mL) and deoxygenated by
sonication as previously described. After deoxygenation, the alkylated-furan solution was added
slowly to the Ni-catalyst solution and the reaction was refluxed at 80°C for 12 hours. The
reaction is then cooled to room temperature and poured into a beaker containing 500 mL of
saturated NH4Cl(aq) and 150 mL of Et2O. The organic layer was isolated and the aqueous layer
was extracted 3 × Et2O (50 mL). The organic layers were pooled together, washed with brine,
dried with MgSO4, filtered, and concentrated. Purification by flash chromatography using 20%
EtOAc/hexanes as the eluent afford 5.17 in 61% yield.

1

H NMR (300 MHz, Chloroform-d) δ

5.30 – 4.95 (m, 2H), 3.57 (p, J = 5.9, 4.8 Hz, 2H), 2.41 – 2.19 (m, 2H), 2.02 (tq, J = 10.4, 6.7, 5.3
Hz, 4H), 1.73 (s, 1H), 1.64 (d, J = 1.5 Hz, 3H), 1.60 (d, J = 1.3 Hz, 3H), 1.56 (d, J = 1.3 Hz, 3H).

167
13

C NMR (75 MHz, Chloroform-d) δ 138.91, 131.81, 124.30, 120.07, 62.50, 39.96, 31.63, 26.71,

25.85, 17.85, 16.33.
I

(E)-9-iodo-2,6-dimethylnona-2,6-diene (5.18):
To a round bottom flask was added 5.17 (1 eq, 18.34mmol), PPh3 (1.3 eq, 23.84 mmol)
and imidazole (1.7 eq, 31.17 mmol) dissolved in dichloromethane (70mL). Next, the solution
was cooled to 0°C with and ice-bath and I2 (1.3 eq, 23.84 mmol) was added to the reaction flask.
The reaction was allowed to stir 0.5 hour at 0°C then allowed to warm to room temperature and
stirred for an additional 1.5 hour. Upon completion of the reaction, 10% Na2S2O3 was added to
the flask and stirred for 20 minutes. The organic layer was isolated and the aqueous layer was
extracted 3 × DCM (50 mL). The organic layers were pooled together, washed with brine, dried
with MgSO4, filtered and concentrated. Purification by flash chromatography using hexanes as
the eluent afforded 5.18 in 81% yield. 1H NMR (300 MHz, Chloroform-d) δ 5.08 (ddq, J = 8.5,
5.4, 1.4 Hz, 2H), 3.09 (t, J = 7.4 Hz, 2H), 2.56 (q, J = 7.3 Hz, 2H), 2.16 – 1.82 (m, 4H), 1.66 (s,
3H), 1.58 (s, 6H).

13

C NMR (75 MHz, Chloroform-d) δ 138.20, 131.66, 124.21, 123.14, 39.79,

32.57, 26.62, 25.92, 17.92, 16.47, 6.25.

(3Z,7E)-8,12-dimethyl-4-(3-(trimethylsilyl)prop-2-yn-1-yl)trideca-3,7,11-trien-1-ol (5.22):
To an oven-dried round bottom flask was added powdered molecular sieves and is cooled
under argon. The round bottom was then flamed-dried under vacuum and cooled under argon;
this process was repeated 3 times. Next, iodide 5.19 (1.0 eq, 7.29 mmol) and 11 mL of anhydrous
Et2O was added to the round bottom flask which was sonicated under vacuum for 30 seconds and
then the atomosphere was replaced with argon for 30 seconds; this process was also repeated 3
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times. The solution was cooled to -78°C and t-BuLi (1.7 M in heptanes, 2.2 eq, 16 mmol) was
added dropwise to the reaction mixture over a period of 5-10 minutes. The solution was allowed
to stir for 30 minutes at -78°C and for 1 hour at 0°C. Next, THF (1.1 mL) was added to the
reaction and it continued to stir for 1 hour at room temperature.
In a second oven-dried round bottom flask was added powdered molecular sieves and is
cooled under argon. The round bottom was charged with CuCN (0.5 eq, 3.65 mmol) then flameddried under vacuum and cooled under argon; this process was repeated 3 times. Next, 7.3 mL of
Et2O followed by dimethyl sulfide (9.1 mL) were added to the round bottom flask and sonicated
as previously described. The mixture was cooled to -78°C and the organo-lithium solution of
5.19 was added dropwise. The mixture was stirred for 15 minutes at -78°C and then 30 minutes

at 0°C to furnish the corresponding organocuprate.
To a third oven-dried round bottom flask was added powdered molecular sieves and is
cooled under argon. This flask was also flame-dried as described previously and then was
charged with 2,3-dihydrofuran (1.0 eq, 7.3 mmol) and 1.5 mL of THF and sonicated a described
above. The solution was then cooled to -78°C and t-BuLi (1.7 M in heptanes, 1.0 eq, 7.3 mmol)
was added dropwise over a 5-10 minute period. The solution was then warmed to 0°C and stirred
for 45 minutes. After the allotted time, Et2O (6.7 mL) was added to dilute the organo-lithium
solution which was then slowly added to the organocuprate solution at -78°C. The reaction was
stirred at this temperature for 15 minutes and then placed in a 0°C ice bath and allowed to slowly
warm to room temperature over 16 hours. Next, the mixture was cooled back down to 0°C and
PBu3 (0.55 eq, 4.0 mmol) was added to the round bottom flask and stirred for 15 minutes.
Following this addition, 5.19 (1.5 eq, 10.9 mmol) dissolved in 19 mL of Et2O and added to the
reaction mixture which was allowed to warm to room temperature and stirred for 3 hours. The
reaction was quenched by the addition of 10% NH4Cl and the organic layer was isolated. The
aqueous layer was extracted 3 × Et2O (40 mL), the organic layers were combined, washed with
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brine, dried with MgSO4, filtered, and concentrated. The crude reaction product was purified by
column chromatography using 20% Ethyl Acetate/Hexanes as the mobile phase to afford 5.20 in
19% yield. 1H NMR (300 MHz, Chloroform-d) δ 5.21 (t, J = 7.5 Hz, 1H), 5.16 – 4.96 (m, 2H),
3.62 (t, J = 6.3 Hz, 2H), 2.98 (s, 2H), 2.30 (q, J = 6.6 Hz, 2H), 2.22 – 1.84 (m, 8H), 1.65 (s, 3H),
1.58 (s, 6H), 0.11 (s, 9H).

13

C NMR (75 MHz, Chloroform-d) δ 137.78, 135.68, 131.54, 124.49,

123.95, 122.42, 104.98, 85.04, 62.44, 39.90, 37.34, 31.69, 26.92, 26.72, 25.92, 21.54, 17.90,
16.28, 0.25.

((4Z,7E)-4-(3-iodopropylidene)-8,12-dimethyltrideca-7,11-dien-1-yn-1-yl)trimethylsilane (5.23):
The synthesis or 5.21 was achieved using the same procedure utilized for 5.18. The
crude reaction product was purified by column chromatography using 0.5 to 1.0% Ethyl
Acetate/Hexanes as the mobile phase to afford alcohol 5.21 in 77% yield. 1H NMR (300 MHz,
Chloroform-d) δ 5.17 (t, J = 7.2 Hz, 1H), 5.14 – 5.03 (m, 2H), 3.12 (t, J = 7.4 Hz, 2H), 2.95 (s,
2H), 2.61 (q, J = 7.3 Hz, 2H), 2.19 – 2.09 (m, 4H), 2.10 – 1.86 (m, 4H), 1.66 (s, 3H), 1.58 (d, J =
2.1 Hz, 6H), 0.12 (s, 9H).

13

C NMR (75 MHz, Chloroform-d) δ 137.09, 135.64, 131.52, 125.18,

124.52, 123.86, 104.51, 85.16, 39.91, 37.34, 32.46, 26.94, 26.58, 25.94, 21.72, 17.93, 16.32, 5.42,
0.28.

(2E,6Z,10E)-3,11,15-trimethyl-7-(prop-2-yn-1-yl)hexadeca-2,6,10,14-tetraen-1-ol (5.24):
An oven-dried round-bottom flask containing powdered molecular sieves was charged
with 5.16 (stored over sieves; 1.5 eq, 1.1 mmol) which was dissolved in 3.6 mL of anhydrous
Et2O and cooled to -78°C. Next, t-BuLi (1.7M in pentane; 3.0 eq, 1.64 mmol) was slowly added
to the reaction flask and stirred for 1 hour at -78°C.

Afterward, β-MeO-9-BBN (1.0M in
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Hexanes; 3.8 eq, 2.07 mmol) was slowly added to the reaction vessel and the mixture was stirred
for 16 hours slowly warming to room temperature.
In a scintillation vial, 3.14 (1.0 eq, 0.72 mmol) and Pd(dppf)Cl2 (0.3 eq, 0.22 mmol) are
dissolved in 2.8 mL of DMF. Next, K3PO4 (3.0 eq, 2.16 mmol) is added to the vial and after
deoxygenating the solvent, the vinyl-iodide solution is added to the round-bottom flask
containing the newly formed organoborane. The reaction mixture is allowed to stir for an
additional 16 hours at 85°C after which it is poured into a separatory funnel containing water and
Et2O and the aqueous layer was extracted 3 × 20 mL Et2O. The organic layers were combined
and washed with water then brine, dried with magnesium sulfate, and concentrated. The crude
reaction product was run through a silica column (20% EtOAc/Hexanes) to remove most of the
impurities and any oxidizing species.
In a scintillation vial, the semi-crude product was dissolved in 5.0 mL of THF, cooled to
0°C, and TBAF (4.9 eq, 3.5 mmol, 1.0 M in THF) was added to the vial. The reaction was
allowed to stir for 4 hours and then quenched with 10% NH4Cl(aq). Next, the organic layer was
removed, and the aqueous layer was extracted 3 × Et2O (10 mL). The organic layers are
combined, washed with brine, dried with MgSO4, filtered, and concentrated. The crude reaction
product was purified by column chromatography using 20% Ethyl Acetate/Hexanes as the mobile
phase to afford alcohol 5.22 in 6% yield. 1H NMR (300 MHz, Chloroform-d) δ 5.49 – 5.40 (m,
1H), 5.22 (t, J = 6.7 Hz, 1H), 5.18 – 4.98 (m, 2H), 4.15 (d, J = 7.0 Hz, 2H), 2.93 (d, J = 2.8 Hz,
2H), 2.28 – 1.87 (m, 13H), 1.68 (s, 6H), 1.60 (s, 6H).

13

C NMR (75 MHz, Chloroform-d) δ

139.44, 135.47, 134.23, 131.48, 126.12, 124.46, 123.94, 123.85, 82.56, 68.34, 59.51, 39.85,
39.39, 36.83, 26.87, 26.65, 26.36, 25.86, 19.84, 17.84, 16.46, 16.20. MS (EI) m/z 296 [M+-H2O];
MS (CI) m/z 297 [(M++H)-H2O].
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Representative procedure for the synthesis of non-triazole containing pyrophosphates:

(2E,6E,10E)-3,7,11-trimethylpentadeca-2,6,10-trien-14-yn-1-yl diphosphate (5.7):
To an oven-dried round bottom flask equipped with a magnetic stir bar was added NCS
(2.5 eq, 0.24 mmol) in 0.5 mL of CH2Cl2 and cooled to -30°C where dimethyl sulfide (2.5 eq,
0.24 mmol) was added dropwise to the reaction. Following the addition, the mixture is then
placed in a 0°C ice bath and stirred for 5 minutes before being recooled back to -30°C. Next,
alcohol 5.5 (1 eq, 0.096 mmol) is dissolved in 0.2 mL CH2Cl2 and added dropwise to the reaction
mixture. The mixture is then placed in a 0°C ice bath and stirred for 2.5 hours coming to room
temperature. After the allotted time, brine is added to the reaction mixture and the organic layer
was extracted. The aqueous layer was further extracted 3 × 5 mL CH2Cl2 and the organic layers
were combined, dried with magnesium sulfate, and concentrated. The crude reaction product was
used immediately in the following step.
To another oven-dried round bottom flask equipped with a magnetic stir bar was added
tris (tetrabutylammonium) hydrogen pyrophosphate (3.0eq, 0.29 mmol) dissolved in 1.3 mL of
acetonitrile. Next, a solution of crude allylic chloride dissolve in 0.9 mL acetonitrile was added
dropwise to the reaction vessel. The reaction was stirred for 3 hours at room temperature and
then the solvent was removed by rotary evaporation at 34°C. The residue was the dissolve in a
minimal amount of ion exchange NH3HCO3 buffer (700mg NH3HCO3, 1 L of deionized H2O, 20
mL of isopropanol) and the resulting solution was passed through a Dowex AG 50 × 8 ion
exchange column (2 × 8 cm) using the NH3HCO3 buffer as an eluent and 25 mL was collected in
a flask. The resulting solution was lyophilized for 3-5 hours. The resulting residue was then
redissolved in deionized watered and purified by cellulose flash column chromatography (3 × 15
cm) using isopropanol:deionized H2O:acetonitrile: NH3HCO3 buffer (500 mL : 250 mL : 250 mL
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: 4 g) as the eluent. In a beaker was collected 40 mL of eluent, then twenty-four 2.5 mL fractions
were collected. Typically, fractions 12-18 were collected and the organic solvents were removed
by rotary evaporation at 34°C.

The resulting solution was then lyophilized to afford

pyrophosphate (5.6) as a white fluffy solid in 84% yield. 1H NMR (500 MHz, Deuterium Oxide)
δ 5.39 (s, 1H), 5.13 (d, J = 6.3 Hz, 2H), 4.41 (s, 2H), 2.33 – 1.98 (m, 12H), 1.95 (d, J = 6.1 Hz,
1H), 1.66 (s, 3H), 1.56 (s, 6H).

31

P NMR (202 MHz, D2O) δ -9.89, -13.73. HRMS 419.1391

[M+2H]-, calculated 419.1389 (C18H29O7P2).

(2E,6E,10E)-3,7,11-trimethyltetradeca-2,6,10-trien-13-yn-1-yl diphosphate (5.6):
Yield (91%). 1H NMR (500 MHz, Deuterium Oxide) δ 5.41 (s, 2H), 5.15 (s, 1H), 4.43 (s,
2H), 2.26 – 1.84 (m, 10H), 1.73 (s, 1H), 1.66 (s, 3H), 1.62 (s, 3H), 1.57 (s, 3H).

31

P NMR (202

MHz, Deuterium Oxide) δ -10.08 (d, J = 37.0 Hz), -13.92 (d, J = 40.4 Hz). HRMS 405.1237
[M+2H]-, calculated 405.1232 (C17H27O7P2).

(2E,6Z,10E)-3,11,15-trimethyl-7-(prop-2-yn-1-yl)hexadeca-2,6,10,14-tetraen-1-yl
(5.25):

Yield (71%). 31P NMR (202 MHz, Deuterium Oxide) δ -10.12, -14.20.

diphosphate
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Representative procedure for the synthesis of triazole containing pyrophosphates:

(2E,6E)-10-(4-(but-3-yn-1-yl)-1H-1,2,3-triazol-1-yl)-3,7-dimethyldeca-2,6-dien-1-yl diphosphate
(5.11):

To an oven-dried round bottom flask equipped with a magnetic stir bar was added
methanesulfonyl chloride (1.3 eq, 0.15 mmol), DMAP (1.5 eq, 0.17 mmol) and 0.6 mL of
dichloromethane. The mixture was cooled to 0°C and a solution of alcohol 5.10 in 0.2 mL of
dichloromethane was added dropwise to the reaction vessel and allowed to stir for 2.5 hours.
Hexanes were then added to the reaction vessel and the solution was filtered and concentrated.
Next, Et2O was added to the crude product and was again filtered and concentrated. The crude
allylic chloride was then converted to the pyrophosphate following the same method described
for 5.6. Yield (80%). 1H NMR (500 MHz, Deuterium Oxide) δ 7.79 (s, 1H), 5.39 (d, J = 6.9 Hz,
1H), 5.06 (s, 1H), 4.41 (t, J = 6.3 Hz, 2H), 4.29 (t, J = 6.3 Hz, 2H), 2.85 (t, J = 6.8 Hz, 2H), 2.58
– 2.46 (m, 2H), 2.28 (s, 1H), 2.04 (dd, J = 12.9, 5.8 Hz, 4H), 1.99 – 1.93 (m, 2H), 1.90 (d, J = 6.5
Hz, 2H), 1.66 (s, 3H), 1.51 (s, 3H).

31

P NMR (202 MHz, Deuterium Oxide) δ -10.07 (d, J = 21.3

Hz), -13.96 (d, J = 22.0 Hz). HRMS 460.1403 [M+2H]-, calculated 460.1403 (C18H28N3O7P2).

(2E,6E)-3,7-dimethyl-10-(4-(prop-2-yn-1-yl)-1H-1,2,3-triazol-1-yl)deca-2,6-dien-1-yl
diphosphate (5.14):
Yield (73%). 1H NMR (500 MHz, Deuterium Oxide) δ 7.84 (s, 1H), 5.41 (t, J = 6.7 Hz,
1H), 5.07 (t, J = 6.8 Hz, 1H), 4.43 (t, J = 6.1 Hz, 2H), 4.32 (td, J = 6.7, 2.4 Hz, 2H), 3.65 (t, 1H),
2.11 – 2.02 (m, 4H), 2.01 – 1.87 (m, 4H), 1.67 (s, 3H), 1.52 (s, 3H).

31

P NMR (202 MHz,
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Deuterium Oxide) δ -13.07 (d, J = 16.7 Hz), -14.29 (d, J = 17.3 Hz). HRMS 446.1250 [M+2H]-,
calculated 446.1246 (C17H27N3O7P2).

General procedure for in vitro biochemical substrate screening:

All biochemical evaluations were performed in our collaborator Dr. Carol Fierke’s
laboratory at the University of Michigan by Elia Wright.

Preliminary evaluation of all

pyrophosphate analogs were performed using GGPP analog (1, 5, or 10 µM), the peptide dansylGCVLL (5 µM), recombinant mammalian GGTase-I (50 nM), 50 nM HEPPSO pH 7.8, 5 mM
tris(2carboxyethyl)phosphine (TCEP), and 5 mM MgCl2 at 25°C in 96 well plates (Corning).
Protein prenylation was determined by monitoring the dansylated peptide using a continuous
spectrofluorometic assay and all assays were performed in triplicate. Upon prenylation of the
peptide, the activity was measured by an increase in fluorescence intensity of the dansyl group
(λex = 340 nm, λem = 520 nm) in a POLARstar Galaxy plate reader. Peptide in assay buffer was
utilized as a negative control and the baseline fluorescence of the peptide was subtracted from the
reaction signal.
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CHAPTER 6. CONCLUSIONS & FUTURE DIRECTONS

This work served as a preliminary study of the isoprene requirements and their effect on
GGTase-I activity.

Several small libraries of aryl-modified, saturated, frame-shifted, and

alkynyl-GGPP compounds were synthesized and evaluated as co-substrates with dansyl-GCVLL
in a fluorescence-based assay. Interestingly, the majority of our compounds displayed in vitro
biochemical activity and provided us with interesting insights into GGTase-I binding (Figure
6.1).

6.1

Aryl-Modified GGPP Analogs

Replacing the ω-isoprene unit with an aryl motif was well tolerated by the enzyme;
however, the number of methylene spacers between the aryl group and the γ-isoprene unit was
important.

When the number of methylene spacers was two, this yielded compounds that had

substrate activity comparable to GGPP (2.6a, d, f; Figure 2.6). The longer carbon chain allows
the aryl-moiety to be positioned in a more spacious area of the exit grove (Figure 6.3, yellow).
When the number of methylene spacers were decreased by one, there was diminished substrate
activity, although these compounds still retained some ability to be turned over by the GGTase-I.
One possible reason for the observations noticed with the shorter chain analogs (2.6b-d) could be
that the aryl-analogs bind in such a way that the pyrophosphate head group is further away from
the Zn2+ ion (i.e. bound deeper within the pocket). Therefore, coordination to the zinc ion would
be attenuated and in return the catalytic ability of the enzyme to transfer the isoprenoid chain
would be diminished (Figure 6.2 & 6.4A).
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Additionally, the aryl-group of the shorter chained analog (2.6b) is less flexible and
modeling in the exit grove indicates a potential unfavorable interaction (Figure 6.3). Due to the
sp2 carbons being more electronegative than the hydrogen atoms, the benzene ring exhibits a
negative potential on the pi face. This could result in an unfavorable interaction with the
electrons of the carbonyl backbone group of the neighboring P317β. Alternatively, aligning the
aryl-moiety of 2.6b (Figure 6.3, purple) with the ω-isoprene of GGPP (Figure 6.3, green)
indicates that in this position the steric bulk of the aryl-motif would potentially be too great to fit
into the narrow exit groove. In order to alleviate these issues, the aryl-motif of 2.6b could rotate
into an alternative pocket of the exit grove which would allow the analog to adopt a more
extended conformation into a different pocket of the exit grove which may or may not affect
product release (Figure 6.3, dashed circle).
Surprisingly, the cyclohexyl analog (2.6c) also displayed substrate activity; in fact, it
appeared to be a more efficient substrate than its aryl-counterpart (2.6b). This led us to question
whether or not the aryl-motif is beneficial or if it is simply a matter of hydrophobicity. An
alternative explanation could lie in the differences in flexibility between the two motifs and the
product release of the prenylated protein. In order for the product to be released from the
enzyme, the isoprenoid group must rotate into an exit grove of the enzyme followed by the biding
of a new molecule of the pyrophosphate analog. The cyclohexyl motif is a much more flexible
group; thus, it could be speculated that as the isoprenoid chain is shifting into the exit grove, the
more flexible cyclohexyl group is able to undergo conformational changes in order to allow the
isoprenoid shift to occur more efficiently (Figure 6.3, red). The aryl-motif, which is a more rigid
structure, could potentially hinder the ability of the isoprenoid chain to undergo this
conformational shift into the exit grove.
Another potential benefit of the cyclohexyl group of 2.6c is lack of aromaticity when the
carbon chain is shorter than GGPP. This would remove any potential unfavorable electronic
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interaction between the carbonyl backbone of P317β and the pi face. It would be intriguing to
synthesize a cyclohexyl-analog that contains two methylene spacers between the cyclic group and
the γ-isoprene unit to determine if any additional activity could be gained by increasing the length
of the isoprene chain (Figure 6.1). In general, the length of the carbon chain seems to greatly
influence whether or not the aromatic moiety is a beneficial modification.

6.2

Saturated GGPP Analogs

The saturated analogs revealed that GGTase-I can recognize and utilize compounds that
contain only the α-isoprene unit; however, length of the analog has a significant effect upon
substrate activity. Generally, compounds that are the same length as GGPP display the greatest
amount of substrate activity. The attenuated activity of the shorter analogs could be due to the
position of the isoprene in the binding pocket (Figure 6.4). One possibility is that the carbon
chain binds in the pocket in such a way that the carbon adjacent to the pyrophosphate head group
is further away from the Zn2+ ion (Figure 6.4A, yellow) which could diminish catalysis.
Analogs containing only the α-isoprene unit (3.3a-c) revealed that only α-isoprene is
required for enzyme recognition and catalysis; however, only moderate substrate activity was
observed. Possible explanations for this observation include: 1) loss of potential pi interactions
between the β, γ, and ω-isoprene units with aromatic groups aligning the binding pocket and/or 2)
effects of changing hydrophobicity on the dansyl-fluorophore. By taking a closer look at the
binding pocket of GGTase-I, it is possible that the β and γ-isoprene units could interact with
W275β via pi-pi interactions (Figure 6.4C). Additionally, the γ and ω-isoprene units have the
potential to have pi-pi interactions with Y176β and the ω-isoprene unit could have additional pipi interactions with F52β, F53β, Y126β, W275β, and F324β. Therefore, the lack of these
interactions may result in the observed decrease in enzymatic catalysis by potentially lowering
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the affinity of the enzyme for the saturated analogs. On the other hand, the observation could be
due to the nature of the pyrophosphate analogs. The substrate assays were developed for the use
of an isoprenoid chain with a dansyl-fluorophore. Increasing the hydrophobic environment
around the dansyl-fluorophore with an isoprenoid chain leads to an increase in fluorescence
which can be easily measured. This begs the question of whether or not the fluorescence
change/intensity will be the same between a saturated analog and GGPP. Thus, further studies
need to done to address this issue and any definitive conclusions cannot be made until such
experiments have been conducted. One possible method is to use HPLC analyses which would
allow us to quantify the amount of unprenylated peptide versus prenylated product which could
then be related back to the change in fluorescence observed.
The saturated analogs also revealed that incorporation of the ω-isoprene unit is very
beneficial for substrate activity, but only when the carbon chain is the length of GGPP. This
modification yields a compound (3.16b) that was comparable to GGPP and indicated that the βand γ- isoprene units are not essential for GGTase-I recognition and turn over. However, by
decreasing the length of the carbon chain by one (3.16a) resulted in a drastic decrease in enzyme
activity.

Once again, this could potentially be due to pi-pi interactions.

As mentioned

previously, the ω-isoprene unit has the potential to have pi-pi interactions with F52β, F53β,
Y126β, Y176β, W275β, and F324β (Figure 6.4C). By decreasing the carbon length by one
methylene unit, this increases the distance between the ω-isoprene unit and four of the aromatic
residues lining the binding pocket (F52β, F53β, Y126β, and F324β) (Figure 6.4B). Therefore,
the decrease in or lose of pi-pi interactions could account for the observed decrease in enzymatic
activity.
Interestingly, replacing the β-isoprene has little effect on substrate activity when the
carbon chain is the length of GGPP. Instead, the replacement of the β-isoprene has the most
pronounced effect on compounds that are lacking in length. As mentioned previously, the
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attenuated activity of the shorter analogs could be due to the position of the isoprene in the
binding pocket (Figure 6.2 & 6.4A). Without the β-isoprene unit, perhaps it is more likely that
the carbon chain binds in the pocket in such a way that the carbon adjacent to the pyrophosphate
head group is further away from the Zn2+ ion (Figure 6.4A, yellow) which could diminish
catalytic ability. However, by reintroducing the β-isoprene unit back into the molecule, this could
provide an additional pi-pi interaction between the β-isoprene unit and W275β (Figure 6.4C).
Therefore, instead of binding deep in the pocket (Figure 6.3A, yellow) where the pyrophosphate
group is further away from the Zn2+ ion, perhaps the added pi-pi interaction aids in the analogs
binding in the correct orientation (i.e. the pyrophosphate head group is near the Zn2+). Thus, for
analogs which shorter carbons chains, this modification would be beneficial.

6.3

Frame-Shifted GGPP Analogs

The majority of the compounds in our frame-shifted GGPP library were determined to
display substrate activity.

The information gained from these results can be helpful when

designing new analogs. Once again, the length of the carbon chain appears to be a major factor in
determining substrate ability. As mentioned previously, this is most likely due to the ω-isoprene
unit having pi-pi interactions with F52β, F53β, Y126β, Y176β, W275β, and F324β (Figure
6.4C). Interestingly, compounds 1,2,2,1-OPP and 5,2,1-OPP have similar substrate abilities

indicated that chain length is more important than flexibility. It is possible that both molecules
bind to the enzyme as shown in Figure 6.4B. Both analogs increase the distance between the ωisoprene unit and four of the aromatic residues lining the binding pocket (F52β, F53β, Y126β,
and F324β) (Figure 6.4B). Therefore, the decrease in or lose of pi-pi interactions could account
for the observed decrease in enzymatic activity and similar activities.
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Additionally, increasing the number of methylene spacers between the α- and β- isoprene
units from two to three seems to be very detrimental to substrate ability. Preliminary docking of
analogs 2,3,1-OPP (4.17, Figure 6.5B) and 3,3,1-OPP (4.11, Figure 6.5C) indicates that this
modification could lead to potential unwanted steric interactions with C177β and C225β (Figure
6.5B & 6.5C, dashed circles). This could potentially explain their poor substrate ability. By

reverting back to the two methylene units between the α and β-subunits, analog 3,2,1-OPP (4.28)
does not appear to have these steric interactions and regains minimal substrate activity (Figure
6.5A). It seems for analog 3,2,1-OPP the major factor is carbon chain length. An analog

synthesized by Dr. Andrew Placzek (2,2,1,1-OPP) where the number of methylene units between
the α- and β- isoprene units was decreased to one was also determined to be a poor substrate of
GGTase-I. Thus, the position and orientation of the β-isoprene unit is crucial.
This class of compounds also revealed the γ-isoprene unit is unnecessary for activity
(4.40c; 6,2,1-OPP). This is perhaps not surprising when taken into consideration the majority of
possible pi-pi interactions occur between the enzyme and the β and ω-isoprene units (Figure
6.4C).

Moreover, converting the allylic pyrophosphate into a homo-allylic pyrophosphate

produced an inhibitor. This is most likely do to the decreased nucleophilicity of the non-allylic
pyrophosphate. It would be interesting to synthesized frame-shifted analogs with a carbon chain
length of 16 such as 1,3,2,1-OPP, 2,3,1,1-OPP and 3,2,1,1-OPP (Figure 6.1). Additionally, it
would also be interesting to synthesize an analog in which all the isoprene units except the βisoprene are present (2,6,1-OPP) (Figure 6.1). These new analogs could provide further insight
into GGTase-I activity.
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6.4

Alkynyl-GGPP Analogs

Unfortunately, the alkynyl-GGPP analogs did not show as much promise in our in vitro
biochemical screening assays. Looking at the transformations that occurs throughout the reaction
pathway of GGTase-I could provide a possible understanding of why the triazole compounds did
not behave as substrates. Preliminary modeling of analog 5.11 in the catalytic site to GGTase-I
indicates the possibility of an unfavorable steric interaction with C177β (Figure 6.6A, dashed
circle). This observation taken together with the fact that introduction of the triazole into the

compound decreases the flexibility of the analog could hinder binding to GGTase-I.
Additionally, due to increased rigidity, it is possible that the prenylated product cannot shift
readily into the exit grove of GGTase-I which would hinder product releases (Figure 6.1). It is
also possible that the prenylated product may not fit into the exit grove (Figure 6.6B, orange).
Moreover, analog 5.11 could adopt an alternate conformation with in the exit grove (Figure 6.6B,
violet).

This alternative position allows for favorable, stabilizing interactions between the

triazole nitrogens and the hydroxyl group of Y40β and the backbone carbonyl of P317β. Such
stabilizing interactions could result in attenuated product release.
Only the terminal alkyne (5.7) showed moderate substrate activity; however, as
mentioned previously, it’s important to note that these compounds were only screened with one
dansyl-GCaaX sequence.

Using combinatorial screening in the past, our laboratory has

demonstrated that some modified FPP and GGPP analogs act as selective substrates. These
substrates only modify a very limited amount of CaaX sequences.73, 144 Thus, it is possible these
analogs are substrates of GGTase-I but they are not a co-substrate with dansyl-CVLL. Therefore,
all these compounds will be evaluated more extensively in the future with combinatorial assays in
which several libraries of dansyl-CaaX peptides will be screened. These screens will provide us
with a good indication of whether or not our substrates are global or selective prenyl donors.
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Additionally, compounds that do not display substrate activity will be tested in a similar
fluorescence-based assay to determine if these analogs are inhibitors of GGTase-I. Finally, we
also anticipate screening these analogs in a combinatorial screen and/or inhibitor screen with
FTase. These screens will provide insight into the differences and/or similarities of isoprene
requirements of FTase and GGTase-I leading to a deeper understanding of the dynamic roles
farnesylation and geranylgeranylation play in cellular processes.
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Figure 6.1. Summary of project findings and proposed future analogs for synthesis.
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A)

B)

Figure 6.2. Structure of GGPP and CVLL or CVIL bound in the β-subunit of GGTase-I. A)
Overlay of GGPP (magenta) and CVLL (ligh purple) and prenylated CVIL (blue). B) Overay of
prenylated CVIL (blue) in the catalytic site and prenylated CVIL in the exit grove (green) of
GGTase-I (PDB: 1TNZ, 1N4R, 1N4S).

P317β

Figure 6.3. Aryl-modified analogs bound in the exit grove of GGTase-I. Overlay of analog 2.6a
(yellow, homobenzyl), 2.6b (purple, benzyl), 2.6c (red, cyclohexyl), & GGPP (green).
Alternative binding mode of 2.6b is highlighted in dashed circle (PDB: 1N4S).

185

A)

B)

Zn2+

Zn2+

F324β

F53β

Y176β
F52β

Y126β
C)

Zn2+

W275β
F324β

Y176β
F53β

Y126β

F52β

Figure 6.4. Analyzing the distances between the Zn2+ ion or aromatic residues in the binding
pocket of GGTase-I with isoprenoid chains. A) Shorter carbon chain analogs (yellow) that could
bind deep in the GGTase-I pocket. B) Bound isopreind that is one carbon shorter than GGPP
(1,2,2,1-OPP; red). C) Bound GGPP (blue) (PDB: 1TNZ).
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A)

B)
C225β

C177β
C)
C225β

Figure 6.5. Analyzing the affects of increasing the number of carbons between the α and βisoprene units to three carbons. Overlay of GGPP (blue ) and A) 3,2,1-OPP (green), B) 2,3,1-OPP
(purple) and C) 3,3,1-OPP (pink). Potential unfavorable steric interactions are shown in dashed
circles (PDB: 1N4R).
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A)

B)
P317β
Y40β

C177β

Figure 6.6. Triazole-containing alkynyl-GGPP analogs bound in GGTase-I. A) Overlay of
analog 5.11 (orange) with GGPP (magenta) bound in the catalytic site. B) Overlay of analog
5.11 (orange) and GGPP (green) bound in the exit grove of GGTase-I. Alternative binding mode
of analog 5.11 is also shown (violet). Unfavorable steric interactions shown dashed circles (PDB:
1TNZ & 1N4S).
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